[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fUCmGRSC4pi5uT6EaMjiqw_iktgdwl1TEFrpUL_yNk58":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":37,"phaseBuckets":86,"rows":93},"University of California, Davis",[4],786,false,183,19,3621452,74,597,[14,17,20,23,26,29,31,34],{"name":15,"count":16},"Healthy",26,{"name":18,"count":19},"Obesity",20,{"name":21,"count":22},"Breast Cancer",16,{"name":24,"count":25},"Unspecified Adult Solid Tumor, Protocol Specific",14,{"name":27,"count":28},"Prostate Cancer",13,{"name":30,"count":28},"Lung Cancer",{"name":32,"count":33},"Metabolic Syndrome",10,{"name":35,"count":36},"Inflammation",9,[38,43,48,53,58,62,67,71,76,81],{"nctId":39,"briefTitle":40,"date":41,"intervention":42},"NCT03999164","Imaging of Neuro-Inflammation and the Risk for Post-Traumatic Epilepsy","2025-08-14","[18F]DPA-714 Positron Emission Tomography Scan",{"nctId":44,"briefTitle":45,"date":46,"intervention":47},"NCT06041048","Investigation of Locus Coeruleus Function in Sustained Attention","2025-12-30","Modafinil",{"nctId":49,"briefTitle":50,"date":51,"intervention":52},"NCT04007510","California Collaborative Network to Promote Data Driven Care and Improve Outcomes in Early Psychosis","2026-03-30","EPI-CAL data network",{"nctId":54,"briefTitle":55,"date":56,"intervention":57},"NCT05843448","IDO and PD-L1 Peptide Based Immune-Modulatory Therapeutic (IO102-IO103) in Combination With Pembrolizumab for BCG-Unresponsive or Intolerant, Non-Muscle Invasive Bladder Cancer","2026-06","PD-L1\u002FIDO Peptide Vaccine",{"nctId":59,"briefTitle":60,"date":56,"intervention":61},"NCT04804241","Senicapoc in Alzheimer's Disease","Senicapoc",{"nctId":63,"briefTitle":64,"date":65,"intervention":66},"NCT06461442","Efficacy and Safety of Cryotherapy Versus 5-Fluorouracil in the Treatment of Actinic Keratosis","2026-06-01","5Fluorouracil",{"nctId":68,"briefTitle":69,"date":65,"intervention":70},"NCT06920381","Ethyl Chloride Spray to Reduce Pain From Local Anesthesia During Mohs Micrographic Surgery","Gebauer's Ethyl Chloride Topical Spray",{"nctId":72,"briefTitle":73,"date":74,"intervention":75},"NCT05967533","The Immune Effects of Fermented Wheat Germ Nutritional Supplementation in Patients With Advanced Solid Tumor Cancers Being Treated With Standard of Care Checkpoint Inhibitors","2026-06-02","Fermented Wheat Germ Extract",{"nctId":77,"briefTitle":78,"date":79,"intervention":80},"NCT03737604","TAP Blocks With Ropivacaine Continuous Infusion Catheters vs Single Dose Liposomal Bupivicaine After Kidney Transplant","2026-06-12","Ropivacaine Continuous Infusion Catheter",{"nctId":82,"briefTitle":83,"date":84,"intervention":85},"NCT04240626","Multimodal Analgesia Effect on Post Surgical Patient","2026-06-24","Neurontin",[87,88,89,90,91,92],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[94,123,151,169,192,210,232,257,278,310,328,346,364,382,400,418,436,454,472,499,517,553,579,597,623,694,729,770,801,819,846,864,882,900,930,991,1015,1038,1065,1083,1101,1127,1154,1179,1207,1228,1256,1300,1368,1392,1413,1437,1455,1473,1501,1525,1549,1577,1595,1618,1653,1685,1732,1754,1783,1801,1819,1837,1855,1874,1900,1918,1952,1974,1998,2031,2070,2095,2124,2142,2168,2195,2218,2242,2267,2294,2312,2330,2348,2366,2384,2408,2434,2452,2477,2495,2520,2538,2556,2574,2602,2620,2647,2665,2691,2709,2732,2757,2783,2801,2825,2850,2875,2905,2923,2941,2959,2990,3014,3084,3131,3176,3209,3241,3286,3312,3353,3384,3411,3444,3466,3488,3523,3555,3601,3623,3657,3688,3721,3743,3768,3786,3804,3830,3848,3873,3903,3921,3939,3957,3980,4004,4046,4064,4086,4104,4129,4153,4171,4198,4216,4234,4252,4270,4288,4306,4324,4342,4366,4390,4408,4432,4456,4474,4492,4514,4540,4567,4585,4603,4621,4651,4681,4711,4733,4760,4799,4821,4845,4868,4892,4918,4936,4954,4972,4990,5013,5038,5056,5080,5098,5116,5134,5152,5170,5188,5214,5232,5250,5272,5295,5320,5343,5361,5379,5397,5415,5433,5451,5469,5493,5517,5541,5565,5589,5615,5633,5662,5685,5709,5727,5776,5802,5827,5861,5884,5907,5930,5954,5979,6003,6027,6052,6070,6091,6113,6138,6163,6181,6203,6227],{"intervention":95,"totalTrials":96,"cells":97},"Reduction in antimetabolite immunosuppression",1,{"EARLY_PHASE1":98,"PHASE1":101,"PHASE2":103,"PHASE3":105,"PHASE4":107,"NA":121},{"trials":99,"activeCount":100},[],0,{"trials":102,"activeCount":100},[],{"trials":104,"activeCount":100},[],{"trials":106,"activeCount":100},[],{"trials":108,"activeCount":96,"soonestReadout":114},[109],{"nctId":110,"briefTitle":111,"status":112,"phases":113,"primaryCompletion":114,"completion":114,"start":115,"enrollment":25,"conditions":116,"interventions":120},"NCT05060991","Impact of Immunosuppression Adjustment on COVID-19 Vaccination Response in Kidney Transplant Recipients","ACTIVE_NOT_RECRUITING",[91],"2026-12-24","2021-09-24",[117,118,119],"COVID-19","Immunosuppression","Vaccine Response Impaired",[95],{"trials":122,"activeCount":100},[],{"intervention":124,"totalTrials":96,"cells":125},"Dopamine administration",{"EARLY_PHASE1":126,"PHASE1":128,"PHASE2":130,"PHASE3":132,"PHASE4":134,"NA":149},{"trials":127,"activeCount":100},[],{"trials":129,"activeCount":100},[],{"trials":131,"activeCount":100},[],{"trials":133,"activeCount":100},[],{"trials":135,"activeCount":96,"soonestReadout":141},[136],{"nctId":137,"briefTitle":138,"status":139,"phases":140,"primaryCompletion":141,"completion":141,"start":65,"enrollment":142,"conditions":143,"interventions":147},"NCT07322133","Dopamine vs. Norepinephrine for Hypotension in Neonates With Pulmonary Hypertension (DONE)","RECRUITING",[91],"2028-01-31",30,[144,145,146],"Hypotension and Shock","Pulmonary Hypertension of the Newborn (PPHN)","Hypoxemic Respiratory Failure",[124,148],"Norepinephrine",{"trials":150,"activeCount":100},[],{"intervention":148,"totalTrials":96,"cells":152},{"EARLY_PHASE1":153,"PHASE1":155,"PHASE2":157,"PHASE3":159,"PHASE4":161,"NA":167},{"trials":154,"activeCount":100},[],{"trials":156,"activeCount":100},[],{"trials":158,"activeCount":100},[],{"trials":160,"activeCount":100},[],{"trials":162,"activeCount":96,"soonestReadout":141},[163],{"nctId":137,"briefTitle":138,"status":139,"phases":164,"primaryCompletion":141,"completion":141,"start":65,"enrollment":142,"conditions":165,"interventions":166},[91],[144,145,146],[124,148],{"trials":168,"activeCount":100},[],{"intervention":80,"totalTrials":96,"cells":170},{"EARLY_PHASE1":171,"PHASE1":173,"PHASE2":175,"PHASE3":177,"PHASE4":179,"NA":190},{"trials":172,"activeCount":100},[],{"trials":174,"activeCount":100},[],{"trials":176,"activeCount":100},[],{"trials":178,"activeCount":100},[],{"trials":180,"activeCount":96,"soonestReadout":79},[181],{"nctId":77,"briefTitle":78,"status":139,"phases":182,"primaryCompletion":79,"completion":79,"start":183,"enrollment":184,"conditions":185,"interventions":188},[91],"2018-10-04",200,[186,187],"Transplant;Failure,Kidney","Pain, Postoperative",[80,189],"Single Dose Liposomal Bupivicaine",{"trials":191,"activeCount":100},[],{"intervention":189,"totalTrials":96,"cells":193},{"EARLY_PHASE1":194,"PHASE1":196,"PHASE2":198,"PHASE3":200,"PHASE4":202,"NA":208},{"trials":195,"activeCount":100},[],{"trials":197,"activeCount":100},[],{"trials":199,"activeCount":100},[],{"trials":201,"activeCount":100},[],{"trials":203,"activeCount":96,"soonestReadout":79},[204],{"nctId":77,"briefTitle":78,"status":139,"phases":205,"primaryCompletion":79,"completion":79,"start":183,"enrollment":184,"conditions":206,"interventions":207},[91],[186,187],[80,189],{"trials":209,"activeCount":100},[],{"intervention":66,"totalTrials":96,"cells":211},{"EARLY_PHASE1":212,"PHASE1":214,"PHASE2":216,"PHASE3":218,"PHASE4":220,"NA":230},{"trials":213,"activeCount":100},[],{"trials":215,"activeCount":100},[],{"trials":217,"activeCount":100},[],{"trials":219,"activeCount":100},[],{"trials":221,"activeCount":96,"soonestReadout":65},[222],{"nctId":63,"briefTitle":64,"status":223,"phases":224,"primaryCompletion":65,"completion":65,"start":225,"enrollment":226,"conditions":227,"interventions":229},"ENROLLING_BY_INVITATION",[91],"2024-07-01",73,[228],"Actinic Keratoses",[66],{"trials":231,"activeCount":100},[],{"intervention":233,"totalTrials":96,"cells":234},"Hydroquinone Topical",{"EARLY_PHASE1":235,"PHASE1":237,"PHASE2":239,"PHASE3":241,"PHASE4":243,"NA":255},{"trials":236,"activeCount":100},[],{"trials":238,"activeCount":100},[],{"trials":240,"activeCount":100},[],{"trials":242,"activeCount":100},[],{"trials":244,"activeCount":96,"soonestReadout":249},[245],{"nctId":246,"briefTitle":247,"status":139,"phases":248,"primaryCompletion":249,"completion":249,"start":250,"enrollment":251,"conditions":252,"interventions":254},"NCT04875715","Prospective Evaluation of Topical Almond Oil vs Hydroquinone",[91],"2026-08-01","2021-07-01",50,[253],"Skin Pigmentation",[233],{"trials":256,"activeCount":100},[],{"intervention":47,"totalTrials":96,"cells":258},{"EARLY_PHASE1":259,"PHASE1":261,"PHASE2":263,"PHASE3":265,"PHASE4":267,"NA":276},{"trials":260,"activeCount":100},[],{"trials":262,"activeCount":100},[],{"trials":264,"activeCount":100},[],{"trials":266,"activeCount":100},[],{"trials":268,"activeCount":96,"soonestReadout":46},[269],{"nctId":44,"briefTitle":45,"status":139,"phases":270,"primaryCompletion":46,"completion":46,"start":271,"enrollment":272,"conditions":273,"interventions":275},[91],"2023-10-01",40,[274],"Attention - no Condition is Being Assessed - Healthy Adults",[47],{"trials":277,"activeCount":100},[],{"intervention":85,"totalTrials":96,"cells":279},{"EARLY_PHASE1":280,"PHASE1":282,"PHASE2":284,"PHASE3":286,"PHASE4":288,"NA":308},{"trials":281,"activeCount":100},[],{"trials":283,"activeCount":100},[],{"trials":285,"activeCount":100},[],{"trials":287,"activeCount":100},[],{"trials":289,"activeCount":96,"soonestReadout":84},[290],{"nctId":82,"briefTitle":83,"status":112,"phases":291,"primaryCompletion":84,"completion":84,"start":292,"enrollment":293,"conditions":294,"interventions":298},[91],"2021-01-20",60,[295,296,297],"Obesity, Morbid","Surgery","Bariatric Surgery Candidate",[85,299,300,301,302,303,304,305,306,307],"Dilaudid Injectable Product","Marcaine Injectable Product","Oxycodone Hydrochloride","Hycet 7.5Mg-325Mg\u002F15Ml Solution","Zofran","Scopolamine patch","Ativan","Flexeril Oral Product","Tylenol Suspension",{"trials":309,"activeCount":100},[],{"intervention":299,"totalTrials":96,"cells":311},{"EARLY_PHASE1":312,"PHASE1":314,"PHASE2":316,"PHASE3":318,"PHASE4":320,"NA":326},{"trials":313,"activeCount":100},[],{"trials":315,"activeCount":100},[],{"trials":317,"activeCount":100},[],{"trials":319,"activeCount":100},[],{"trials":321,"activeCount":96,"soonestReadout":84},[322],{"nctId":82,"briefTitle":83,"status":112,"phases":323,"primaryCompletion":84,"completion":84,"start":292,"enrollment":293,"conditions":324,"interventions":325},[91],[295,296,297],[85,299,300,301,302,303,304,305,306,307],{"trials":327,"activeCount":100},[],{"intervention":300,"totalTrials":96,"cells":329},{"EARLY_PHASE1":330,"PHASE1":332,"PHASE2":334,"PHASE3":336,"PHASE4":338,"NA":344},{"trials":331,"activeCount":100},[],{"trials":333,"activeCount":100},[],{"trials":335,"activeCount":100},[],{"trials":337,"activeCount":100},[],{"trials":339,"activeCount":96,"soonestReadout":84},[340],{"nctId":82,"briefTitle":83,"status":112,"phases":341,"primaryCompletion":84,"completion":84,"start":292,"enrollment":293,"conditions":342,"interventions":343},[91],[295,296,297],[85,299,300,301,302,303,304,305,306,307],{"trials":345,"activeCount":100},[],{"intervention":301,"totalTrials":96,"cells":347},{"EARLY_PHASE1":348,"PHASE1":350,"PHASE2":352,"PHASE3":354,"PHASE4":356,"NA":362},{"trials":349,"activeCount":100},[],{"trials":351,"activeCount":100},[],{"trials":353,"activeCount":100},[],{"trials":355,"activeCount":100},[],{"trials":357,"activeCount":96,"soonestReadout":84},[358],{"nctId":82,"briefTitle":83,"status":112,"phases":359,"primaryCompletion":84,"completion":84,"start":292,"enrollment":293,"conditions":360,"interventions":361},[91],[295,296,297],[85,299,300,301,302,303,304,305,306,307],{"trials":363,"activeCount":100},[],{"intervention":302,"totalTrials":96,"cells":365},{"EARLY_PHASE1":366,"PHASE1":368,"PHASE2":370,"PHASE3":372,"PHASE4":374,"NA":380},{"trials":367,"activeCount":100},[],{"trials":369,"activeCount":100},[],{"trials":371,"activeCount":100},[],{"trials":373,"activeCount":100},[],{"trials":375,"activeCount":96,"soonestReadout":84},[376],{"nctId":82,"briefTitle":83,"status":112,"phases":377,"primaryCompletion":84,"completion":84,"start":292,"enrollment":293,"conditions":378,"interventions":379},[91],[295,296,297],[85,299,300,301,302,303,304,305,306,307],{"trials":381,"activeCount":100},[],{"intervention":303,"totalTrials":96,"cells":383},{"EARLY_PHASE1":384,"PHASE1":386,"PHASE2":388,"PHASE3":390,"PHASE4":392,"NA":398},{"trials":385,"activeCount":100},[],{"trials":387,"activeCount":100},[],{"trials":389,"activeCount":100},[],{"trials":391,"activeCount":100},[],{"trials":393,"activeCount":96,"soonestReadout":84},[394],{"nctId":82,"briefTitle":83,"status":112,"phases":395,"primaryCompletion":84,"completion":84,"start":292,"enrollment":293,"conditions":396,"interventions":397},[91],[295,296,297],[85,299,300,301,302,303,304,305,306,307],{"trials":399,"activeCount":100},[],{"intervention":304,"totalTrials":96,"cells":401},{"EARLY_PHASE1":402,"PHASE1":404,"PHASE2":406,"PHASE3":408,"PHASE4":410,"NA":416},{"trials":403,"activeCount":100},[],{"trials":405,"activeCount":100},[],{"trials":407,"activeCount":100},[],{"trials":409,"activeCount":100},[],{"trials":411,"activeCount":96,"soonestReadout":84},[412],{"nctId":82,"briefTitle":83,"status":112,"phases":413,"primaryCompletion":84,"completion":84,"start":292,"enrollment":293,"conditions":414,"interventions":415},[91],[295,296,297],[85,299,300,301,302,303,304,305,306,307],{"trials":417,"activeCount":100},[],{"intervention":305,"totalTrials":96,"cells":419},{"EARLY_PHASE1":420,"PHASE1":422,"PHASE2":424,"PHASE3":426,"PHASE4":428,"NA":434},{"trials":421,"activeCount":100},[],{"trials":423,"activeCount":100},[],{"trials":425,"activeCount":100},[],{"trials":427,"activeCount":100},[],{"trials":429,"activeCount":96,"soonestReadout":84},[430],{"nctId":82,"briefTitle":83,"status":112,"phases":431,"primaryCompletion":84,"completion":84,"start":292,"enrollment":293,"conditions":432,"interventions":433},[91],[295,296,297],[85,299,300,301,302,303,304,305,306,307],{"trials":435,"activeCount":100},[],{"intervention":306,"totalTrials":96,"cells":437},{"EARLY_PHASE1":438,"PHASE1":440,"PHASE2":442,"PHASE3":444,"PHASE4":446,"NA":452},{"trials":439,"activeCount":100},[],{"trials":441,"activeCount":100},[],{"trials":443,"activeCount":100},[],{"trials":445,"activeCount":100},[],{"trials":447,"activeCount":96,"soonestReadout":84},[448],{"nctId":82,"briefTitle":83,"status":112,"phases":449,"primaryCompletion":84,"completion":84,"start":292,"enrollment":293,"conditions":450,"interventions":451},[91],[295,296,297],[85,299,300,301,302,303,304,305,306,307],{"trials":453,"activeCount":100},[],{"intervention":307,"totalTrials":96,"cells":455},{"EARLY_PHASE1":456,"PHASE1":458,"PHASE2":460,"PHASE3":462,"PHASE4":464,"NA":470},{"trials":457,"activeCount":100},[],{"trials":459,"activeCount":100},[],{"trials":461,"activeCount":100},[],{"trials":463,"activeCount":100},[],{"trials":465,"activeCount":96,"soonestReadout":84},[466],{"nctId":82,"briefTitle":83,"status":112,"phases":467,"primaryCompletion":84,"completion":84,"start":292,"enrollment":293,"conditions":468,"interventions":469},[91],[295,296,297],[85,299,300,301,302,303,304,305,306,307],{"trials":471,"activeCount":100},[],{"intervention":473,"totalTrials":96,"cells":474},"Magnesium Sulfate in Parenteral Dosage Form",{"EARLY_PHASE1":475,"PHASE1":477,"PHASE2":479,"PHASE3":481,"PHASE4":483,"NA":497},{"trials":476,"activeCount":100},[],{"trials":478,"activeCount":100},[],{"trials":480,"activeCount":100},[],{"trials":482,"activeCount":100},[],{"trials":484,"activeCount":96,"soonestReadout":489},[485],{"nctId":486,"briefTitle":487,"status":139,"phases":488,"primaryCompletion":489,"completion":489,"start":490,"enrollment":491,"conditions":492,"interventions":495},"NCT04166877","Magnesium Infusion for Pain Management in Critically Ill Trauma Patients",[91],"2026-12-31","2019-12-07",156,[493,494],"Trauma","Acute Pain",[473,496],"Normal saline placebo",{"trials":498,"activeCount":100},[],{"intervention":496,"totalTrials":96,"cells":500},{"EARLY_PHASE1":501,"PHASE1":503,"PHASE2":505,"PHASE3":507,"PHASE4":509,"NA":515},{"trials":502,"activeCount":100},[],{"trials":504,"activeCount":100},[],{"trials":506,"activeCount":100},[],{"trials":508,"activeCount":100},[],{"trials":510,"activeCount":96,"soonestReadout":489},[511],{"nctId":486,"briefTitle":487,"status":139,"phases":512,"primaryCompletion":489,"completion":489,"start":490,"enrollment":491,"conditions":513,"interventions":514},[91],[493,494],[473,496],{"trials":516,"activeCount":100},[],{"intervention":518,"totalTrials":519,"cells":520},"Gabapentin",2,{"EARLY_PHASE1":521,"PHASE1":523,"PHASE2":525,"PHASE3":527,"PHASE4":549,"NA":551},{"trials":522,"activeCount":100},[],{"trials":524,"activeCount":100},[],{"trials":526,"activeCount":100},[],{"trials":528,"activeCount":96,"soonestReadout":489},[529,542],{"nctId":530,"briefTitle":531,"status":532,"phases":533,"primaryCompletion":534,"completion":535,"start":536,"enrollment":537,"conditions":538,"interventions":541},"NCT03682367","Perioperative Analgesia Using Gabapentin in Head and Neck Cancer Surgery","TERMINATED",[90],"2020-04-01","2020-04-06","2018-12-01",8,[539,540],"Cancer of Head and Neck","Narcotic Use",[518],{"nctId":543,"briefTitle":544,"status":139,"phases":545,"primaryCompletion":489,"completion":489,"start":546,"enrollment":293,"conditions":547,"interventions":548},"NCT04724252","Gabapentin to Reduce Opioid Use Postoperatively (GROUP) in Children",[89,90],"2021-08-23",[187],[518],{"trials":550,"activeCount":100},[],{"trials":552,"activeCount":100},[],{"intervention":554,"totalTrials":96,"cells":555},"Oxybutynin Transdermal Patch",{"EARLY_PHASE1":556,"PHASE1":558,"PHASE2":560,"PHASE3":562,"PHASE4":575,"NA":577},{"trials":557,"activeCount":100},[],{"trials":559,"activeCount":100},[],{"trials":561,"activeCount":100},[],{"trials":563,"activeCount":96,"soonestReadout":489},[564],{"nctId":565,"briefTitle":566,"status":139,"phases":567,"primaryCompletion":489,"completion":489,"start":568,"enrollment":569,"conditions":570,"interventions":573},"NCT03952299","Oxybutynin for Post-surgical Bladder Pain and Urgency",[90],"2021-09-01",100,[571,572],"Overactive Bladder Syndrome","Neuropathic Bladder",[554,574],"Oral Oxybutynin",{"trials":576,"activeCount":100},[],{"trials":578,"activeCount":100},[],{"intervention":574,"totalTrials":96,"cells":580},{"EARLY_PHASE1":581,"PHASE1":583,"PHASE2":585,"PHASE3":587,"PHASE4":593,"NA":595},{"trials":582,"activeCount":100},[],{"trials":584,"activeCount":100},[],{"trials":586,"activeCount":100},[],{"trials":588,"activeCount":96,"soonestReadout":489},[589],{"nctId":565,"briefTitle":566,"status":139,"phases":590,"primaryCompletion":489,"completion":489,"start":568,"enrollment":569,"conditions":591,"interventions":592},[90],[571,572],[554,574],{"trials":594,"activeCount":100},[],{"trials":596,"activeCount":100},[],{"intervention":598,"totalTrials":96,"cells":599},"Transnasal sphenopalatine ganglion block",{"EARLY_PHASE1":600,"PHASE1":602,"PHASE2":604,"PHASE3":606,"PHASE4":619,"NA":621},{"trials":601,"activeCount":100},[],{"trials":603,"activeCount":100},[],{"trials":605,"activeCount":100},[],{"trials":607,"activeCount":96,"soonestReadout":612},[608],{"nctId":609,"briefTitle":610,"status":139,"phases":611,"primaryCompletion":612,"completion":613,"start":614,"enrollment":272,"conditions":615,"interventions":618},"NCT06621329","Transnasal Sphenopalatine Ganglion Block for Treatment of Acute Subarachnoid Hemorrhage Associated Headache",[89,90],"2026-07","2026-10","2024-10-17",[616,617],"SAH (Subarachnoid Hemorrhage)","Headache",[598],{"trials":620,"activeCount":100},[],{"trials":622,"activeCount":100},[],{"intervention":624,"totalTrials":625,"cells":626},"Ibrutinib",4,{"EARLY_PHASE1":627,"PHASE1":629,"PHASE2":647,"PHASE3":688,"PHASE4":690,"NA":692},{"trials":628,"activeCount":100},[],{"trials":630,"activeCount":100},[631],{"nctId":632,"briefTitle":633,"status":634,"phases":635,"primaryCompletion":636,"completion":637,"start":638,"enrollment":625,"conditions":639,"interventions":645},"NCT03359460","Ibrutinib and Lenalidomide in Treating Patients With Myelodysplastic Syndrome","COMPLETED",[88],"2019-08-29","2019-11-17","2017-12-01",[640,641,642,643,644],"Myelodysplastic Syndrome","Previously Treated Myelodysplastic Syndrome","Refractory High Risk Myelodysplastic Syndrome","Secondary Myelodysplastic Syndrome","Therapy-Related Myelodysplastic Syndrome",[624,646],"Lenalidomide",{"trials":648,"activeCount":96,"soonestReadout":677},[649,662,673],{"nctId":650,"briefTitle":651,"status":634,"phases":652,"primaryCompletion":653,"completion":654,"start":655,"enrollment":656,"conditions":657,"interventions":660},"NCT02899078","Ibrutinib and Nivolumab in Treating Patients With Previously-Treated Metastatic Kidney Cancer",[88,89],"2020-08-05","2021-02-24","2016-11-15",31,[658,659],"Metastatic Renal Cell Cancer","Stage IV Renal Cell Cancer",[624,661],"Nivolumab",{"nctId":663,"briefTitle":664,"status":634,"phases":665,"primaryCompletion":666,"completion":666,"start":667,"enrollment":9,"conditions":668,"interventions":671},"NCT02997761","Ibrutinib and Blinatumomab in Treating Patients With Relapsed or Refractory B Acute Lymphoblastic Leukemia",[89],"2025-07-17","2017-06-27",[669,670],"Adult B Acute Lymphoblastic Leukemia","Philadelphia Chromosome Positive",[672,624],"Blinatumomab",{"nctId":674,"briefTitle":675,"status":112,"phases":676,"primaryCompletion":677,"completion":677,"start":654,"enrollment":272,"conditions":678,"interventions":685},"NCT04450173","Obinutuzumab, Ibrutinib, and Venetoclax for the Treatment of Previously Untreated Stage II-IV Follicular Lymphoma",[89],"2027-04",[679,680,681,682,683,684],"Ann Arbor Stage II Follicular Lymphoma","Ann Arbor Stage III Follicular Lymphoma","Ann Arbor Stage IV Follicular Lymphoma","Grade 1 Follicular Lymphoma","Grade 2 Follicular Lymphoma","Grade 3a Follicular Lymphoma",[624,686,687],"Obinutuzumab","Venetoclax",{"trials":689,"activeCount":100},[],{"trials":691,"activeCount":100},[],{"trials":693,"activeCount":100},[],{"intervention":695,"totalTrials":519,"cells":696},"Doxycycline",{"EARLY_PHASE1":697,"PHASE1":710,"PHASE2":712,"PHASE3":723,"PHASE4":725,"NA":727},{"trials":698,"activeCount":100},[699],{"nctId":700,"briefTitle":701,"status":634,"phases":702,"primaryCompletion":703,"completion":250,"start":704,"enrollment":142,"conditions":705,"interventions":709},"NCT03655197","Lipidome and Microbiome Profile of the Eye in Rosacea",[87],"2021-06-30","2017-11-02",[706,707,708],"Rosacea","Ocular Rosacea","Cutaneous Rosacea",[695],{"trials":711,"activeCount":100},[],{"trials":713,"activeCount":96,"soonestReadout":718},[714],{"nctId":715,"briefTitle":716,"status":112,"phases":717,"primaryCompletion":718,"completion":718,"start":719,"enrollment":142,"conditions":720,"interventions":722},"NCT02713607","Lipidome and Microbiome Profile of Acne",[88,89],"2027-01","2016-03",[721],"Acne Vulgaris",[695],{"trials":724,"activeCount":100},[],{"trials":726,"activeCount":100},[],{"trials":728,"activeCount":100},[],{"intervention":730,"totalTrials":519,"cells":731},"Prednisone",{"EARLY_PHASE1":732,"PHASE1":734,"PHASE2":736,"PHASE3":764,"PHASE4":766,"NA":768},{"trials":733,"activeCount":100},[],{"trials":735,"activeCount":100},[],{"trials":737,"activeCount":96,"soonestReadout":742},[738,753],{"nctId":739,"briefTitle":740,"status":139,"phases":741,"primaryCompletion":742,"completion":743,"start":744,"enrollment":745,"conditions":746,"interventions":750},"NCT06173362","Abiraterone and Prednisone or Darolutamide for the Treatment of Advanced Prostate Cancer",[89],"2026-11","2027-05","2023-11-09",75,[747,748,749],"Advanced Prostate Adenocarcinoma","Stage III Prostate Cancer AJCC v8","Stage IV Prostate Cancer AJCC v8",[751,752,730],"Abiraterone","Darolutamide",{"nctId":754,"briefTitle":755,"status":532,"phases":756,"primaryCompletion":757,"completion":757,"start":758,"enrollment":519,"conditions":759,"interventions":762},"NCT02844582","Cabazitaxel and Prednisone in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer",[89],"2019-06-04","2017-12-20",[760,761],"Hormone-Resistant Prostate Cancer","Stage IV Prostate Adenocarcinoma",[763,730],"Cabazitaxel",{"trials":765,"activeCount":100},[],{"trials":767,"activeCount":100},[],{"trials":769,"activeCount":100},[],{"intervention":771,"totalTrials":96,"cells":772},"Systemic (ICI)-based therapy informed by the PROphet CB assay and the CARG-TT assessment.",{"EARLY_PHASE1":773,"PHASE1":775,"PHASE2":777,"PHASE3":795,"PHASE4":797,"NA":799},{"trials":774,"activeCount":100},[],{"trials":776,"activeCount":100},[],{"trials":778,"activeCount":96,"soonestReadout":783},[779],{"nctId":780,"briefTitle":781,"status":139,"phases":782,"primaryCompletion":783,"completion":784,"start":785,"enrollment":786,"conditions":787,"interventions":793},"NCT07250477","Risk-adapted, Proteomic-guided Systemic Therapy for Previously Untreated Advanced Non-small Cell Lung Cancer",[89],"2036-05","2036-12","2026-01-30",56,[788,789,790,791,792],"Non-small Cell Lung Cancer Stage IIIC","Non-small Cell Lung Cancer Stage IV","Non Small Cell Lung Cancer","Non-small Cell Lung Cancer Metastatic","Non-small Cell Lung Cancer Unresectable",[771,794],"Standard of Care",{"trials":796,"activeCount":100},[],{"trials":798,"activeCount":100},[],{"trials":800,"activeCount":100},[],{"intervention":794,"totalTrials":96,"cells":802},{"EARLY_PHASE1":803,"PHASE1":805,"PHASE2":807,"PHASE3":813,"PHASE4":815,"NA":817},{"trials":804,"activeCount":100},[],{"trials":806,"activeCount":100},[],{"trials":808,"activeCount":96,"soonestReadout":783},[809],{"nctId":780,"briefTitle":781,"status":139,"phases":810,"primaryCompletion":783,"completion":784,"start":785,"enrollment":786,"conditions":811,"interventions":812},[89],[788,789,790,791,792],[771,794],{"trials":814,"activeCount":100},[],{"trials":816,"activeCount":100},[],{"trials":818,"activeCount":100},[],{"intervention":820,"totalTrials":96,"cells":821},"Azacitidine",{"EARLY_PHASE1":822,"PHASE1":824,"PHASE2":826,"PHASE3":840,"PHASE4":842,"NA":844},{"trials":823,"activeCount":100},[],{"trials":825,"activeCount":100},[],{"trials":827,"activeCount":96,"soonestReadout":832},[828],{"nctId":829,"briefTitle":830,"status":139,"phases":831,"primaryCompletion":832,"completion":833,"start":834,"enrollment":835,"conditions":836,"interventions":838},"NCT07304011","Olutasidenib With Azacitidine Followed by Olutasidenib Maintenance for the Treatment of IDH1-mutated Acute Myeloid Leukemia in Patients With Prior Treatment With Venetoclax Plus a Hypomethylating Agent",[89],"2031-01-01","2032-01-01","2025-12-17",28,[837],"Acute Myeloid Leukemia",[820,839],"Olutasidenib",{"trials":841,"activeCount":100},[],{"trials":843,"activeCount":100},[],{"trials":845,"activeCount":100},[],{"intervention":839,"totalTrials":96,"cells":847},{"EARLY_PHASE1":848,"PHASE1":850,"PHASE2":852,"PHASE3":858,"PHASE4":860,"NA":862},{"trials":849,"activeCount":100},[],{"trials":851,"activeCount":100},[],{"trials":853,"activeCount":96,"soonestReadout":832},[854],{"nctId":829,"briefTitle":830,"status":139,"phases":855,"primaryCompletion":832,"completion":833,"start":834,"enrollment":835,"conditions":856,"interventions":857},[89],[837],[820,839],{"trials":859,"activeCount":100},[],{"trials":861,"activeCount":100},[],{"trials":863,"activeCount":100},[],{"intervention":751,"totalTrials":96,"cells":865},{"EARLY_PHASE1":866,"PHASE1":868,"PHASE2":870,"PHASE3":876,"PHASE4":878,"NA":880},{"trials":867,"activeCount":100},[],{"trials":869,"activeCount":100},[],{"trials":871,"activeCount":96,"soonestReadout":742},[872],{"nctId":739,"briefTitle":740,"status":139,"phases":873,"primaryCompletion":742,"completion":743,"start":744,"enrollment":745,"conditions":874,"interventions":875},[89],[747,748,749],[751,752,730],{"trials":877,"activeCount":100},[],{"trials":879,"activeCount":100},[],{"trials":881,"activeCount":100},[],{"intervention":752,"totalTrials":96,"cells":883},{"EARLY_PHASE1":884,"PHASE1":886,"PHASE2":888,"PHASE3":894,"PHASE4":896,"NA":898},{"trials":885,"activeCount":100},[],{"trials":887,"activeCount":100},[],{"trials":889,"activeCount":96,"soonestReadout":742},[890],{"nctId":739,"briefTitle":740,"status":139,"phases":891,"primaryCompletion":742,"completion":743,"start":744,"enrollment":745,"conditions":892,"interventions":893},[89],[747,748,749],[751,752,730],{"trials":895,"activeCount":100},[],{"trials":897,"activeCount":100},[],{"trials":899,"activeCount":100},[],{"intervention":901,"totalTrials":96,"cells":902},"Sodium bicarbonate",{"EARLY_PHASE1":903,"PHASE1":905,"PHASE2":907,"PHASE3":924,"PHASE4":926,"NA":928},{"trials":904,"activeCount":100},[],{"trials":906,"activeCount":100},[],{"trials":908,"activeCount":96,"soonestReadout":489},[909],{"nctId":910,"briefTitle":911,"status":139,"phases":912,"primaryCompletion":489,"completion":489,"start":913,"enrollment":914,"conditions":915,"interventions":923},"NCT04984226","Sodium Bicarbonate and Mitochondrial Energetics in Persons With CKD",[89],"2023-09-08",80,[916,917,918,919,920,921,922],"Chronic Kidney Diseases","Metabolic Acidosis","Fatigue","Physical Endurance","Insulin Resistance","Mitochondrial Energetics","Diabetes",[901],{"trials":925,"activeCount":100},[],{"trials":927,"activeCount":100},[],{"trials":929,"activeCount":100},[],{"intervention":931,"totalTrials":96,"cells":932},"Tart Cherry Juice",{"EARLY_PHASE1":933,"PHASE1":935,"PHASE2":937,"PHASE3":985,"PHASE4":987,"NA":989},{"trials":934,"activeCount":100},[],{"trials":936,"activeCount":100},[],{"trials":938,"activeCount":96,"soonestReadout":943},[939],{"nctId":940,"briefTitle":941,"status":139,"phases":942,"primaryCompletion":943,"completion":944,"start":945,"enrollment":946,"conditions":947,"interventions":984},"NCT06268665","Tart Cherry Juice as a Dietary Supplement for the Prevention of Paclitaxel-Induced Neuropathy",[89],"2027-10","2027-12","2024-08-15",86,[21,948,949,950,951,952,953,954,955,956,957,958,959,960,961,962,963,964,965,966,967,968,969,970,971,972,973,974,975,976,977,978,979,980,981,982,983],"Breast Cancer Stage I","Breast Cancer Stage II","Breast Cancer Stage III","Breast Cancer Stage IV","Invasive Breast Cancer","Ovarian Cancer","Ovarian Cancer Stage 1","Ovarian Cancer Stage II","Ovarian Cancer Stage III","Ovarian Cancer Stage IV","Ovarian Cancer Stage IA","Ovarian Cancer Stage IB","Ovarian Cancer Stage IC","Ovarian Cancer Stage 2","Ovarian Cancer Stage 3","Ovarian Cancer Stage IIIb","Ovarian Cancer Stage IIIC","Breast Cancer Stage IIIA","Breast Cancer Invasive","Breast Cancer, Stage IA","Breast Cancer, Stage IB","Breast Cancer Stage IIA","Breast Cancer Stage IIB","Breast Cancer Stage IIIB","Breast Cancer Stage IIIc","Cancer, Breast","Tumors, Breast","Mammary Cancer","Mammary Carcinoma","Breast Carcinoma","Breast Neoplasm","Malignant Breast Neoplasm","Malignant Tumor of Breast","Cancer of Ovary","Ovary Cancer","Ovary Neoplasm",[931],{"trials":986,"activeCount":100},[],{"trials":988,"activeCount":100},[],{"trials":990,"activeCount":100},[],{"intervention":992,"totalTrials":96,"cells":993},"Autologous Muscle Derived Cells for Gastro-Intestinal Repair",{"EARLY_PHASE1":994,"PHASE1":996,"PHASE2":998,"PHASE3":1009,"PHASE4":1011,"NA":1013},{"trials":995,"activeCount":100},[],{"trials":997,"activeCount":100},[],{"trials":999,"activeCount":96,"soonestReadout":489},[1000],{"nctId":1001,"briefTitle":1002,"status":112,"phases":1003,"primaryCompletion":489,"completion":489,"start":1004,"enrollment":1005,"conditions":1006,"interventions":1008},"NCT05421689","Autologous Muscle Derived Cells for Treatment of Tongue Dysphagia",[88,89],"2022-05-26",66,[1007],"Oropharyngeal Dysphagia",[992],{"trials":1010,"activeCount":100},[],{"trials":1012,"activeCount":100},[],{"trials":1014,"activeCount":100},[],{"intervention":1016,"totalTrials":96,"cells":1017},"Pneumovax-23",{"EARLY_PHASE1":1018,"PHASE1":1020,"PHASE2":1022,"PHASE3":1032,"PHASE4":1034,"NA":1036},{"trials":1019,"activeCount":100},[],{"trials":1021,"activeCount":100},[],{"trials":1023,"activeCount":96,"soonestReadout":612},[1024],{"nctId":1025,"briefTitle":1026,"status":139,"phases":1027,"primaryCompletion":612,"completion":612,"start":1028,"enrollment":745,"conditions":1029,"interventions":1031},"NCT02232191","Immunologic Response to Pneumococcal Polysaccharide Vaccine in Splenic Injury Patients",[89],"2014-12",[1030],"Asplenia",[1016],{"trials":1033,"activeCount":100},[],{"trials":1035,"activeCount":100},[],{"trials":1037,"activeCount":100},[],{"intervention":1039,"totalTrials":96,"cells":1040},"Timolol 0.5% Ophthalmic Solution",{"EARLY_PHASE1":1041,"PHASE1":1043,"PHASE2":1045,"PHASE3":1059,"PHASE4":1061,"NA":1063},{"trials":1042,"activeCount":100},[],{"trials":1044,"activeCount":100},[],{"trials":1046,"activeCount":96,"soonestReadout":1052},[1047],{"nctId":1048,"briefTitle":1049,"status":1050,"phases":1051,"primaryCompletion":1052,"completion":1053,"start":65,"enrollment":1054,"conditions":1055,"interventions":1058},"NCT07384767","Efficacy and Safety of Topical Timolol in Secondary Intention Surgical Wounds Healing","NOT_YET_RECRUITING",[89],"2027-09-01","2027-12-31",220,[1056,1057],"Mohs Micrographic Surgery","Excision Margin",[1039],{"trials":1060,"activeCount":100},[],{"trials":1062,"activeCount":100},[],{"trials":1064,"activeCount":100},[],{"intervention":686,"totalTrials":96,"cells":1066},{"EARLY_PHASE1":1067,"PHASE1":1069,"PHASE2":1071,"PHASE3":1077,"PHASE4":1079,"NA":1081},{"trials":1068,"activeCount":100},[],{"trials":1070,"activeCount":100},[],{"trials":1072,"activeCount":96,"soonestReadout":677},[1073],{"nctId":674,"briefTitle":675,"status":112,"phases":1074,"primaryCompletion":677,"completion":677,"start":654,"enrollment":272,"conditions":1075,"interventions":1076},[89],[679,680,681,682,683,684],[624,686,687],{"trials":1078,"activeCount":100},[],{"trials":1080,"activeCount":100},[],{"trials":1082,"activeCount":100},[],{"intervention":687,"totalTrials":96,"cells":1084},{"EARLY_PHASE1":1085,"PHASE1":1087,"PHASE2":1089,"PHASE3":1095,"PHASE4":1097,"NA":1099},{"trials":1086,"activeCount":100},[],{"trials":1088,"activeCount":100},[],{"trials":1090,"activeCount":96,"soonestReadout":677},[1091],{"nctId":674,"briefTitle":675,"status":112,"phases":1092,"primaryCompletion":677,"completion":677,"start":654,"enrollment":272,"conditions":1093,"interventions":1094},[89],[679,680,681,682,683,684],[624,686,687],{"trials":1096,"activeCount":100},[],{"trials":1098,"activeCount":100},[],{"trials":1100,"activeCount":100},[],{"intervention":1102,"totalTrials":96,"cells":1103},"Chemotherapy",{"EARLY_PHASE1":1104,"PHASE1":1106,"PHASE2":1108,"PHASE3":1121,"PHASE4":1123,"NA":1125},{"trials":1105,"activeCount":100},[],{"trials":1107,"activeCount":100},[],{"trials":1109,"activeCount":96,"soonestReadout":489},[1110],{"nctId":1111,"briefTitle":1112,"status":112,"phases":1113,"primaryCompletion":489,"completion":1114,"start":1115,"enrollment":19,"conditions":1116,"interventions":1120},"NCT05763199","Standardized Extract of Cultured Lentinula Edodes Mycelia (AHCC®) in Ovarian Cancer Patients on Adjuvant Chemotherapy",[89],"2027-03-01","2023-08-01",[1117,1118,1119],"Ovarian Epithelial Carcinoma","Fallopian Tube Carcinoma","Peritoneal Carcinoma",[1102],{"trials":1122,"activeCount":100},[],{"trials":1124,"activeCount":100},[],{"trials":1126,"activeCount":100},[],{"intervention":1128,"totalTrials":96,"cells":1129},"Alendronate Sodium",{"EARLY_PHASE1":1130,"PHASE1":1132,"PHASE2":1134,"PHASE3":1148,"PHASE4":1150,"NA":1152},{"trials":1131,"activeCount":100},[],{"trials":1133,"activeCount":100},[],{"trials":1135,"activeCount":96,"soonestReadout":489},[1136],{"nctId":1137,"briefTitle":1138,"status":139,"phases":1139,"primaryCompletion":489,"completion":1053,"start":1140,"enrollment":142,"conditions":1141,"interventions":1147},"NCT06016634","Alendronate for Osteonecrosis in Adults With Sickle Cell Disease",[89],"2026-03-09",[1142,1143,1144,1145,1146],"Sickle Cell Disease","Sickle Cell Anemia","Osteonecrosis","Ischemic Necrosis","Avascular Necrosis",[1128],{"trials":1149,"activeCount":100},[],{"trials":1151,"activeCount":100},[],{"trials":1153,"activeCount":100},[],{"intervention":1155,"totalTrials":96,"cells":1156},"Placental Mesenchymal Stem Cells seeded on a commercially available dural graft extracellular matrix",{"EARLY_PHASE1":1157,"PHASE1":1159,"PHASE2":1161,"PHASE3":1173,"PHASE4":1175,"NA":1177},{"trials":1158,"activeCount":100},[],{"trials":1160,"activeCount":100},[],{"trials":1162,"activeCount":96,"soonestReadout":1167},[1163],{"nctId":1164,"briefTitle":1165,"status":139,"phases":1166,"primaryCompletion":1167,"completion":1167,"start":1168,"enrollment":1169,"conditions":1170,"interventions":1172},"NCT04652908","Cellular Therapy for In Utero Repair of Myelomeningocele - The CuRe Trial",[88,89],"2027-03","2021-06-21",55,[1171],"Myelomeningocele",[1155],{"trials":1174,"activeCount":100},[],{"trials":1176,"activeCount":100},[],{"trials":1178,"activeCount":100},[],{"intervention":1180,"totalTrials":96,"cells":1181},"Signatera Genome ultra-sensitive ctDNA blood test + total neoadjuvant therapy",{"EARLY_PHASE1":1182,"PHASE1":1184,"PHASE2":1186,"PHASE3":1201,"PHASE4":1203,"NA":1205},{"trials":1183,"activeCount":100},[],{"trials":1185,"activeCount":100},[],{"trials":1187,"activeCount":96,"soonestReadout":1192},[1188],{"nctId":1189,"briefTitle":1190,"status":1050,"phases":1191,"primaryCompletion":1192,"completion":1193,"start":1194,"enrollment":184,"conditions":1195,"interventions":1200},"NCT07209215","ctDNA-Informed Management of Early-Stage Rectal Cancer",[89],"2027-11","2028-05","2026-03",[1196,1197,1198,1199],"Rectal Adenocarcinoma","Rectal Cancer","Early-stage Rectal Cancer","Locally Advanced Rectal Adenocarcinoma",[1180],{"trials":1202,"activeCount":100},[],{"trials":1204,"activeCount":100},[],{"trials":1206,"activeCount":100},[],{"intervention":61,"totalTrials":96,"cells":1208},{"EARLY_PHASE1":1209,"PHASE1":1211,"PHASE2":1213,"PHASE3":1222,"PHASE4":1224,"NA":1226},{"trials":1210,"activeCount":100},[],{"trials":1212,"activeCount":100},[],{"trials":1214,"activeCount":96,"soonestReadout":56},[1215],{"nctId":59,"briefTitle":60,"status":139,"phases":1216,"primaryCompletion":56,"completion":56,"start":1217,"enrollment":1169,"conditions":1218,"interventions":1221},[89],"2022-03-18",[1219,1220],"Mild Cognitive Impairment","Alzheimer Disease",[61],{"trials":1223,"activeCount":100},[],{"trials":1225,"activeCount":100},[],{"trials":1227,"activeCount":100},[],{"intervention":1229,"totalTrials":96,"cells":1230},"Adjuvant Definitive Therapy",{"EARLY_PHASE1":1231,"PHASE1":1233,"PHASE2":1235,"PHASE3":1250,"PHASE4":1252,"NA":1254},{"trials":1232,"activeCount":100},[],{"trials":1234,"activeCount":100},[],{"trials":1236,"activeCount":96,"soonestReadout":1241},[1237],{"nctId":1238,"briefTitle":1239,"status":139,"phases":1240,"primaryCompletion":1241,"completion":1242,"start":1243,"enrollment":1244,"conditions":1245,"interventions":1249},"NCT06990737","Phase 2 Pragmatic Trial of Sentinel Lymph Node Biopsy (SLNB) in Patients With Clinically Node-Negative (cN0), High-Risk Cutaneous Squamous Cell Carcinoma (cSCC) of the Head and Neck",[89],"2031-08-01","2032-08-01","2025-06-25",24,[1246,1247,1248],"Cutaneous Squamous Cell Carcinoma of the Head and Neck","Clinically Node-Negative (cN0)","High-Risk Cutaneous Squamous Cell Carcinoma (cSCC) of the Head and Neck",[1229],{"trials":1251,"activeCount":100},[],{"trials":1253,"activeCount":100},[],{"trials":1255,"activeCount":100},[],{"intervention":1257,"totalTrials":1258,"cells":1259},"[68Ga]Ga DOTA-5G and [177Lu]Lu DOTA-ABM-5G.",3,{"EARLY_PHASE1":1260,"PHASE1":1272,"PHASE2":1292,"PHASE3":1294,"PHASE4":1296,"NA":1298},{"trials":1261,"activeCount":96,"soonestReadout":1266},[1262],{"nctId":1263,"briefTitle":1264,"status":139,"phases":1265,"primaryCompletion":1266,"completion":1053,"start":1267,"enrollment":142,"conditions":1268,"interventions":1271},"NCT04665947","First-in-human Study of the Theranostic Pair [68Ga]Ga DOTA-5G and [177Lu]Lu DOTA-ABM-5G in Pancreatic Cancer",[87],"2027-07-31","2020-12-18",[1269,1270],"Metastatic Pancreatic Cancer","Locally Advanced Pancreatic Adenocarcinoma",[1257],{"trials":1273,"activeCount":519,"soonestReadout":718},[1274,1282],{"nctId":1275,"briefTitle":1276,"status":139,"phases":1277,"primaryCompletion":718,"completion":718,"start":1278,"enrollment":272,"conditions":1279,"interventions":1281},"NCT06228482","Molecularly Targeted Radionuclide Therapy Via the Integrin Alphavbeta6",[88],"2024-01-22",[1280],"Metastatic Nonsmall Cell Lung Cancer",[1257],{"nctId":1283,"briefTitle":1284,"status":139,"phases":1285,"primaryCompletion":1286,"completion":1287,"start":1288,"enrollment":272,"conditions":1289,"interventions":1291},"NCT06389123","Molecularly Targeted Theranostic Approach for the Detection and Treatment of Metastatic Carcinomas",[88],"2029-07-31","2029-12-31","2024-04-01",[1290],"Metastatic Cancer",[1257],{"trials":1293,"activeCount":100},[],{"trials":1295,"activeCount":100},[],{"trials":1297,"activeCount":100},[],{"trials":1299,"activeCount":100},[],{"intervention":1301,"totalTrials":625,"cells":1302},"Pembrolizumab",{"EARLY_PHASE1":1303,"PHASE1":1315,"PHASE2":1360,"PHASE3":1362,"PHASE4":1364,"NA":1366},{"trials":1304,"activeCount":100},[1305],{"nctId":1306,"briefTitle":1307,"status":634,"phases":1308,"primaryCompletion":1309,"completion":1309,"start":1310,"enrollment":1258,"conditions":1311,"interventions":1313},"NCT03224871","UCDCC#269: A Pilot Study of Interlesional IL-2 and RT in Patients With NSCLC.",[87],"2020-01-10","2017-08-11",[1312],"METASTATIC NON-SMALL CELL LUNG CANCER",[1314,661,1301],"Intralesional IL-2",{"trials":1316,"activeCount":519,"soonestReadout":56},[1317,1327,1348],{"nctId":54,"briefTitle":55,"status":139,"phases":1318,"primaryCompletion":56,"completion":1319,"start":1320,"enrollment":142,"conditions":1321,"interventions":1326},[88],"2026-12","2023-04-19",[1322,1323,1324,1325],"High Risk Non-Muscle Invasive Bladder Urothelial Carcinoma","Stage 0a Bladder Cancer AJCC v8","Stage 0is Bladder Cancer AJCC v8","Stage I Bladder Cancer AJCC v8",[57,1301],{"nctId":1328,"briefTitle":1329,"status":634,"phases":1330,"primaryCompletion":1331,"completion":1332,"start":1333,"enrollment":1334,"conditions":1335,"interventions":1345},"NCT02437370","Pembrolizumab and Docetaxel or Gemcitabine Hydrochloride in Treating Patients Urothelial Cancer",[88],"2019-08-07","2020-03-10","2015-09-01",32,[1336,1337,1338,1339,1340,1341,1342,1343,1344],"Metastatic Urothelial Carcinoma of the Renal Pelvis and Ureter","Recurrent Bladder Carcinoma","Recurrent Urothelial Carcinoma of the Renal Pelvis and Ureter","Regional Urothelial Carcinoma of the Renal Pelvis and Ureter","Stage III Bladder Urothelial Carcinoma","Stage III Urethral Cancer","Stage IV Bladder Urothelial Carcinoma","Stage IV Urethral Cancer","Urethral Urothelial Carcinoma",[1301,1346,1347],"Docetaxel","Gemcitabine Hydrochloride",{"nctId":1349,"briefTitle":1350,"status":139,"phases":1351,"primaryCompletion":1319,"completion":1352,"start":1353,"enrollment":1244,"conditions":1354,"interventions":1358},"NCT06211335","Losartan, Pembrolizumab and Stereotactic Body Radiation Therapy for the Treatment of Patients With Locally Recurrent, Refractory or Oligometastatic Head and Neck Squamous Cell Carcinoma",[88],"2027-06","2023-12-07",[1355,1356,1357],"Locally Recurrent Head and Neck Squamous Cell Carcinoma","Metastatic Head and Neck Squamous Cell Carcinoma","Refractory Head and Neck Squamous Cell Carcinoma",[1359,1301],"Losartan",{"trials":1361,"activeCount":100},[],{"trials":1363,"activeCount":100},[],{"trials":1365,"activeCount":100},[],{"trials":1367,"activeCount":100},[],{"intervention":1369,"totalTrials":96,"cells":1370},"PLZ4-coated paclitaxel loaded micelles",{"EARLY_PHASE1":1371,"PHASE1":1373,"PHASE2":1384,"PHASE3":1386,"PHASE4":1388,"NA":1390},{"trials":1372,"activeCount":100},[],{"trials":1374,"activeCount":96,"soonestReadout":1319},[1375],{"nctId":1376,"briefTitle":1377,"status":139,"phases":1378,"primaryCompletion":1319,"completion":1352,"start":1379,"enrollment":1380,"conditions":1381,"interventions":1383},"NCT06173349","PLZ4-Coated Paclitaxel-Loaded Micelles for the Treatment of Patients With Recurrent or Refractory Non-Muscle Invasive Bladder Cancer",[88],"2023-11-22",12,[1382,1323,1324,1325],"Recurrent Non-Muscle Invasive Bladder Carcinoma",[1369],{"trials":1385,"activeCount":100},[],{"trials":1387,"activeCount":100},[],{"trials":1389,"activeCount":100},[],{"trials":1391,"activeCount":100},[],{"intervention":42,"totalTrials":96,"cells":1393},{"EARLY_PHASE1":1394,"PHASE1":1396,"PHASE2":1405,"PHASE3":1407,"PHASE4":1409,"NA":1411},{"trials":1395,"activeCount":100},[],{"trials":1397,"activeCount":96,"soonestReadout":41},[1398],{"nctId":39,"briefTitle":40,"status":112,"phases":1399,"primaryCompletion":41,"completion":1400,"start":1401,"enrollment":142,"conditions":1402,"interventions":1404},[88],"2026-08-14","2020-02-01",[1403],"Epilepsy, Post-Traumatic",[42],{"trials":1406,"activeCount":100},[],{"trials":1408,"activeCount":100},[],{"trials":1410,"activeCount":100},[],{"trials":1412,"activeCount":100},[],{"intervention":1414,"totalTrials":96,"cells":1415},"Desonide 0.05%",{"EARLY_PHASE1":1416,"PHASE1":1418,"PHASE2":1429,"PHASE3":1431,"PHASE4":1433,"NA":1435},{"trials":1417,"activeCount":100},[],{"trials":1419,"activeCount":96,"soonestReadout":1424},[1420],{"nctId":1421,"briefTitle":1422,"status":139,"phases":1423,"primaryCompletion":1424,"completion":1424,"start":1425,"enrollment":1244,"conditions":1426,"interventions":1427},"NCT03437005","Alternation in the Human Microbiome With Commonly Used Topical Medications",[88],"2026-09-28","2013-01-28",[15],[1414,1428],"Ketoconazole 2%",{"trials":1430,"activeCount":100},[],{"trials":1432,"activeCount":100},[],{"trials":1434,"activeCount":100},[],{"trials":1436,"activeCount":100},[],{"intervention":1428,"totalTrials":96,"cells":1438},{"EARLY_PHASE1":1439,"PHASE1":1441,"PHASE2":1447,"PHASE3":1449,"PHASE4":1451,"NA":1453},{"trials":1440,"activeCount":100},[],{"trials":1442,"activeCount":96,"soonestReadout":1424},[1443],{"nctId":1421,"briefTitle":1422,"status":139,"phases":1444,"primaryCompletion":1424,"completion":1424,"start":1425,"enrollment":1244,"conditions":1445,"interventions":1446},[88],[15],[1414,1428],{"trials":1448,"activeCount":100},[],{"trials":1450,"activeCount":100},[],{"trials":1452,"activeCount":100},[],{"trials":1454,"activeCount":100},[],{"intervention":57,"totalTrials":96,"cells":1456},{"EARLY_PHASE1":1457,"PHASE1":1459,"PHASE2":1465,"PHASE3":1467,"PHASE4":1469,"NA":1471},{"trials":1458,"activeCount":100},[],{"trials":1460,"activeCount":96,"soonestReadout":56},[1461],{"nctId":54,"briefTitle":55,"status":139,"phases":1462,"primaryCompletion":56,"completion":1319,"start":1320,"enrollment":142,"conditions":1463,"interventions":1464},[88],[1322,1323,1324,1325],[57,1301],{"trials":1466,"activeCount":100},[],{"trials":1468,"activeCount":100},[],{"trials":1470,"activeCount":100},[],{"trials":1472,"activeCount":100},[],{"intervention":1474,"totalTrials":96,"cells":1475},"Methylphenidate Oral Solution",{"EARLY_PHASE1":1476,"PHASE1":1478,"PHASE2":1493,"PHASE3":1495,"PHASE4":1497,"NA":1499},{"trials":1477,"activeCount":100},[],{"trials":1479,"activeCount":96,"soonestReadout":1484},[1480],{"nctId":1481,"briefTitle":1482,"status":223,"phases":1483,"primaryCompletion":1484,"completion":1484,"start":1485,"enrollment":1486,"conditions":1487,"interventions":1492},"NCT05301361","Sensitivity of the NIH Toolbox to Stimulant Treatment in Intellectual Disabilities",[88],"2026-09-29","2023-02-01",68,[1488,1489,1490,1491],"Intellectual Disability","Fragile X Syndrome","Down Syndrome","Attention Deficit Hyperactivity Disorder",[1474],{"trials":1494,"activeCount":100},[],{"trials":1496,"activeCount":100},[],{"trials":1498,"activeCount":100},[],{"trials":1500,"activeCount":100},[],{"intervention":1502,"totalTrials":96,"cells":1503},"Lomustine",{"EARLY_PHASE1":1504,"PHASE1":1506,"PHASE2":1517,"PHASE3":1519,"PHASE4":1521,"NA":1523},{"trials":1505,"activeCount":100},[],{"trials":1507,"activeCount":96,"soonestReadout":1512},[1508],{"nctId":1509,"briefTitle":1510,"status":139,"phases":1511,"primaryCompletion":1512,"completion":944,"start":1513,"enrollment":19,"conditions":1514,"interventions":1516},"NCT07145112","Laser Interstitial Thermal Therapy (LITT) and Lomustine (CCNU) for Recurrent Glioblastoma",[88],"2027-07","2025-10-01",[1515],"Glioblastoma",[1502],{"trials":1518,"activeCount":100},[],{"trials":1520,"activeCount":100},[],{"trials":1522,"activeCount":100},[],{"trials":1524,"activeCount":100},[],{"intervention":1526,"totalTrials":96,"cells":1527},"[18F]-αvβ6-BP",{"EARLY_PHASE1":1528,"PHASE1":1530,"PHASE2":1541,"PHASE3":1543,"PHASE4":1545,"NA":1547},{"trials":1529,"activeCount":100},[],{"trials":1531,"activeCount":96,"soonestReadout":489},[1532],{"nctId":1533,"briefTitle":1534,"status":139,"phases":1535,"primaryCompletion":489,"completion":489,"start":1536,"enrollment":19,"conditions":1537,"interventions":1540},"NCT05452005","Fluorine-18-AlphaVBeta6-Binding Peptide Positron Emission Tomography in Metastatic Non-Small Cell Lung Cancer",[88],"2022-09-13",[30,1538,1539,790],"Lung Cancer Metastatic","Brain Metastases",[1526],{"trials":1542,"activeCount":100},[],{"trials":1544,"activeCount":100},[],{"trials":1546,"activeCount":100},[],{"trials":1548,"activeCount":100},[],{"intervention":1550,"totalTrials":96,"cells":1551},"CD34+ bone marrow stem cells intravitreal",{"EARLY_PHASE1":1552,"PHASE1":1554,"PHASE2":1569,"PHASE3":1571,"PHASE4":1573,"NA":1575},{"trials":1553,"activeCount":100},[],{"trials":1555,"activeCount":96,"soonestReadout":613},[1556],{"nctId":1557,"briefTitle":1558,"status":112,"phases":1559,"primaryCompletion":613,"completion":613,"start":1560,"enrollment":1561,"conditions":1562,"interventions":1568},"NCT01736059","Clinical Trial of Autologous Intravitreal Bone-marrow CD34+ Stem Cells for Retinopathy",[88],"2012-07",15,[1563,1564,1565,1566,1567],"Non-exudative Age-related Macular Degeneration","Diabetic Retinopathy","Retina Vein Occlusion","Retinitis Pigmentosa","Hereditary Macular Degeneration",[1550],{"trials":1570,"activeCount":100},[],{"trials":1572,"activeCount":100},[],{"trials":1574,"activeCount":100},[],{"trials":1576,"activeCount":100},[],{"intervention":1359,"totalTrials":96,"cells":1578},{"EARLY_PHASE1":1579,"PHASE1":1581,"PHASE2":1587,"PHASE3":1589,"PHASE4":1591,"NA":1593},{"trials":1580,"activeCount":100},[],{"trials":1582,"activeCount":96,"soonestReadout":1319},[1583],{"nctId":1349,"briefTitle":1350,"status":139,"phases":1584,"primaryCompletion":1319,"completion":1352,"start":1353,"enrollment":1244,"conditions":1585,"interventions":1586},[88],[1355,1356,1357],[1359,1301],{"trials":1588,"activeCount":100},[],{"trials":1590,"activeCount":100},[],{"trials":1592,"activeCount":100},[],{"trials":1594,"activeCount":100},[],{"intervention":1596,"totalTrials":96,"cells":1597},"[68Ga]Ga DOTA-5G",{"EARLY_PHASE1":1598,"PHASE1":1600,"PHASE2":1610,"PHASE3":1612,"PHASE4":1614,"NA":1616},{"trials":1599,"activeCount":100},[],{"trials":1601,"activeCount":96,"soonestReadout":1352},[1602],{"nctId":1603,"briefTitle":1604,"status":139,"phases":1605,"primaryCompletion":1352,"completion":1352,"start":1606,"enrollment":142,"conditions":1607,"interventions":1609},"NCT07020806","[68Ga]Ga DOTA-5G as a Diagnostic Imaging Agent for Metastatic\u002FAdvanced Invasive Lobular Breast Cancer (LBC)",[88],"2025-11-18",[1608],"Metastatic Lobular Breast Carcinoma",[1596],{"trials":1611,"activeCount":100},[],{"trials":1613,"activeCount":100},[],{"trials":1615,"activeCount":100},[],{"trials":1617,"activeCount":100},[],{"intervention":75,"totalTrials":96,"cells":1619},{"EARLY_PHASE1":1620,"PHASE1":1622,"PHASE2":1645,"PHASE3":1647,"PHASE4":1649,"NA":1651},{"trials":1621,"activeCount":100},[],{"trials":1623,"activeCount":96,"soonestReadout":74},[1624],{"nctId":72,"briefTitle":73,"status":139,"phases":1625,"primaryCompletion":74,"completion":1319,"start":1626,"enrollment":569,"conditions":1627,"interventions":1644},[88],"2023-06-02",[1628,1629,1630,1631,1632,1633,1634,1635,1636,1637,1638,1639,1640,1641,1642,1643],"Advanced Colorectal Carcinoma","Advanced Lung Non-Small Cell Carcinoma","Advanced Malignant Solid Neoplasm","Advanced Melanoma","Advanced Renal Cell Carcinoma","Advanced Triple-Negative Breast Carcinoma","Anatomic Stage III Breast Cancer AJCC v8","Anatomic Stage IV Breast Cancer (AJCC) v8","Clinical Stage III Cutaneous Melanoma AJCC v8","Clinical Stage IV Cutaneous Melanoma AJCC v8","Stage III Colorectal Cancer AJCC v8","Stage III Lung Cancer AJCC v8","Stage III Renal Cell Cancer AJCC v8","Stage IV Colorectal Cancer AJCC v8","Stage IV Lung Cancer AJCC v8","Stage IV Renal Cell Cancer AJCC v8",[75],{"trials":1646,"activeCount":100},[],{"trials":1648,"activeCount":100},[],{"trials":1650,"activeCount":100},[],{"trials":1652,"activeCount":100},[],{"intervention":1654,"totalTrials":96,"cells":1655},"TR-002",{"EARLY_PHASE1":1656,"PHASE1":1658,"PHASE2":1677,"PHASE3":1679,"PHASE4":1681,"NA":1683},{"trials":1657,"activeCount":100},[],{"trials":1659,"activeCount":96,"soonestReadout":1664},[1660],{"nctId":1661,"briefTitle":1662,"status":139,"phases":1663,"primaryCompletion":1664,"completion":1665,"start":1666,"enrollment":1667,"conditions":1668,"interventions":1676},"NCT07189195","TR-002 for the Treatment of Advanced, Unresectable or Metastatic Solid Tumors and Unresectable or Metastatic, Refractory Pancreatic Adenocarcinoma",[88],"2029-11-07","2030-02-07","2025-11-07",52,[1630,1669,1670,1671,1672,1673,1674,1675],"Metastatic Malignant Solid Neoplasm","Metastatic Pancreatic Adenocarcinoma","Refractory Pancreatic Adenocarcinoma","Stage III Pancreatic Cancer AJCC v8","Stage IV Pancreatic Cancer AJCC v8","Unresectable Malignant Solid Neoplasm","Unresectable Pancreatic Adenocarcinoma",[1654],{"trials":1678,"activeCount":100},[],{"trials":1680,"activeCount":100},[],{"trials":1682,"activeCount":100},[],{"trials":1684,"activeCount":100},[],{"intervention":1686,"totalTrials":1258,"cells":1687},"18F-FDG",{"EARLY_PHASE1":1688,"PHASE1":1722,"PHASE2":1724,"PHASE3":1726,"PHASE4":1728,"NA":1730},{"trials":1689,"activeCount":1258,"soonestReadout":612},[1690,1702,1711],{"nctId":1691,"briefTitle":1692,"status":112,"phases":1693,"primaryCompletion":1694,"completion":1695,"start":1696,"enrollment":1697,"conditions":1698,"interventions":1700},"NCT05876858","EXPLORER Total Body PET\u002FCT Imaging for Myofascial Pain",[87],"2026-09","2027-09","2023-06-13",53,[1699],"Myofascial Pain",[1686,1701],"11C-butanol",{"nctId":1703,"briefTitle":1704,"status":139,"phases":1705,"primaryCompletion":612,"completion":1512,"start":1706,"enrollment":1380,"conditions":1707,"interventions":1709},"NCT06453915","NeuroFLiPP: Parametric PET of Neuroinflammation in Fatty Liver Disease",[87],"2025-04-30",[1708],"Positron Emission Tomography",[1710,1686],"18F-DPA-714",{"nctId":1712,"briefTitle":1713,"status":139,"phases":1714,"primaryCompletion":1715,"completion":1716,"start":1717,"enrollment":293,"conditions":1718,"interventions":1721},"NCT06014515","Single-tracer Multiparametric PET Imaging",[87],"2028-08","2033-08","2024-02-14",[1719,1720],"Healthy Subjects","Cardiovascular Disease",[1686,1701],{"trials":1723,"activeCount":100},[],{"trials":1725,"activeCount":100},[],{"trials":1727,"activeCount":100},[],{"trials":1729,"activeCount":100},[],{"trials":1731,"activeCount":100},[],{"intervention":1701,"totalTrials":519,"cells":1733},{"EARLY_PHASE1":1734,"PHASE1":1744,"PHASE2":1746,"PHASE3":1748,"PHASE4":1750,"NA":1752},{"trials":1735,"activeCount":519,"soonestReadout":1694},[1736,1740],{"nctId":1691,"briefTitle":1692,"status":112,"phases":1737,"primaryCompletion":1694,"completion":1695,"start":1696,"enrollment":1697,"conditions":1738,"interventions":1739},[87],[1699],[1686,1701],{"nctId":1712,"briefTitle":1713,"status":139,"phases":1741,"primaryCompletion":1715,"completion":1716,"start":1717,"enrollment":293,"conditions":1742,"interventions":1743},[87],[1719,1720],[1686,1701],{"trials":1745,"activeCount":100},[],{"trials":1747,"activeCount":100},[],{"trials":1749,"activeCount":100},[],{"trials":1751,"activeCount":100},[],{"trials":1753,"activeCount":100},[],{"intervention":1755,"totalTrials":96,"cells":1756},"A.1 - [¹⁸F]F-AraG PET\u002FCT",{"EARLY_PHASE1":1757,"PHASE1":1773,"PHASE2":1775,"PHASE3":1777,"PHASE4":1779,"NA":1781},{"trials":1758,"activeCount":96,"soonestReadout":1763},[1759],{"nctId":1760,"briefTitle":1761,"status":139,"phases":1762,"primaryCompletion":1763,"completion":1764,"start":1765,"enrollment":1766,"conditions":1767,"interventions":1769},"NCT07076862","Multiparametric [18F]F-AraG Imaging in Post-Acute Sequelae of COVID-19 (PASC)",[87],"2028-12","2029-12","2025-12-04",51,[1768],"PASC Post Acute Sequelae of COVID-19",[1755,1770,1771,1772],"A.2 - [¹⁸F]F-AraG PET\u002FCT","B.1 - [¹⁸F]F-AraG PET\u002FCT","B.2 - [¹⁸F]F-AraG PET\u002FCT",{"trials":1774,"activeCount":100},[],{"trials":1776,"activeCount":100},[],{"trials":1778,"activeCount":100},[],{"trials":1780,"activeCount":100},[],{"trials":1782,"activeCount":100},[],{"intervention":1770,"totalTrials":96,"cells":1784},{"EARLY_PHASE1":1785,"PHASE1":1791,"PHASE2":1793,"PHASE3":1795,"PHASE4":1797,"NA":1799},{"trials":1786,"activeCount":96,"soonestReadout":1763},[1787],{"nctId":1760,"briefTitle":1761,"status":139,"phases":1788,"primaryCompletion":1763,"completion":1764,"start":1765,"enrollment":1766,"conditions":1789,"interventions":1790},[87],[1768],[1755,1770,1771,1772],{"trials":1792,"activeCount":100},[],{"trials":1794,"activeCount":100},[],{"trials":1796,"activeCount":100},[],{"trials":1798,"activeCount":100},[],{"trials":1800,"activeCount":100},[],{"intervention":1771,"totalTrials":96,"cells":1802},{"EARLY_PHASE1":1803,"PHASE1":1809,"PHASE2":1811,"PHASE3":1813,"PHASE4":1815,"NA":1817},{"trials":1804,"activeCount":96,"soonestReadout":1763},[1805],{"nctId":1760,"briefTitle":1761,"status":139,"phases":1806,"primaryCompletion":1763,"completion":1764,"start":1765,"enrollment":1766,"conditions":1807,"interventions":1808},[87],[1768],[1755,1770,1771,1772],{"trials":1810,"activeCount":100},[],{"trials":1812,"activeCount":100},[],{"trials":1814,"activeCount":100},[],{"trials":1816,"activeCount":100},[],{"trials":1818,"activeCount":100},[],{"intervention":1772,"totalTrials":96,"cells":1820},{"EARLY_PHASE1":1821,"PHASE1":1827,"PHASE2":1829,"PHASE3":1831,"PHASE4":1833,"NA":1835},{"trials":1822,"activeCount":96,"soonestReadout":1763},[1823],{"nctId":1760,"briefTitle":1761,"status":139,"phases":1824,"primaryCompletion":1763,"completion":1764,"start":1765,"enrollment":1766,"conditions":1825,"interventions":1826},[87],[1768],[1755,1770,1771,1772],{"trials":1828,"activeCount":100},[],{"trials":1830,"activeCount":100},[],{"trials":1832,"activeCount":100},[],{"trials":1834,"activeCount":100},[],{"trials":1836,"activeCount":100},[],{"intervention":1710,"totalTrials":96,"cells":1838},{"EARLY_PHASE1":1839,"PHASE1":1845,"PHASE2":1847,"PHASE3":1849,"PHASE4":1851,"NA":1853},{"trials":1840,"activeCount":96,"soonestReadout":612},[1841],{"nctId":1703,"briefTitle":1704,"status":139,"phases":1842,"primaryCompletion":612,"completion":1512,"start":1706,"enrollment":1380,"conditions":1843,"interventions":1844},[87],[1708],[1710,1686],{"trials":1846,"activeCount":100},[],{"trials":1848,"activeCount":100},[],{"trials":1850,"activeCount":100},[],{"trials":1852,"activeCount":100},[],{"trials":1854,"activeCount":100},[],{"intervention":70,"totalTrials":96,"cells":1856},{"EARLY_PHASE1":1857,"PHASE1":1864,"PHASE2":1866,"PHASE3":1868,"PHASE4":1870,"NA":1872},{"trials":1858,"activeCount":96,"soonestReadout":65},[1859],{"nctId":68,"briefTitle":69,"status":139,"phases":1860,"primaryCompletion":65,"completion":65,"start":1861,"enrollment":914,"conditions":1862,"interventions":1863},[87],"2025-06-01",[296],[70],{"trials":1865,"activeCount":100},[],{"trials":1867,"activeCount":100},[],{"trials":1869,"activeCount":100},[],{"trials":1871,"activeCount":100},[],{"trials":1873,"activeCount":100},[],{"intervention":1875,"totalTrials":96,"cells":1876},"CycloSPORINE Injectable Product",{"EARLY_PHASE1":1877,"PHASE1":1890,"PHASE2":1892,"PHASE3":1894,"PHASE4":1896,"NA":1898},{"trials":1878,"activeCount":96,"soonestReadout":1883},[1879],{"nctId":1880,"briefTitle":1881,"status":139,"phases":1882,"primaryCompletion":1883,"completion":1884,"start":1885,"enrollment":1380,"conditions":1886,"interventions":1888},"NCT07029204","Intralesional Cyclosporine for Alopecia Areata",[87],"2026-07-01","2026-10-01","2025-08-19",[1887],"Alopecia Areata",[1875,1889],"Saline Solution",{"trials":1891,"activeCount":100},[],{"trials":1893,"activeCount":100},[],{"trials":1895,"activeCount":100},[],{"trials":1897,"activeCount":100},[],{"trials":1899,"activeCount":100},[],{"intervention":1889,"totalTrials":96,"cells":1901},{"EARLY_PHASE1":1902,"PHASE1":1908,"PHASE2":1910,"PHASE3":1912,"PHASE4":1914,"NA":1916},{"trials":1903,"activeCount":96,"soonestReadout":1883},[1904],{"nctId":1880,"briefTitle":1881,"status":139,"phases":1905,"primaryCompletion":1883,"completion":1884,"start":1885,"enrollment":1380,"conditions":1906,"interventions":1907},[87],[1887],[1875,1889],{"trials":1909,"activeCount":100},[],{"trials":1911,"activeCount":100},[],{"trials":1913,"activeCount":100},[],{"trials":1915,"activeCount":100},[],{"trials":1917,"activeCount":100},[],{"intervention":1919,"totalTrials":519,"cells":1920},"Ropivacaine",{"EARLY_PHASE1":1921,"PHASE1":1923,"PHASE2":1925,"PHASE3":1927,"PHASE4":1929,"NA":1942},{"trials":1922,"activeCount":100},[],{"trials":1924,"activeCount":100},[],{"trials":1926,"activeCount":100},[],{"trials":1928,"activeCount":100},[],{"trials":1930,"activeCount":100},[1931],{"nctId":1932,"briefTitle":1933,"status":634,"phases":1934,"primaryCompletion":1935,"completion":1935,"start":1936,"enrollment":946,"conditions":1937,"interventions":1940},"NCT03080142","TAP Block Catheters vs Liposomal Bupivacaine for Pain Control After Colorectal Surgery",[91],"2019-05-29","2017-03-01",[1938,1939],"Colorectal Surgery","TAP Blocks",[1941,1919],"Exparel",{"trials":1943,"activeCount":96,"soonestReadout":1883},[1944],{"nctId":1945,"briefTitle":1946,"status":223,"phases":1947,"primaryCompletion":1883,"completion":1883,"start":1948,"enrollment":293,"conditions":1949,"interventions":1951},"NCT03365908","Pain Management of ACL Reconstruction",[92],"2017-10-09",[1950],"Anterior Cruciate Ligament Rupture",[1919],{"intervention":52,"totalTrials":96,"cells":1953},{"EARLY_PHASE1":1954,"PHASE1":1956,"PHASE2":1958,"PHASE3":1960,"PHASE4":1962,"NA":1964},{"trials":1955,"activeCount":100},[],{"trials":1957,"activeCount":100},[],{"trials":1959,"activeCount":100},[],{"trials":1961,"activeCount":100},[],{"trials":1963,"activeCount":100},[],{"trials":1965,"activeCount":96,"soonestReadout":51},[1966],{"nctId":49,"briefTitle":50,"status":223,"phases":1967,"primaryCompletion":51,"completion":1968,"start":1969,"enrollment":1970,"conditions":1971,"interventions":1973},[92],"2026-06-30","2019-09-10",1329,[1972],"First Episode Psychosis (FEP)",[52],{"intervention":1975,"totalTrials":96,"cells":1976},"Topical Diclofenac gel 1%",{"EARLY_PHASE1":1977,"PHASE1":1979,"PHASE2":1981,"PHASE3":1983,"PHASE4":1985,"NA":1987},{"trials":1978,"activeCount":100},[],{"trials":1980,"activeCount":100},[],{"trials":1982,"activeCount":100},[],{"trials":1984,"activeCount":100},[],{"trials":1986,"activeCount":100},[],{"trials":1988,"activeCount":96,"soonestReadout":1993},[1989],{"nctId":1990,"briefTitle":1991,"status":139,"phases":1992,"primaryCompletion":1993,"completion":1993,"start":1994,"enrollment":1054,"conditions":1995,"interventions":1997},"NCT06574191","The Effects of Patient and Visit Characteristics on Health Outcomes in Knee Osteoarthritis",[92],"2028-01-27","2025-01-29",[1996],"Knee Osteoarthritis",[1975],{"intervention":1999,"totalTrials":519,"cells":2000},"Etonogestrel contraceptive implant",{"EARLY_PHASE1":2001,"PHASE1":2003,"PHASE2":2005,"PHASE3":2007,"PHASE4":2009,"NA":2029},{"trials":2002,"activeCount":100},[],{"trials":2004,"activeCount":100},[],{"trials":2006,"activeCount":100},[],{"trials":2008,"activeCount":100},[],{"trials":2010,"activeCount":100},[2011,2020],{"nctId":2012,"briefTitle":2013,"status":634,"phases":2014,"primaryCompletion":2015,"completion":2015,"start":2016,"enrollment":19,"conditions":2017,"interventions":2019},"NCT02852265","Nexplanon and Combined Oral Contraceptive (COC) Combined Use Study",[91],"2017-07-26","2016-09-15",[2018],"Contraception",[1999],{"nctId":2021,"briefTitle":2022,"status":634,"phases":2023,"primaryCompletion":2024,"completion":2024,"start":2025,"enrollment":2026,"conditions":2027,"interventions":2028},"NCT04423055","Nexplanon Use in Women Primarily Choosing a Combined Oral Contraceptive",[91],"2024-04-09","2020-08-13",120,[2018],[1999],{"trials":2030,"activeCount":100},[],{"intervention":2032,"totalTrials":519,"cells":2033},"Acetaminophen",{"EARLY_PHASE1":2034,"PHASE1":2036,"PHASE2":2038,"PHASE3":2040,"PHASE4":2042,"NA":2068},{"trials":2035,"activeCount":100},[],{"trials":2037,"activeCount":100},[],{"trials":2039,"activeCount":100},[],{"trials":2041,"activeCount":100},[],{"trials":2043,"activeCount":100},[2044,2058],{"nctId":2045,"briefTitle":2046,"status":2047,"phases":2048,"primaryCompletion":2049,"completion":2049,"start":2050,"enrollment":100,"conditions":2051,"interventions":2054},"NCT03651804","Radiofrequency Ablation: Treatment for Posterior Element Pain From Vertebral Compression Fractures","WITHDRAWN",[91],"2023-12-19","2019-04-10",[2052,2053],"Vertebral Compression Fracture","Facet Joint Pain",[2055,2056,2032,2057],"Non-steroidal anti-inflammatory drugs","Bisphosphonates","Opioids",{"nctId":2059,"briefTitle":2060,"status":634,"phases":2061,"primaryCompletion":2062,"completion":2062,"start":2063,"enrollment":11,"conditions":2064,"interventions":2067},"NCT02994940","Modified Pre-operative Oral Doses Acetaminophen Versus Intravenous Acetaminophen",[91],"2019-07-03","2017-08-28",[2065,2066],"Tonsillectomy","Adenoidectomy",[2032],{"trials":2069,"activeCount":100},[],{"intervention":2071,"totalTrials":96,"cells":2072},"darunavir with ritonavir and fixed-dose viread+emtricitabine daily",{"EARLY_PHASE1":2073,"PHASE1":2075,"PHASE2":2077,"PHASE3":2079,"PHASE4":2081,"NA":2093},{"trials":2074,"activeCount":100},[],{"trials":2076,"activeCount":100},[],{"trials":2078,"activeCount":100},[],{"trials":2080,"activeCount":100},[],{"trials":2082,"activeCount":100},[2083],{"nctId":2084,"briefTitle":2085,"status":634,"phases":2086,"primaryCompletion":2087,"completion":2087,"start":2088,"enrollment":2089,"conditions":2090,"interventions":2092},"NCT01869634","Mechanisms of Immune Reconstitution & Reduced Immune Activation Following Darunavir-based ART",[91],"2016-12","2013-06",37,[2091],"Human Immunodeficiency Virus Infection",[2071],{"trials":2094,"activeCount":100},[],{"intervention":2096,"totalTrials":96,"cells":2097},"Envarsus",{"EARLY_PHASE1":2098,"PHASE1":2100,"PHASE2":2102,"PHASE3":2104,"PHASE4":2106,"NA":2122},{"trials":2099,"activeCount":100},[],{"trials":2101,"activeCount":100},[],{"trials":2103,"activeCount":100},[],{"trials":2105,"activeCount":100},[],{"trials":2107,"activeCount":100},[2108],{"nctId":2109,"briefTitle":2110,"status":634,"phases":2111,"primaryCompletion":2112,"completion":2112,"start":2113,"enrollment":2114,"conditions":2115,"interventions":2120},"NCT03461445","Effect of Tacrolimus Formulation on Neurological Side Effects in Older Kidney Transplant Recipients",[91],"2023-07-31","2018-04-01",64,[2116,2117,2118,2119],"Kidney Transplant; Complications","Toxicity","Drug Toxicity","Neurotoxicity",[2096,2121],"IR Tacrolimus",{"trials":2123,"activeCount":100},[],{"intervention":2121,"totalTrials":96,"cells":2125},{"EARLY_PHASE1":2126,"PHASE1":2128,"PHASE2":2130,"PHASE3":2132,"PHASE4":2134,"NA":2140},{"trials":2127,"activeCount":100},[],{"trials":2129,"activeCount":100},[],{"trials":2131,"activeCount":100},[],{"trials":2133,"activeCount":100},[],{"trials":2135,"activeCount":100},[2136],{"nctId":2109,"briefTitle":2110,"status":634,"phases":2137,"primaryCompletion":2112,"completion":2112,"start":2113,"enrollment":2114,"conditions":2138,"interventions":2139},[91],[2116,2117,2118,2119],[2096,2121],{"trials":2141,"activeCount":100},[],{"intervention":2143,"totalTrials":96,"cells":2144},"EE 30mcg\u002FLNG 150mcg",{"EARLY_PHASE1":2145,"PHASE1":2147,"PHASE2":2149,"PHASE3":2151,"PHASE4":2153,"NA":2166},{"trials":2146,"activeCount":100},[],{"trials":2148,"activeCount":100},[],{"trials":2150,"activeCount":100},[],{"trials":2152,"activeCount":100},[],{"trials":2154,"activeCount":100},[2155],{"nctId":2156,"briefTitle":2157,"status":532,"phases":2158,"primaryCompletion":2159,"completion":2160,"start":2161,"enrollment":16,"conditions":2162,"interventions":2165},"NCT01963403","Treatment of Unacceptable Bleeding Patterns in ETG Implant Users With an Oral Contraceptive",[91],"2015-07","2015-09","2013-12",[2163,2164],"Abnormal Uterine Bleeding, Unspecified","Uterine Bleeding Heavy",[2143],{"trials":2167,"activeCount":100},[],{"intervention":2169,"totalTrials":96,"cells":2170},"Omalizumab",{"EARLY_PHASE1":2171,"PHASE1":2173,"PHASE2":2175,"PHASE3":2177,"PHASE4":2179,"NA":2193},{"trials":2172,"activeCount":100},[],{"trials":2174,"activeCount":100},[],{"trials":2176,"activeCount":100},[],{"trials":2178,"activeCount":100},[],{"trials":2180,"activeCount":100},[2181],{"nctId":2182,"briefTitle":2183,"status":634,"phases":2184,"primaryCompletion":2185,"completion":2185,"start":2186,"enrollment":2187,"conditions":2188,"interventions":2192},"NCT00367016","Immunologic Basis of Anti-IgE Therapy (Study II: On Patients With Asthma)",[91],"2012-10-17","2004-02",6,[2189,2190,2191],"Asthma","Allergic Rhinitis","Atopic Dermatitis",[2169],{"trials":2194,"activeCount":100},[],{"intervention":2196,"totalTrials":96,"cells":2197},"Tacrolimus",{"EARLY_PHASE1":2198,"PHASE1":2200,"PHASE2":2202,"PHASE3":2204,"PHASE4":2206,"NA":2216},{"trials":2199,"activeCount":100},[],{"trials":2201,"activeCount":100},[],{"trials":2203,"activeCount":100},[],{"trials":2205,"activeCount":100},[],{"trials":2207,"activeCount":100},[2208],{"nctId":2209,"briefTitle":2210,"status":2047,"phases":2211,"completion":2212,"start":2213,"enrollment":100,"conditions":2214,"interventions":2215},"NCT00368719","Evaluation to Assess the Long Term Safety of Tacrolimus Ointment for Atopic Dermatitis",[91],"2016-07","2007-09",[2191],[2196],{"trials":2217,"activeCount":100},[],{"intervention":2219,"totalTrials":96,"cells":2220},"Flumazenil",{"EARLY_PHASE1":2221,"PHASE1":2223,"PHASE2":2225,"PHASE3":2227,"PHASE4":2229,"NA":2240},{"trials":2222,"activeCount":100},[],{"trials":2224,"activeCount":100},[],{"trials":2226,"activeCount":100},[],{"trials":2228,"activeCount":100},[],{"trials":2230,"activeCount":100},[2231],{"nctId":2232,"briefTitle":2233,"status":532,"phases":2234,"primaryCompletion":2235,"completion":2235,"start":719,"enrollment":2236,"conditions":2237,"interventions":2239},"NCT02899156","Flumazenil for Hypoactive Delirium Secondary to Benzodiazepine Exposure",[91],"2019-04-16",22,[2238],"Hypoactive Delirium",[2219],{"trials":2241,"activeCount":100},[],{"intervention":2243,"totalTrials":96,"cells":2244},"Micronutrient supplements",{"EARLY_PHASE1":2245,"PHASE1":2247,"PHASE2":2249,"PHASE3":2251,"PHASE4":2253,"NA":2265},{"trials":2246,"activeCount":100},[],{"trials":2248,"activeCount":100},[],{"trials":2250,"activeCount":100},[],{"trials":2252,"activeCount":100},[],{"trials":2254,"activeCount":100},[2255],{"nctId":2256,"briefTitle":2257,"status":634,"phases":2258,"completion":2259,"start":2260,"enrollment":2261,"conditions":2262,"interventions":2264},"NCT00379158","Comparison of the Efficacy and Acceptability of Three Types of Micronutrient Supplements in Ghana",[91],"2005-04","2003-10",393,[2263],"Micronutrients",[2243],{"trials":2266,"activeCount":100},[],{"intervention":2268,"totalTrials":96,"cells":2269},"maraviroc in combination with 2 NRTIs",{"EARLY_PHASE1":2270,"PHASE1":2272,"PHASE2":2274,"PHASE3":2276,"PHASE4":2278,"NA":2292},{"trials":2271,"activeCount":100},[],{"trials":2273,"activeCount":100},[],{"trials":2275,"activeCount":100},[],{"trials":2277,"activeCount":100},[],{"trials":2279,"activeCount":100},[2280],{"nctId":2281,"briefTitle":2282,"status":634,"phases":2283,"primaryCompletion":2284,"completion":2284,"start":2285,"enrollment":2286,"conditions":2287,"interventions":2289},"NCT00870363","A Pilot Project of Virologic, Pharmacologic and Immunologic Correlates of Gastrointestinal-Associated Lymphoid Tissue Immune Reconstitution Following Maraviroc Therapy",[91],"2013-04","2009-04",44,[2288],"HIV Infections",[2268,2290,2291],"maraviroc plus raltegravir in combination with 2 NRTIs","efavirenz [or other NNRTI (non-nucleoside reverse transcriptase inhibitor)]",{"trials":2293,"activeCount":100},[],{"intervention":2290,"totalTrials":96,"cells":2295},{"EARLY_PHASE1":2296,"PHASE1":2298,"PHASE2":2300,"PHASE3":2302,"PHASE4":2304,"NA":2310},{"trials":2297,"activeCount":100},[],{"trials":2299,"activeCount":100},[],{"trials":2301,"activeCount":100},[],{"trials":2303,"activeCount":100},[],{"trials":2305,"activeCount":100},[2306],{"nctId":2281,"briefTitle":2282,"status":634,"phases":2307,"primaryCompletion":2284,"completion":2284,"start":2285,"enrollment":2286,"conditions":2308,"interventions":2309},[91],[2288],[2268,2290,2291],{"trials":2311,"activeCount":100},[],{"intervention":2291,"totalTrials":96,"cells":2313},{"EARLY_PHASE1":2314,"PHASE1":2316,"PHASE2":2318,"PHASE3":2320,"PHASE4":2322,"NA":2328},{"trials":2315,"activeCount":100},[],{"trials":2317,"activeCount":100},[],{"trials":2319,"activeCount":100},[],{"trials":2321,"activeCount":100},[],{"trials":2323,"activeCount":100},[2324],{"nctId":2281,"briefTitle":2282,"status":634,"phases":2325,"primaryCompletion":2284,"completion":2284,"start":2285,"enrollment":2286,"conditions":2326,"interventions":2327},[91],[2288],[2268,2290,2291],{"trials":2329,"activeCount":100},[],{"intervention":2055,"totalTrials":96,"cells":2331},{"EARLY_PHASE1":2332,"PHASE1":2334,"PHASE2":2336,"PHASE3":2338,"PHASE4":2340,"NA":2346},{"trials":2333,"activeCount":100},[],{"trials":2335,"activeCount":100},[],{"trials":2337,"activeCount":100},[],{"trials":2339,"activeCount":100},[],{"trials":2341,"activeCount":100},[2342],{"nctId":2045,"briefTitle":2046,"status":2047,"phases":2343,"primaryCompletion":2049,"completion":2049,"start":2050,"enrollment":100,"conditions":2344,"interventions":2345},[91],[2052,2053],[2055,2056,2032,2057],{"trials":2347,"activeCount":100},[],{"intervention":2056,"totalTrials":96,"cells":2349},{"EARLY_PHASE1":2350,"PHASE1":2352,"PHASE2":2354,"PHASE3":2356,"PHASE4":2358,"NA":2364},{"trials":2351,"activeCount":100},[],{"trials":2353,"activeCount":100},[],{"trials":2355,"activeCount":100},[],{"trials":2357,"activeCount":100},[],{"trials":2359,"activeCount":100},[2360],{"nctId":2045,"briefTitle":2046,"status":2047,"phases":2361,"primaryCompletion":2049,"completion":2049,"start":2050,"enrollment":100,"conditions":2362,"interventions":2363},[91],[2052,2053],[2055,2056,2032,2057],{"trials":2365,"activeCount":100},[],{"intervention":2057,"totalTrials":96,"cells":2367},{"EARLY_PHASE1":2368,"PHASE1":2370,"PHASE2":2372,"PHASE3":2374,"PHASE4":2376,"NA":2382},{"trials":2369,"activeCount":100},[],{"trials":2371,"activeCount":100},[],{"trials":2373,"activeCount":100},[],{"trials":2375,"activeCount":100},[],{"trials":2377,"activeCount":100},[2378],{"nctId":2045,"briefTitle":2046,"status":2047,"phases":2379,"primaryCompletion":2049,"completion":2049,"start":2050,"enrollment":100,"conditions":2380,"interventions":2381},[91],[2052,2053],[2055,2056,2032,2057],{"trials":2383,"activeCount":100},[],{"intervention":2385,"totalTrials":96,"cells":2386},"Lovastatin",{"EARLY_PHASE1":2387,"PHASE1":2389,"PHASE2":2391,"PHASE3":2393,"PHASE4":2395,"NA":2406},{"trials":2388,"activeCount":100},[],{"trials":2390,"activeCount":100},[],{"trials":2392,"activeCount":100},[],{"trials":2394,"activeCount":100},[],{"trials":2396,"activeCount":100},[2397],{"nctId":2398,"briefTitle":2399,"status":634,"phases":2400,"primaryCompletion":2401,"completion":2401,"start":2402,"enrollment":142,"conditions":2403,"interventions":2405},"NCT02642653","Combining Lovastatin and a Parent-Implemented Language Intervention for Fragile X Syndrome",[91],"2018-07","2016-01",[1489,2404],"Genetic Diseases",[2385],{"trials":2407,"activeCount":100},[],{"intervention":2409,"totalTrials":96,"cells":2410},"Risedronate",{"EARLY_PHASE1":2411,"PHASE1":2413,"PHASE2":2415,"PHASE3":2417,"PHASE4":2419,"NA":2432},{"trials":2412,"activeCount":100},[],{"trials":2414,"activeCount":100},[],{"trials":2416,"activeCount":100},[],{"trials":2418,"activeCount":100},[],{"trials":2420,"activeCount":100},[2421],{"nctId":2422,"briefTitle":2423,"status":634,"phases":2424,"primaryCompletion":2425,"completion":2426,"start":2427,"enrollment":293,"conditions":2428,"interventions":2430},"NCT00221299","Risedronate and Parathyroid Hormone to Reverse Osteoporosis Caused by Chronic Steroid Use",[91],"2009-03","2009-05","2005-09",[2429],"Osteoporosis",[2409,2431],"Parathyroid Hormone",{"trials":2433,"activeCount":100},[],{"intervention":2431,"totalTrials":96,"cells":2435},{"EARLY_PHASE1":2436,"PHASE1":2438,"PHASE2":2440,"PHASE3":2442,"PHASE4":2444,"NA":2450},{"trials":2437,"activeCount":100},[],{"trials":2439,"activeCount":100},[],{"trials":2441,"activeCount":100},[],{"trials":2443,"activeCount":100},[],{"trials":2445,"activeCount":100},[2446],{"nctId":2422,"briefTitle":2423,"status":634,"phases":2447,"primaryCompletion":2425,"completion":2426,"start":2427,"enrollment":293,"conditions":2448,"interventions":2449},[91],[2429],[2409,2431],{"trials":2451,"activeCount":100},[],{"intervention":2453,"totalTrials":96,"cells":2454},"ER Morphine",{"EARLY_PHASE1":2455,"PHASE1":2457,"PHASE2":2459,"PHASE3":2461,"PHASE4":2463,"NA":2475},{"trials":2456,"activeCount":100},[],{"trials":2458,"activeCount":100},[],{"trials":2460,"activeCount":100},[],{"trials":2462,"activeCount":100},[],{"trials":2464,"activeCount":100},[2465],{"nctId":2466,"briefTitle":2467,"status":634,"phases":2468,"primaryCompletion":2469,"completion":2469,"start":2470,"enrollment":1380,"conditions":2471,"interventions":2473},"NCT00314340","A Comparison of the Addiction Liability of Hydrocodone and Sustained Release Morphine",[91],"2008-04","2005-11",[2472],"Chronic Pain",[2453,2474],"hydrocodone plus acetaminophen",{"trials":2476,"activeCount":100},[],{"intervention":2474,"totalTrials":96,"cells":2478},{"EARLY_PHASE1":2479,"PHASE1":2481,"PHASE2":2483,"PHASE3":2485,"PHASE4":2487,"NA":2493},{"trials":2480,"activeCount":100},[],{"trials":2482,"activeCount":100},[],{"trials":2484,"activeCount":100},[],{"trials":2486,"activeCount":100},[],{"trials":2488,"activeCount":100},[2489],{"nctId":2466,"briefTitle":2467,"status":634,"phases":2490,"primaryCompletion":2469,"completion":2469,"start":2470,"enrollment":1380,"conditions":2491,"interventions":2492},[91],[2472],[2453,2474],{"trials":2494,"activeCount":100},[],{"intervention":2496,"totalTrials":96,"cells":2497},"Propofol 2mg\u002Fkg",{"EARLY_PHASE1":2498,"PHASE1":2500,"PHASE2":2502,"PHASE3":2504,"PHASE4":2506,"NA":2518},{"trials":2499,"activeCount":100},[],{"trials":2501,"activeCount":100},[],{"trials":2503,"activeCount":100},[],{"trials":2505,"activeCount":100},[],{"trials":2507,"activeCount":100},[2508],{"nctId":2509,"briefTitle":2510,"status":634,"phases":2511,"primaryCompletion":2512,"completion":2512,"start":638,"enrollment":745,"conditions":2513,"interventions":2514},"NCT03820388","Comparison of Etomidate Plus Propofol, Etomidate Alone on Induction of Anesthesia",[91],"2018-07-13",[296],[2496,2515,2516,2517],"Etomidate 0.3 mg\u002Fkg","Propofol 1 mg\u002Fkg","Etomidate 0.15 mg\u002Fkg",{"trials":2519,"activeCount":100},[],{"intervention":2515,"totalTrials":96,"cells":2521},{"EARLY_PHASE1":2522,"PHASE1":2524,"PHASE2":2526,"PHASE3":2528,"PHASE4":2530,"NA":2536},{"trials":2523,"activeCount":100},[],{"trials":2525,"activeCount":100},[],{"trials":2527,"activeCount":100},[],{"trials":2529,"activeCount":100},[],{"trials":2531,"activeCount":100},[2532],{"nctId":2509,"briefTitle":2510,"status":634,"phases":2533,"primaryCompletion":2512,"completion":2512,"start":638,"enrollment":745,"conditions":2534,"interventions":2535},[91],[296],[2496,2515,2516,2517],{"trials":2537,"activeCount":100},[],{"intervention":2516,"totalTrials":96,"cells":2539},{"EARLY_PHASE1":2540,"PHASE1":2542,"PHASE2":2544,"PHASE3":2546,"PHASE4":2548,"NA":2554},{"trials":2541,"activeCount":100},[],{"trials":2543,"activeCount":100},[],{"trials":2545,"activeCount":100},[],{"trials":2547,"activeCount":100},[],{"trials":2549,"activeCount":100},[2550],{"nctId":2509,"briefTitle":2510,"status":634,"phases":2551,"primaryCompletion":2512,"completion":2512,"start":638,"enrollment":745,"conditions":2552,"interventions":2553},[91],[296],[2496,2515,2516,2517],{"trials":2555,"activeCount":100},[],{"intervention":2517,"totalTrials":96,"cells":2557},{"EARLY_PHASE1":2558,"PHASE1":2560,"PHASE2":2562,"PHASE3":2564,"PHASE4":2566,"NA":2572},{"trials":2559,"activeCount":100},[],{"trials":2561,"activeCount":100},[],{"trials":2563,"activeCount":100},[],{"trials":2565,"activeCount":100},[],{"trials":2567,"activeCount":100},[2568],{"nctId":2509,"briefTitle":2510,"status":634,"phases":2569,"primaryCompletion":2512,"completion":2512,"start":638,"enrollment":745,"conditions":2570,"interventions":2571},[91],[296],[2496,2515,2516,2517],{"trials":2573,"activeCount":100},[],{"intervention":2575,"totalTrials":96,"cells":2576},"Gabapentin 600mg",{"EARLY_PHASE1":2577,"PHASE1":2579,"PHASE2":2581,"PHASE3":2583,"PHASE4":2585,"NA":2600},{"trials":2578,"activeCount":100},[],{"trials":2580,"activeCount":100},[],{"trials":2582,"activeCount":100},[],{"trials":2584,"activeCount":100},[],{"trials":2586,"activeCount":100},[2587],{"nctId":2588,"briefTitle":2589,"status":634,"phases":2590,"primaryCompletion":2591,"completion":2591,"start":2592,"enrollment":2593,"conditions":2594,"interventions":2598},"NCT03080493","Gabapentin for Pain Control After Osmotic Dilator Insertion and Prior to D&E Procedure: a Randomized Controlled Trial",[91],"2018-11-05","2017-03-20",121,[2595,2596,2597],"Abortion, Induced","Cervical Preparation","Pain",[2575,2599],"acetaminophen\u002Fcodeine and ibuprofen",{"trials":2601,"activeCount":100},[],{"intervention":2599,"totalTrials":96,"cells":2603},{"EARLY_PHASE1":2604,"PHASE1":2606,"PHASE2":2608,"PHASE3":2610,"PHASE4":2612,"NA":2618},{"trials":2605,"activeCount":100},[],{"trials":2607,"activeCount":100},[],{"trials":2609,"activeCount":100},[],{"trials":2611,"activeCount":100},[],{"trials":2613,"activeCount":100},[2614],{"nctId":2588,"briefTitle":2589,"status":634,"phases":2615,"primaryCompletion":2591,"completion":2591,"start":2592,"enrollment":2593,"conditions":2616,"interventions":2617},[91],[2595,2596,2597],[2575,2599],{"trials":2619,"activeCount":100},[],{"intervention":2621,"totalTrials":96,"cells":2622},"Ondansetron",{"EARLY_PHASE1":2623,"PHASE1":2625,"PHASE2":2627,"PHASE3":2629,"PHASE4":2631,"NA":2645},{"trials":2624,"activeCount":100},[],{"trials":2626,"activeCount":100},[],{"trials":2628,"activeCount":100},[],{"trials":2630,"activeCount":100},[],{"trials":2632,"activeCount":100},[2633],{"nctId":2634,"briefTitle":2635,"status":532,"phases":2636,"primaryCompletion":2637,"completion":2638,"start":2639,"enrollment":2640,"conditions":2641,"interventions":2644},"NCT03075163","Post-Operative Therapy for Nausea or Vomiting",[91],"2017-04","2018-12","2016-10-18",300,[2642,2643],"Vomiting","Nausea",[2621],{"trials":2646,"activeCount":100},[],{"intervention":1941,"totalTrials":96,"cells":2648},{"EARLY_PHASE1":2649,"PHASE1":2651,"PHASE2":2653,"PHASE3":2655,"PHASE4":2657,"NA":2663},{"trials":2650,"activeCount":100},[],{"trials":2652,"activeCount":100},[],{"trials":2654,"activeCount":100},[],{"trials":2656,"activeCount":100},[],{"trials":2658,"activeCount":100},[2659],{"nctId":1932,"briefTitle":1933,"status":634,"phases":2660,"primaryCompletion":1935,"completion":1935,"start":1936,"enrollment":946,"conditions":2661,"interventions":2662},[91],[1938,1939],[1941,1919],{"trials":2664,"activeCount":100},[],{"intervention":2666,"totalTrials":96,"cells":2667},"Tranexamic Acid",{"EARLY_PHASE1":2668,"PHASE1":2670,"PHASE2":2672,"PHASE3":2674,"PHASE4":2676,"NA":2689},{"trials":2669,"activeCount":100},[],{"trials":2671,"activeCount":100},[],{"trials":2673,"activeCount":100},[],{"trials":2675,"activeCount":100},[],{"trials":2677,"activeCount":100},[2678],{"nctId":2679,"briefTitle":2680,"status":532,"phases":2681,"primaryCompletion":2682,"completion":2682,"start":2683,"enrollment":2684,"conditions":2685,"interventions":2687},"NCT02930941","Topical Intranasal Tranexamic Acid for Epistaxis in the Emergency Department",[91],"2020-12-31","2016-02",35,[2686],"Epistaxis",[2666,2688],"0.9% Sodium Chloride",{"trials":2690,"activeCount":100},[],{"intervention":2688,"totalTrials":96,"cells":2692},{"EARLY_PHASE1":2693,"PHASE1":2695,"PHASE2":2697,"PHASE3":2699,"PHASE4":2701,"NA":2707},{"trials":2694,"activeCount":100},[],{"trials":2696,"activeCount":100},[],{"trials":2698,"activeCount":100},[],{"trials":2700,"activeCount":100},[],{"trials":2702,"activeCount":100},[2703],{"nctId":2679,"briefTitle":2680,"status":532,"phases":2704,"primaryCompletion":2682,"completion":2682,"start":2683,"enrollment":2684,"conditions":2705,"interventions":2706},[91],[2686],[2666,2688],{"trials":2708,"activeCount":100},[],{"intervention":2710,"totalTrials":96,"cells":2711},"Lisdexamfetamine",{"EARLY_PHASE1":2712,"PHASE1":2714,"PHASE2":2716,"PHASE3":2718,"PHASE4":2720,"NA":2730},{"trials":2713,"activeCount":100},[],{"trials":2715,"activeCount":100},[],{"trials":2717,"activeCount":100},[],{"trials":2719,"activeCount":100},[],{"trials":2721,"activeCount":100},[2722],{"nctId":2723,"briefTitle":2724,"status":532,"phases":2725,"primaryCompletion":2726,"completion":2726,"start":2727,"enrollment":2187,"conditions":2728,"interventions":2729},"NCT02170298","Lisdexamfetamine's Effect In ADHD in the Brain and Cognition",[91],"2015-06","2014-02",[1491],[2710],{"trials":2731,"activeCount":100},[],{"intervention":2733,"totalTrials":96,"cells":2734},"Wilate",{"EARLY_PHASE1":2735,"PHASE1":2737,"PHASE2":2739,"PHASE3":2741,"PHASE4":2743,"NA":2755},{"trials":2736,"activeCount":100},[],{"trials":2738,"activeCount":100},[],{"trials":2740,"activeCount":100},[],{"trials":2742,"activeCount":100},[],{"trials":2744,"activeCount":100},[2745],{"nctId":2746,"briefTitle":2747,"status":532,"phases":2748,"primaryCompletion":2749,"completion":2749,"start":2750,"enrollment":96,"conditions":2751,"interventions":2754},"NCT03204539","INdividualized ITI Based on Fviii(ATE) Protection by VWF",[91],"2019-07-19","2017-06-01",[2752,2753],"Hemophilia A With Inhibitor","Hemophilia A",[2733],{"trials":2756,"activeCount":100},[],{"intervention":2758,"totalTrials":96,"cells":2759},"Intravenous Infusion group",{"EARLY_PHASE1":2760,"PHASE1":2762,"PHASE2":2764,"PHASE3":2766,"PHASE4":2779,"NA":2781},{"trials":2761,"activeCount":100},[],{"trials":2763,"activeCount":100},[],{"trials":2765,"activeCount":100},[],{"trials":2767,"activeCount":100},[2768],{"nctId":2769,"briefTitle":2770,"status":634,"phases":2771,"primaryCompletion":2772,"completion":2772,"start":2773,"enrollment":2774,"conditions":2775,"interventions":2777},"NCT04562610","Enhanced Recovery After Surgery in Orthopaedic Spine Surgery",[89,90],"2024-10-09","2020-11-18",33,[2776],"Lumbar Surgery",[2758,2778],"All oral administration group",{"trials":2780,"activeCount":100},[],{"trials":2782,"activeCount":100},[],{"intervention":2778,"totalTrials":96,"cells":2784},{"EARLY_PHASE1":2785,"PHASE1":2787,"PHASE2":2789,"PHASE3":2791,"PHASE4":2797,"NA":2799},{"trials":2786,"activeCount":100},[],{"trials":2788,"activeCount":100},[],{"trials":2790,"activeCount":100},[],{"trials":2792,"activeCount":100},[2793],{"nctId":2769,"briefTitle":2770,"status":634,"phases":2794,"primaryCompletion":2772,"completion":2772,"start":2773,"enrollment":2774,"conditions":2795,"interventions":2796},[89,90],[2776],[2758,2778],{"trials":2798,"activeCount":100},[],{"trials":2800,"activeCount":100},[],{"intervention":2802,"totalTrials":96,"cells":2803},"GCP - Genistein Combined Polysaccharide",{"EARLY_PHASE1":2804,"PHASE1":2806,"PHASE2":2808,"PHASE3":2810,"PHASE4":2821,"NA":2823},{"trials":2805,"activeCount":100},[],{"trials":2807,"activeCount":100},[],{"trials":2809,"activeCount":100},[],{"trials":2811,"activeCount":100},[2812],{"nctId":2813,"briefTitle":2814,"status":634,"phases":2815,"primaryCompletion":2816,"completion":2817,"start":2818,"enrollment":1005,"conditions":2819,"interventions":2820},"NCT00584532","Effects of a Genistein Concentrated Polysaccharide (GCP) for Prostate Cancer on Active Surveillance.",[89,90],"2005-12","2007-12","2003-11",[27],[2802],{"trials":2822,"activeCount":100},[],{"trials":2824,"activeCount":100},[],{"intervention":2826,"totalTrials":96,"cells":2827},"Rituximab combined with Omalizumab",{"EARLY_PHASE1":2828,"PHASE1":2830,"PHASE2":2832,"PHASE3":2834,"PHASE4":2846,"NA":2848},{"trials":2829,"activeCount":100},[],{"trials":2831,"activeCount":100},[],{"trials":2833,"activeCount":100},[],{"trials":2835,"activeCount":100},[2836],{"nctId":2837,"briefTitle":2838,"status":2047,"phases":2839,"primaryCompletion":2840,"completion":2841,"start":2842,"enrollment":100,"conditions":2843,"interventions":2845},"NCT04128176","Efficacy and Safety of Rituximab Combined With Omalizumab in Patients With Bullous Pemphigoid",[90],"2023-05-25","2023-11-25","2017-03",[2844],"Bullous Pemphigoid",[2826],{"trials":2847,"activeCount":100},[],{"trials":2849,"activeCount":100},[],{"intervention":2851,"totalTrials":96,"cells":2852},"S-adenosylmethionine",{"EARLY_PHASE1":2853,"PHASE1":2855,"PHASE2":2857,"PHASE3":2859,"PHASE4":2871,"NA":2873},{"trials":2854,"activeCount":100},[],{"trials":2856,"activeCount":100},[],{"trials":2858,"activeCount":100},[],{"trials":2860,"activeCount":100},[2861],{"nctId":2862,"briefTitle":2863,"status":634,"phases":2864,"primaryCompletion":2865,"completion":2866,"start":2427,"enrollment":2867,"conditions":2868,"interventions":2870},"NCT00573313","Effects of SAMe in Patients With Alcoholic Liver Disease",[90],"2009-06","2009-09",94,[2869],"Liver Disease, Alcoholic",[2851],{"trials":2872,"activeCount":100},[],{"trials":2874,"activeCount":100},[],{"intervention":2876,"totalTrials":96,"cells":2877},"0.45% saline replacement fluid",{"EARLY_PHASE1":2878,"PHASE1":2880,"PHASE2":2882,"PHASE3":2884,"PHASE4":2901,"NA":2903},{"trials":2879,"activeCount":100},[],{"trials":2881,"activeCount":100},[],{"trials":2883,"activeCount":100},[],{"trials":2885,"activeCount":100},[2886],{"nctId":2887,"briefTitle":2888,"status":634,"phases":2889,"primaryCompletion":2890,"completion":2891,"start":2892,"enrollment":2893,"conditions":2894,"interventions":2897},"NCT01365793","Randomized Control Trial of Fluid Therapy for Pediatric Diabetic Ketoacidosis",[90],"2016-09","2017-01","2010-11",1389,[2895,2896],"Cerebral Edema","Diabetic Ketoacidosis",[2876,2898,2899,2900],"0.9% saline replacement fluid","0.45% saline intravenous fluid","0.9% saline Intravenous fluid",{"trials":2902,"activeCount":100},[],{"trials":2904,"activeCount":100},[],{"intervention":2898,"totalTrials":96,"cells":2906},{"EARLY_PHASE1":2907,"PHASE1":2909,"PHASE2":2911,"PHASE3":2913,"PHASE4":2919,"NA":2921},{"trials":2908,"activeCount":100},[],{"trials":2910,"activeCount":100},[],{"trials":2912,"activeCount":100},[],{"trials":2914,"activeCount":100},[2915],{"nctId":2887,"briefTitle":2888,"status":634,"phases":2916,"primaryCompletion":2890,"completion":2891,"start":2892,"enrollment":2893,"conditions":2917,"interventions":2918},[90],[2895,2896],[2876,2898,2899,2900],{"trials":2920,"activeCount":100},[],{"trials":2922,"activeCount":100},[],{"intervention":2899,"totalTrials":96,"cells":2924},{"EARLY_PHASE1":2925,"PHASE1":2927,"PHASE2":2929,"PHASE3":2931,"PHASE4":2937,"NA":2939},{"trials":2926,"activeCount":100},[],{"trials":2928,"activeCount":100},[],{"trials":2930,"activeCount":100},[],{"trials":2932,"activeCount":100},[2933],{"nctId":2887,"briefTitle":2888,"status":634,"phases":2934,"primaryCompletion":2890,"completion":2891,"start":2892,"enrollment":2893,"conditions":2935,"interventions":2936},[90],[2895,2896],[2876,2898,2899,2900],{"trials":2938,"activeCount":100},[],{"trials":2940,"activeCount":100},[],{"intervention":2900,"totalTrials":96,"cells":2942},{"EARLY_PHASE1":2943,"PHASE1":2945,"PHASE2":2947,"PHASE3":2949,"PHASE4":2955,"NA":2957},{"trials":2944,"activeCount":100},[],{"trials":2946,"activeCount":100},[],{"trials":2948,"activeCount":100},[],{"trials":2950,"activeCount":100},[2951],{"nctId":2887,"briefTitle":2888,"status":634,"phases":2952,"primaryCompletion":2890,"completion":2891,"start":2892,"enrollment":2893,"conditions":2953,"interventions":2954},[90],[2895,2896],[2876,2898,2899,2900],{"trials":2956,"activeCount":100},[],{"trials":2958,"activeCount":100},[],{"intervention":2960,"totalTrials":96,"cells":2961},"Metformin",{"EARLY_PHASE1":2962,"PHASE1":2964,"PHASE2":2966,"PHASE3":2968,"PHASE4":2986,"NA":2988},{"trials":2963,"activeCount":100},[],{"trials":2965,"activeCount":100},[],{"trials":2967,"activeCount":100},[],{"trials":2969,"activeCount":100},[2970],{"nctId":2971,"briefTitle":2972,"status":634,"phases":2973,"primaryCompletion":2974,"completion":2974,"start":2975,"enrollment":2026,"conditions":2976,"interventions":2985},"NCT03479476","A Trial of Metformin in Individuals With Fragile X Syndrome",[89,90],"2024-05-22","2018-04-30",[1489,2977,2978,2979,2980,2981,1488,2982,2983,2984],"Fragile X Mental Retardation Syndrome","Mental Retardation, X Linked","Genetic Diseases, X-Linked","Trinucleotide Repeat Expansion","Fra(X) Syndrome","FXS","Neurobehavioral Manifestations","Sex Chromosome Disorders",[2960],{"trials":2987,"activeCount":100},[],{"trials":2989,"activeCount":100},[],{"intervention":2991,"totalTrials":96,"cells":2992},"Lactobacillus acidophilus L-92",{"EARLY_PHASE1":2993,"PHASE1":2995,"PHASE2":2997,"PHASE3":2999,"PHASE4":3010,"NA":3012},{"trials":2994,"activeCount":100},[],{"trials":2996,"activeCount":100},[],{"trials":2998,"activeCount":100},[],{"trials":3000,"activeCount":100},[3001],{"nctId":3002,"briefTitle":3003,"status":2047,"phases":3004,"primaryCompletion":2817,"completion":3005,"start":3006,"enrollment":100,"conditions":3007,"interventions":3009},"NCT00554736","Lactobacillus Acidophilus L92 on Markers of Allergic Inflammation by Nasal Provocation With Grass Pollen",[90],"2008-08","2006-05",[3008],"Hayfever",[2991],{"trials":3011,"activeCount":100},[],{"trials":3013,"activeCount":100},[],{"intervention":3015,"totalTrials":2187,"cells":3016},"cyclosporine",{"EARLY_PHASE1":3017,"PHASE1":3019,"PHASE2":3061,"PHASE3":3078,"PHASE4":3080,"NA":3082},{"trials":3018,"activeCount":100},[],{"trials":3020,"activeCount":100},[3021,3031,3041,3048,3055],{"nctId":3022,"briefTitle":3023,"status":3024,"phases":3025,"start":3026,"enrollment":3027,"conditions":3028,"interventions":3029},"NCT00003920","Monoclonal Antibody Therapy Plus Cyclosporine and Peripheral Stem Cell Transplantation in Treating Patients With Metastatic Breast Cancer","UNKNOWN",[88],"1996-04",18,[21],[3030,3015],"filgrastim",{"nctId":3032,"briefTitle":3033,"status":3024,"phases":3034,"start":3035,"conditions":3036,"interventions":3038},"NCT00009776","Monoclonal Antibody Therapy, Paclitaxel, and Cyclosporine in Treating Patients With Recurrent or Refractory Non-Hodgkin's Lymphoma",[88],"2001-03",[3037],"Lymphoma",[3039,3015,3040],"monoclonal antibody Lym-1","paclitaxel",{"nctId":3042,"briefTitle":3043,"status":3024,"phases":3044,"start":3045,"conditions":3046,"interventions":3047},"NCT00008021","Monoclonal Antibody Therapy, Chemotherapy, and Peripheral Stem Cell Transplantation in Treating Patients With Refractory Non-Hodgkin's Lymphoma",[88],"2001-02",[3037],[3030,3039,3015,3040],{"nctId":3049,"briefTitle":3050,"status":3024,"phases":3051,"start":3035,"conditions":3052,"interventions":3053},"NCT00009750","Monoclonal Antibody Therapy Plus Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy",[88],[27],[3030,3054,3015,3040],"monoclonal antibody m170",{"nctId":3056,"briefTitle":3057,"status":3024,"phases":3058,"start":3035,"conditions":3059,"interventions":3060},"NCT00009763","Monoclonal Antibody Therapy, Cyclosporine, and Paclitaxel in Treating Patients With Recurrent or Refractory Metastatic Breast Cancer",[88],[21],[3030,3054,3015,3040],{"trials":3062,"activeCount":100},[3063],{"nctId":3064,"briefTitle":3065,"status":634,"phases":3066,"primaryCompletion":3067,"completion":3068,"start":3069,"enrollment":537,"conditions":3070,"interventions":3074},"NCT00619645","Donor Peripheral Stem Cell Transplant, Fludarabine, and Busulfan in Treating Patients With Hematologic Cancers",[89],"2013-10","2013-11","2007-06",[3071,3037,3072,3073],"Leukemia","Multiple Myeloma and Plasma Cell Neoplasm","Myelodysplastic Syndromes",[3075,3015,3076,3077],"busulfan","fludarabine phosphate","mycophenolate mofetil",{"trials":3079,"activeCount":100},[],{"trials":3081,"activeCount":100},[],{"trials":3083,"activeCount":100},[],{"intervention":646,"totalTrials":625,"cells":3085},{"EARLY_PHASE1":3086,"PHASE1":3088,"PHASE2":3103,"PHASE3":3125,"PHASE4":3127,"NA":3129},{"trials":3087,"activeCount":100},[],{"trials":3089,"activeCount":100},[3090,3099],{"nctId":3091,"briefTitle":3092,"status":634,"phases":3093,"primaryCompletion":3094,"completion":3095,"start":3096,"enrollment":22,"conditions":3097,"interventions":3098},"NCT01433965","Study of Lenalidomide in Patients With Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome",[88],"2018-06-12","2021-01-12","2012-08-08",[837,640],[646],{"nctId":632,"briefTitle":633,"status":634,"phases":3100,"primaryCompletion":636,"completion":637,"start":638,"enrollment":625,"conditions":3101,"interventions":3102},[88],[640,641,642,643,644],[624,646],{"trials":3104,"activeCount":100},[3105,3116],{"nctId":3106,"briefTitle":3107,"status":532,"phases":3108,"primaryCompletion":3109,"completion":3110,"start":3111,"enrollment":142,"conditions":3112,"interventions":3114},"NCT01316523","Lenalidomide and Rituximab in Subjects With Previously Untreated Indolent Non-Hodgkin's Lymphoma",[89],"2023-09-12","2024-04-14","2010-12",[3113],"Non Hodgkin's Lymphoma",[3115,646],"Rituximab",{"nctId":3117,"briefTitle":3118,"status":532,"phases":3119,"primaryCompletion":3120,"completion":3121,"start":3122,"enrollment":142,"conditions":3123,"interventions":3124},"NCT00848328","Lenalidomide and Rituximab in Treating Patients With Non-Hodgkin Lymphoma",[89],"2023-06-28","2024-04-15","2008-08-25",[3037],[3115,646],{"trials":3126,"activeCount":100},[],{"trials":3128,"activeCount":100},[],{"trials":3130,"activeCount":100},[],{"intervention":3132,"totalTrials":1258,"cells":3133},"bevacizumab",{"EARLY_PHASE1":3134,"PHASE1":3136,"PHASE2":3138,"PHASE3":3170,"PHASE4":3172,"NA":3174},{"trials":3135,"activeCount":100},[],{"trials":3137,"activeCount":100},[],{"trials":3139,"activeCount":100},[3140,3149,3160],{"nctId":3141,"briefTitle":3142,"status":2047,"phases":3143,"primaryCompletion":2469,"completion":2469,"start":3069,"enrollment":100,"conditions":3144,"interventions":3146},"NCT00408772","Oxaliplatin, Capecitabine, and Bevacizumab Followed By Surgery and\u002For Radiofrequency Ablation in Patients With Colorectal Cancer",[89],[3145,1290],"Colorectal Cancer",[3132,3147,3148],"capecitabine","oxaliplatin",{"nctId":3150,"briefTitle":3151,"status":634,"phases":3152,"primaryCompletion":3153,"completion":3153,"start":3154,"enrollment":3155,"conditions":3156,"interventions":3158},"NCT00795665","Bevacizumab and Carmustine in Treating Patients With Relapsed or Progressive High-Grade Glioma",[89],"2015-12","2008-06",7,[3157],"Glioma",[3132,3159],"carmustine",{"nctId":3161,"briefTitle":3162,"status":2047,"phases":3163,"primaryCompletion":2891,"completion":2891,"start":2402,"enrollment":100,"conditions":3164,"interventions":3167},"NCT02348255","NovoTTF-100A With Bevacizumab and Carmustine in Treating Patients With Glioblastoma Multiforme in First Relapse",[89],[3165,3166],"Adult Brain Glioblastoma","Recurrent Adult Brain Neoplasm",[3168,3169],"Bevacizumab","Carmustine",{"trials":3171,"activeCount":100},[],{"trials":3173,"activeCount":100},[],{"trials":3175,"activeCount":100},[],{"intervention":3115,"totalTrials":1258,"cells":3177},{"EARLY_PHASE1":3178,"PHASE1":3180,"PHASE2":3182,"PHASE3":3203,"PHASE4":3205,"NA":3207},{"trials":3179,"activeCount":100},[],{"trials":3181,"activeCount":100},[],{"trials":3183,"activeCount":100},[3184,3188,3192],{"nctId":3106,"briefTitle":3107,"status":532,"phases":3185,"primaryCompletion":3109,"completion":3110,"start":3111,"enrollment":142,"conditions":3186,"interventions":3187},[89],[3113],[3115,646],{"nctId":3117,"briefTitle":3118,"status":532,"phases":3189,"primaryCompletion":3120,"completion":3121,"start":3122,"enrollment":142,"conditions":3190,"interventions":3191},[89],[3037],[3115,646],{"nctId":3193,"briefTitle":3194,"status":634,"phases":3195,"primaryCompletion":3196,"completion":3197,"start":3198,"enrollment":2187,"conditions":3199,"interventions":3201},"NCT00364819","Initial Study of Rituximab to Treat Primary Biliary Cirrhosis",[88,89],"2009-07","2009-12","2007-01",[3200],"Primary Biliary Cirrhosis",[3202],"rituximab",{"trials":3204,"activeCount":100},[],{"trials":3206,"activeCount":100},[],{"trials":3208,"activeCount":100},[],{"intervention":661,"totalTrials":1258,"cells":3210},{"EARLY_PHASE1":3211,"PHASE1":3217,"PHASE2":3229,"PHASE3":3235,"PHASE4":3237,"NA":3239},{"trials":3212,"activeCount":100},[3213],{"nctId":1306,"briefTitle":1307,"status":634,"phases":3214,"primaryCompletion":1309,"completion":1309,"start":1310,"enrollment":1258,"conditions":3215,"interventions":3216},[87],[1312],[1314,661,1301],{"trials":3218,"activeCount":100},[3219],{"nctId":3220,"briefTitle":3221,"status":634,"phases":3222,"primaryCompletion":3223,"completion":3224,"start":3225,"enrollment":2187,"conditions":3226,"interventions":3227},"NCT04050085","SD-101, Nivolumab, and Radiation Therapy in Treating Patients With Chemotherapy-Refractory Metastatic Pancreatic Cancer",[88],"2021-12-03","2022-05-14","2019-08-15",[1670,1671,1673],[661,3228],"TLR9 Agonist SD-101",{"trials":3230,"activeCount":100},[3231],{"nctId":650,"briefTitle":651,"status":634,"phases":3232,"primaryCompletion":653,"completion":654,"start":655,"enrollment":656,"conditions":3233,"interventions":3234},[88,89],[658,659],[624,661],{"trials":3236,"activeCount":100},[],{"trials":3238,"activeCount":100},[],{"trials":3240,"activeCount":100},[],{"intervention":3242,"totalTrials":1258,"cells":3243},"erlotinib hydrochloride",{"EARLY_PHASE1":3244,"PHASE1":3246,"PHASE2":3258,"PHASE3":3280,"PHASE4":3282,"NA":3284},{"trials":3245,"activeCount":100},[],{"trials":3247,"activeCount":100},[3248],{"nctId":3249,"briefTitle":3250,"status":634,"phases":3251,"primaryCompletion":3252,"completion":3252,"start":3253,"enrollment":2684,"conditions":3254,"interventions":3256},"NCT01911507","INC280 and Erlotinib Hydrochloride in Treating Patients With Non-small Cell Lung Cancer",[88],"2020-08-26","2013-08-27",[3255],"Recurrent Non-small Cell Lung Cancer",[3257,3242],"INC280",{"trials":3259,"activeCount":100},[3260,3270],{"nctId":3261,"briefTitle":3262,"status":634,"phases":3263,"primaryCompletion":3264,"completion":2426,"start":3265,"enrollment":3266,"conditions":3267,"interventions":3268},"NCT00387322","Pemetrexed Disodium and Erlotinib in Treating Patients With Advanced Non-Small Cell Lung Cancer or Other Solid Tumors",[88,89],"2007-10","2005-03",42,[30,24],[3242,3269],"pemetrexed disodium",{"nctId":3271,"briefTitle":3272,"status":634,"phases":3273,"primaryCompletion":3005,"completion":3274,"start":3275,"enrollment":3276,"conditions":3277,"interventions":3278},"NCT00390429","Docetaxel and Erlotinib in Treating Patients With Advanced Non-Small Cell Lung Cancer or Other Solid Tumors",[88,89],"2012-08","2002-07",81,[30,24],[3279,3242],"docetaxel",{"trials":3281,"activeCount":100},[],{"trials":3283,"activeCount":100},[],{"trials":3285,"activeCount":100},[],{"intervention":3148,"totalTrials":519,"cells":3287},{"EARLY_PHASE1":3288,"PHASE1":3298,"PHASE2":3300,"PHASE3":3306,"PHASE4":3308,"NA":3310},{"trials":3289,"activeCount":100},[3290],{"nctId":3291,"briefTitle":3292,"status":634,"phases":3293,"primaryCompletion":3294,"completion":3153,"start":3294,"enrollment":96,"conditions":3295,"interventions":3297},"NCT02077998","Oxaliplatin in Treating Patients With Metastatic Breast Cancer",[87],"2015-05",[3296],"Stage IV Breast Cancer",[3148],{"trials":3299,"activeCount":100},[],{"trials":3301,"activeCount":100},[3302],{"nctId":3141,"briefTitle":3142,"status":2047,"phases":3303,"primaryCompletion":2469,"completion":2469,"start":3069,"enrollment":100,"conditions":3304,"interventions":3305},[89],[3145,1290],[3132,3147,3148],{"trials":3307,"activeCount":100},[],{"trials":3309,"activeCount":100},[],{"trials":3311,"activeCount":100},[],{"intervention":3313,"totalTrials":519,"cells":3314},"Everolimus",{"EARLY_PHASE1":3315,"PHASE1":3317,"PHASE2":3337,"PHASE3":3347,"PHASE4":3349,"NA":3351},{"trials":3316,"activeCount":100},[],{"trials":3318,"activeCount":100},[3319],{"nctId":3320,"briefTitle":3321,"status":634,"phases":3322,"primaryCompletion":3323,"completion":3323,"start":3324,"enrollment":19,"conditions":3325,"interventions":3334},"NCT02240719","Everolimus and Bendamustine Hydrochloride in Treating Patients With Relapsed or Refractory Hematologic Cancer",[88],"2018-04-09","2014-10",[3326,3327,3328,3329,3330,3331,3332,3333],"Recurrent Adult Diffuse Large Cell Lymphoma","Recurrent Adult Hodgkin Lymphoma","Recurrent Grade 1 Follicular Lymphoma","Recurrent Grade 2 Follicular Lymphoma","Recurrent Grade 3 Follicular Lymphoma","Recurrent Mantle Cell Lymphoma","Refractory Chronic Lymphocytic Leukemia","Multiple Myeloma",[3335,3336],"everolimus","bendamustine hydrochloride",{"trials":3338,"activeCount":100},[3339],{"nctId":3340,"briefTitle":3341,"status":634,"phases":3342,"primaryCompletion":3153,"completion":2402,"start":3343,"enrollment":1244,"conditions":3344,"interventions":3345},"NCT00814788","Bicalutamide With or Without Everolimus in Treating Patients With Recurrent or Metastatic Prostate Cancer",[89],"2008-12",[27],[3346,3313],"Bicalutamide",{"trials":3348,"activeCount":100},[],{"trials":3350,"activeCount":100},[],{"trials":3352,"activeCount":100},[],{"intervention":3269,"totalTrials":519,"cells":3354},{"EARLY_PHASE1":3355,"PHASE1":3357,"PHASE2":3359,"PHASE3":3378,"PHASE4":3380,"NA":3382},{"trials":3356,"activeCount":100},[],{"trials":3358,"activeCount":100},[],{"trials":3360,"activeCount":100},[3361,3365],{"nctId":3261,"briefTitle":3262,"status":634,"phases":3362,"primaryCompletion":3264,"completion":2426,"start":3265,"enrollment":3266,"conditions":3363,"interventions":3364},[88,89],[30,24],[3242,3269],{"nctId":3366,"briefTitle":3367,"status":634,"phases":3368,"primaryCompletion":3369,"completion":3069,"start":3265,"enrollment":3370,"conditions":3371,"interventions":3372},"NCT00389805","Bortezomib and Pemetrexed Disodium in Treating Patients With Advanced Non-Small Cell Lung Cancer or Other Solid Tumors",[88,89],"2006-12",27,[30,24],[3373,3269,3374,3375,3376,3377],"bortezomib","gene expression analysis","mutation analysis","protein expression analysis","reverse transcriptase-polymerase chain reaction",{"trials":3379,"activeCount":100},[],{"trials":3381,"activeCount":100},[],{"trials":3383,"activeCount":100},[],{"intervention":3373,"totalTrials":519,"cells":3385},{"EARLY_PHASE1":3386,"PHASE1":3388,"PHASE2":3399,"PHASE3":3405,"PHASE4":3407,"NA":3409},{"trials":3387,"activeCount":100},[],{"trials":3389,"activeCount":100},[3390],{"nctId":3391,"briefTitle":3392,"status":634,"phases":3393,"primaryCompletion":3394,"completion":3154,"start":3395,"enrollment":1244,"conditions":3396,"interventions":3397},"NCT00388089","Bortezomib and Topotecan in Treating Patients With Advanced Solid Tumors",[88],"2007-11","2004-12",[30,24],[3373,3398],"topotecan hydrochloride",{"trials":3400,"activeCount":100},[3401],{"nctId":3366,"briefTitle":3367,"status":634,"phases":3402,"primaryCompletion":3369,"completion":3069,"start":3265,"enrollment":3370,"conditions":3403,"interventions":3404},[88,89],[30,24],[3373,3269,3374,3375,3376,3377],{"trials":3406,"activeCount":100},[],{"trials":3408,"activeCount":100},[],{"trials":3410,"activeCount":100},[],{"intervention":3374,"totalTrials":519,"cells":3412},{"EARLY_PHASE1":3413,"PHASE1":3415,"PHASE2":3432,"PHASE3":3438,"PHASE4":3440,"NA":3442},{"trials":3414,"activeCount":100},[],{"trials":3416,"activeCount":100},[3417],{"nctId":3418,"briefTitle":3419,"status":634,"phases":3420,"primaryCompletion":2285,"completion":3421,"start":2816,"enrollment":2236,"conditions":3422,"interventions":3423},"NCT00389922","Lapatinib and Vinorelbine in Treating Patients With Advanced Solid Tumors",[88],"2011-12",[24],[3424,3425,3426,3427,3374,3375,3428,3429,3430,3377,3424,3431],"lapatinib ditosylate","vinorelbine ditartrate","comparative genomic hybridization","cytogenetic analysis","polymerase chain reaction","polymorphism analysis","proteomic profiling","Vinorelbine ditartrate",{"trials":3433,"activeCount":100},[3434],{"nctId":3366,"briefTitle":3367,"status":634,"phases":3435,"primaryCompletion":3369,"completion":3069,"start":3265,"enrollment":3370,"conditions":3436,"interventions":3437},[88,89],[30,24],[3373,3269,3374,3375,3376,3377],{"trials":3439,"activeCount":100},[],{"trials":3441,"activeCount":100},[],{"trials":3443,"activeCount":100},[],{"intervention":3375,"totalTrials":519,"cells":3445},{"EARLY_PHASE1":3446,"PHASE1":3448,"PHASE2":3454,"PHASE3":3460,"PHASE4":3462,"NA":3464},{"trials":3447,"activeCount":100},[],{"trials":3449,"activeCount":100},[3450],{"nctId":3418,"briefTitle":3419,"status":634,"phases":3451,"primaryCompletion":2285,"completion":3421,"start":2816,"enrollment":2236,"conditions":3452,"interventions":3453},[88],[24],[3424,3425,3426,3427,3374,3375,3428,3429,3430,3377,3424,3431],{"trials":3455,"activeCount":100},[3456],{"nctId":3366,"briefTitle":3367,"status":634,"phases":3457,"primaryCompletion":3369,"completion":3069,"start":3265,"enrollment":3370,"conditions":3458,"interventions":3459},[88,89],[30,24],[3373,3269,3374,3375,3376,3377],{"trials":3461,"activeCount":100},[],{"trials":3463,"activeCount":100},[],{"trials":3465,"activeCount":100},[],{"intervention":3377,"totalTrials":519,"cells":3467},{"EARLY_PHASE1":3468,"PHASE1":3470,"PHASE2":3476,"PHASE3":3482,"PHASE4":3484,"NA":3486},{"trials":3469,"activeCount":100},[],{"trials":3471,"activeCount":100},[3472],{"nctId":3418,"briefTitle":3419,"status":634,"phases":3473,"primaryCompletion":2285,"completion":3421,"start":2816,"enrollment":2236,"conditions":3474,"interventions":3475},[88],[24],[3424,3425,3426,3427,3374,3375,3428,3429,3430,3377,3424,3431],{"trials":3477,"activeCount":100},[3478],{"nctId":3366,"briefTitle":3367,"status":634,"phases":3479,"primaryCompletion":3369,"completion":3069,"start":3265,"enrollment":3370,"conditions":3480,"interventions":3481},[88,89],[30,24],[3373,3269,3374,3375,3376,3377],{"trials":3483,"activeCount":100},[],{"trials":3485,"activeCount":100},[],{"trials":3487,"activeCount":100},[],{"intervention":3489,"totalTrials":519,"cells":3490},"Carboplatin",{"EARLY_PHASE1":3491,"PHASE1":3493,"PHASE2":3505,"PHASE3":3517,"PHASE4":3519,"NA":3521},{"trials":3492,"activeCount":100},[],{"trials":3494,"activeCount":100},[3495],{"nctId":3496,"briefTitle":3497,"status":532,"phases":3498,"primaryCompletion":3499,"completion":3421,"start":2425,"enrollment":3500,"conditions":3501,"interventions":3502},"NCT00807755","Everolimus, Carboplatin, and Etoposide in Treating Patients With Small Cell Lung Cancer or Other Advanced Solid Tumors",[88],"2010-08",5,[30,24],[3489,3503,3504],"Etoposide","RAD001",{"trials":3506,"activeCount":100},[3507],{"nctId":3508,"briefTitle":3509,"status":634,"phases":3510,"primaryCompletion":3005,"completion":3511,"start":3512,"enrollment":914,"conditions":3513,"interventions":3514},"NCT00387660","Irinotecan and Carboplatin in Treating Patients With Metastatic or Recurrent Small Cell Lung Cancer",[89],"2009-01","2001-10",[30],[3515,3516],"carboplatin","irinotecan",{"trials":3518,"activeCount":100},[],{"trials":3520,"activeCount":100},[],{"trials":3522,"activeCount":100},[],{"intervention":3524,"totalTrials":519,"cells":3525},"Simvastatin",{"EARLY_PHASE1":3526,"PHASE1":3528,"PHASE2":3530,"PHASE3":3549,"PHASE4":3551,"NA":3553},{"trials":3527,"activeCount":100},[],{"trials":3529,"activeCount":100},[],{"trials":3531,"activeCount":100},[3532,3541],{"nctId":3533,"briefTitle":3534,"status":634,"phases":3535,"completion":3536,"start":3537,"enrollment":251,"conditions":3538,"interventions":3540},"NCT00441844","Monocyte Function and Inflammation in Type 1 Diabetes and Its Modulation",[89],"2005-07","2002-10",[3539],"Type 1 Diabetes",[3524],{"nctId":3542,"briefTitle":3543,"status":2047,"phases":3544,"primaryCompletion":3545,"completion":3545,"start":2161,"enrollment":100,"conditions":3546,"interventions":3548},"NCT02433535","Trial of Simvastatin for the Treatment of Severe Asthma",[89],"2017-08-22",[3547],"Severe Asthma",[3524],{"trials":3550,"activeCount":100},[],{"trials":3552,"activeCount":100},[],{"trials":3554,"activeCount":100},[],{"intervention":3556,"totalTrials":519,"cells":3557},"irinotecan hydrochloride",{"EARLY_PHASE1":3558,"PHASE1":3560,"PHASE2":3579,"PHASE3":3595,"PHASE4":3597,"NA":3599},{"trials":3559,"activeCount":100},[],{"trials":3561,"activeCount":100},[3562],{"nctId":3563,"briefTitle":3564,"status":634,"phases":3565,"primaryCompletion":3566,"completion":3566,"start":3567,"enrollment":3568,"conditions":3569,"interventions":3577},"NCT01923337","Irinotecan and Alisertib in Treating Patients With Advanced Solid Tumors or Colorectal Cancer",[88],"2016-10-17","2013-08",17,[3570,3571,3572,3573,3574,3575,3576,24],"Mucinous Adenocarcinoma of the Colon","Mucinous Adenocarcinoma of the Rectum","Recurrent Colon Cancer","Recurrent Rectal Cancer","Signet Ring Adenocarcinoma of the Colon","Signet Ring Adenocarcinoma of the Rectum","Stage IIIA Colon Cancer",[3556,3578],"alisertib",{"trials":3580,"activeCount":100},[3581],{"nctId":3582,"briefTitle":3583,"status":634,"phases":3584,"primaryCompletion":3585,"completion":3585,"start":3586,"enrollment":142,"conditions":3587,"interventions":3594},"NCT00389584","Irinotecan and Whole-Brain Radiation Therapy in Treating Patients With Brain Metastases From Solid Tumors",[88,89],"2006-11","2002-12",[3588,3589,3590,3591,3592,24,3593],"Brain and Central Nervous System Tumors","Cognitive\u002FFunctional Effects","Long-term Effects Secondary to Cancer Therapy in Adults","Long-term Effects Secondary to Cancer Therapy in Children","Poor Performance Status","Unspecified Childhood Solid Tumor, Protocol Specific",[3556],{"trials":3596,"activeCount":100},[],{"trials":3598,"activeCount":100},[],{"trials":3600,"activeCount":100},[],{"intervention":1346,"totalTrials":519,"cells":3602},{"EARLY_PHASE1":3603,"PHASE1":3605,"PHASE2":3611,"PHASE3":3617,"PHASE4":3619,"NA":3621},{"trials":3604,"activeCount":100},[],{"trials":3606,"activeCount":100},[3607],{"nctId":1328,"briefTitle":1329,"status":634,"phases":3608,"primaryCompletion":1331,"completion":1332,"start":1333,"enrollment":1334,"conditions":3609,"interventions":3610},[88],[1336,1337,1338,1339,1340,1341,1342,1343,1344],[1301,1346,1347],{"trials":3612,"activeCount":100},[3613],{"nctId":3271,"briefTitle":3272,"status":634,"phases":3614,"primaryCompletion":3005,"completion":3274,"start":3275,"enrollment":3276,"conditions":3615,"interventions":3616},[88,89],[30,24],[3279,3242],{"trials":3618,"activeCount":100},[],{"trials":3620,"activeCount":100},[],{"trials":3622,"activeCount":100},[],{"intervention":3624,"totalTrials":519,"cells":3625},"Mifepristone 200 MG",{"EARLY_PHASE1":3626,"PHASE1":3628,"PHASE2":3630,"PHASE3":3651,"PHASE4":3653,"NA":3655},{"trials":3627,"activeCount":100},[],{"trials":3629,"activeCount":100},[],{"trials":3631,"activeCount":100},[3632,3641],{"nctId":3633,"briefTitle":3634,"status":532,"phases":3635,"primaryCompletion":3636,"completion":3636,"start":3637,"enrollment":2286,"conditions":3638,"interventions":3640},"NCT03714880","Cervical Preparation With Mifepristone Prior to Osmotic Dilators",[89],"2021-02-26","2019-04-26",[3639],"Second Trimester Abortion",[3624],{"nctId":3642,"briefTitle":3643,"status":532,"phases":3644,"primaryCompletion":3645,"completion":3225,"start":3646,"enrollment":1380,"conditions":3647,"interventions":3649},"NCT03774745","Blocking Mifepristone Action With Progesterone",[88,89],"2019-07-29","2019-02-11",[3648],"Pregnancy, Unwanted",[3624,3650],"micronized Progesterone",{"trials":3652,"activeCount":100},[],{"trials":3654,"activeCount":100},[],{"trials":3656,"activeCount":100},[],{"intervention":3658,"totalTrials":519,"cells":3659},"Sorafenib",{"EARLY_PHASE1":3660,"PHASE1":3662,"PHASE2":3664,"PHASE3":3682,"PHASE4":3684,"NA":3686},{"trials":3661,"activeCount":100},[],{"trials":3663,"activeCount":100},[],{"trials":3665,"activeCount":100},[3666,3674],{"nctId":3667,"briefTitle":3668,"status":634,"phases":3669,"primaryCompletion":3670,"completion":3671,"start":3343,"enrollment":251,"conditions":3672,"interventions":3673},"NCT00810394","Sorafenib in Treating Patients With Advanced Malignant Solid Tumors",[89],"2011-10","2012-03",[24],[3658],{"nctId":3675,"briefTitle":3676,"status":634,"phases":3677,"primaryCompletion":3678,"completion":3678,"start":2425,"enrollment":537,"conditions":3679,"interventions":3681},"NCT00864032","Trial of Neoadjuvant Conformal Radiotherapy Plus Sorafenib for Patients With Soft Tissue Sarcoma of the Extremity and Body Wall",[88,89],"2011-08",[3680],"Soft Tissue Sarcoma",[3658],{"trials":3683,"activeCount":100},[],{"trials":3685,"activeCount":100},[],{"trials":3687,"activeCount":100},[],{"intervention":3689,"totalTrials":519,"cells":3690},"Erlotinib",{"EARLY_PHASE1":3691,"PHASE1":3693,"PHASE2":3695,"PHASE3":3715,"PHASE4":3717,"NA":3719},{"trials":3692,"activeCount":100},[],{"trials":3694,"activeCount":100},[],{"trials":3696,"activeCount":100},[3697,3706],{"nctId":3698,"briefTitle":3699,"status":634,"phases":3700,"primaryCompletion":3701,"completion":2161,"start":2285,"enrollment":142,"conditions":3702,"interventions":3704},"NCT00810719","Gemcitabine and Erlotinib in Treating Patients With Metastatic or Recurrent Pancreatic Cancer",[89],"2013-01",[3703],"Pancreatic Cancer",[3689,3705],"gemcitabine",{"nctId":3707,"briefTitle":3708,"status":634,"phases":3709,"primaryCompletion":2285,"completion":3701,"start":3710,"enrollment":2114,"conditions":3711,"interventions":3712},"NCT00408499","Erlotinib and Cetuximab in Treating Patients With Advanced Solid Tumors With Emphasis on Non-Small Cell Lung Cancer",[88,89],"2006-08",[30,24],[3713,3714],"cetuximab","erlotinib",{"trials":3716,"activeCount":100},[],{"trials":3718,"activeCount":100},[],{"trials":3720,"activeCount":100},[],{"intervention":3159,"totalTrials":519,"cells":3722},{"EARLY_PHASE1":3723,"PHASE1":3725,"PHASE2":3727,"PHASE3":3737,"PHASE4":3739,"NA":3741},{"trials":3724,"activeCount":100},[],{"trials":3726,"activeCount":100},[],{"trials":3728,"activeCount":100},[3729,3733],{"nctId":3150,"briefTitle":3151,"status":634,"phases":3730,"primaryCompletion":3153,"completion":3153,"start":3154,"enrollment":3155,"conditions":3731,"interventions":3732},[89],[3157],[3132,3159],{"nctId":3161,"briefTitle":3162,"status":2047,"phases":3734,"primaryCompletion":2891,"completion":2891,"start":2402,"enrollment":100,"conditions":3735,"interventions":3736},[89],[3165,3166],[3168,3169],{"trials":3738,"activeCount":100},[],{"trials":3740,"activeCount":100},[],{"trials":3742,"activeCount":100},[],{"intervention":3713,"totalTrials":519,"cells":3744},{"EARLY_PHASE1":3745,"PHASE1":3747,"PHASE2":3756,"PHASE3":3762,"PHASE4":3764,"NA":3766},{"trials":3746,"activeCount":100},[],{"trials":3748,"activeCount":100},[3749],{"nctId":3750,"briefTitle":3751,"status":634,"phases":3752,"primaryCompletion":3394,"completion":2817,"start":3395,"enrollment":3370,"conditions":3753,"interventions":3754},"NCT00376727","Cetuximab in Treating Patients With Advanced Solid Tumors",[88],[24],[3713,3755],"molecular diagnostic method",{"trials":3757,"activeCount":100},[3758],{"nctId":3707,"briefTitle":3708,"status":634,"phases":3759,"primaryCompletion":2285,"completion":3701,"start":3710,"enrollment":2114,"conditions":3760,"interventions":3761},[88,89],[30,24],[3713,3714],{"trials":3763,"activeCount":100},[],{"trials":3765,"activeCount":100},[],{"trials":3767,"activeCount":100},[],{"intervention":3147,"totalTrials":96,"cells":3769},{"EARLY_PHASE1":3770,"PHASE1":3772,"PHASE2":3774,"PHASE3":3780,"PHASE4":3782,"NA":3784},{"trials":3771,"activeCount":100},[],{"trials":3773,"activeCount":100},[],{"trials":3775,"activeCount":100},[3776],{"nctId":3141,"briefTitle":3142,"status":2047,"phases":3777,"primaryCompletion":2469,"completion":2469,"start":3069,"enrollment":100,"conditions":3778,"interventions":3779},[89],[3145,1290],[3132,3147,3148],{"trials":3781,"activeCount":100},[],{"trials":3783,"activeCount":100},[],{"trials":3785,"activeCount":100},[],{"intervention":3346,"totalTrials":96,"cells":3787},{"EARLY_PHASE1":3788,"PHASE1":3790,"PHASE2":3792,"PHASE3":3798,"PHASE4":3800,"NA":3802},{"trials":3789,"activeCount":100},[],{"trials":3791,"activeCount":100},[],{"trials":3793,"activeCount":100},[3794],{"nctId":3340,"briefTitle":3341,"status":634,"phases":3795,"primaryCompletion":3153,"completion":2402,"start":3343,"enrollment":1244,"conditions":3796,"interventions":3797},[89],[27],[3346,3313],{"trials":3799,"activeCount":100},[],{"trials":3801,"activeCount":100},[],{"trials":3803,"activeCount":100},[],{"intervention":3805,"totalTrials":96,"cells":3806},"epacadostat",{"EARLY_PHASE1":3807,"PHASE1":3809,"PHASE2":3811,"PHASE3":3824,"PHASE4":3826,"NA":3828},{"trials":3808,"activeCount":100},[],{"trials":3810,"activeCount":100},[],{"trials":3812,"activeCount":100},[3813],{"nctId":3814,"briefTitle":3815,"status":634,"phases":3816,"primaryCompletion":3817,"completion":3818,"start":3819,"enrollment":19,"conditions":3820,"interventions":3822},"NCT03322384","UCDCC#271: Phase I\u002FII Trial of Epacadostat, Intralesional SD101, Radiotherapy in Patients With Lymphoma",[88,89],"2020-02-24","2020-04-08","2018-01-17",[3821,3037],"Advanced Solid Tumors",[3805,3823],"SD-101",{"trials":3825,"activeCount":100},[],{"trials":3827,"activeCount":100},[],{"trials":3829,"activeCount":100},[],{"intervention":3823,"totalTrials":96,"cells":3831},{"EARLY_PHASE1":3832,"PHASE1":3834,"PHASE2":3836,"PHASE3":3842,"PHASE4":3844,"NA":3846},{"trials":3833,"activeCount":100},[],{"trials":3835,"activeCount":100},[],{"trials":3837,"activeCount":100},[3838],{"nctId":3814,"briefTitle":3815,"status":634,"phases":3839,"primaryCompletion":3817,"completion":3818,"start":3819,"enrollment":19,"conditions":3840,"interventions":3841},[88,89],[3821,3037],[3805,3823],{"trials":3843,"activeCount":100},[],{"trials":3845,"activeCount":100},[],{"trials":3847,"activeCount":100},[],{"intervention":3849,"totalTrials":96,"cells":3850},"Ketamine",{"EARLY_PHASE1":3851,"PHASE1":3853,"PHASE2":3855,"PHASE3":3867,"PHASE4":3869,"NA":3871},{"trials":3852,"activeCount":100},[],{"trials":3854,"activeCount":100},[],{"trials":3856,"activeCount":100},[3857],{"nctId":3858,"briefTitle":3859,"status":2047,"phases":3860,"primaryCompletion":3861,"completion":3861,"start":3862,"enrollment":100,"conditions":3863,"interventions":3866},"NCT03502551","ED Treatment of Suicidal Patients With Ketamine Infusion",[89],"2019-06-30","2019-04-01",[3864,3865],"Suicide","Suicidal Ideation",[3849],{"trials":3868,"activeCount":100},[],{"trials":3870,"activeCount":100},[],{"trials":3872,"activeCount":100},[],{"intervention":3874,"totalTrials":96,"cells":3875},"Mild dose cannabis",{"EARLY_PHASE1":3876,"PHASE1":3878,"PHASE2":3880,"PHASE3":3897,"PHASE4":3899,"NA":3901},{"trials":3877,"activeCount":100},[],{"trials":3879,"activeCount":100},[],{"trials":3881,"activeCount":100},[3882],{"nctId":3883,"briefTitle":3884,"status":634,"phases":3885,"primaryCompletion":3886,"completion":3886,"start":3197,"enrollment":2286,"conditions":3887,"interventions":3894},"NCT01037088","Effects of Vaporized Marijuana on Neuropathic Pain",[88,89],"2012-11",[3888,3889,3890,3891,3892,3893],"Neuropathic Pain","Reflex Sympathetic Dystrophy","Peripheral Neuropathy","Post-herpetic Neuralgia","Spinal Cord Injury","Multiple Sclerosis",[3874,3895,3896],"Low dose cannabis","Cannabis",{"trials":3898,"activeCount":100},[],{"trials":3900,"activeCount":100},[],{"trials":3902,"activeCount":100},[],{"intervention":3895,"totalTrials":96,"cells":3904},{"EARLY_PHASE1":3905,"PHASE1":3907,"PHASE2":3909,"PHASE3":3915,"PHASE4":3917,"NA":3919},{"trials":3906,"activeCount":100},[],{"trials":3908,"activeCount":100},[],{"trials":3910,"activeCount":100},[3911],{"nctId":3883,"briefTitle":3884,"status":634,"phases":3912,"primaryCompletion":3886,"completion":3886,"start":3197,"enrollment":2286,"conditions":3913,"interventions":3914},[88,89],[3888,3889,3890,3891,3892,3893],[3874,3895,3896],{"trials":3916,"activeCount":100},[],{"trials":3918,"activeCount":100},[],{"trials":3920,"activeCount":100},[],{"intervention":3896,"totalTrials":96,"cells":3922},{"EARLY_PHASE1":3923,"PHASE1":3925,"PHASE2":3927,"PHASE3":3933,"PHASE4":3935,"NA":3937},{"trials":3924,"activeCount":100},[],{"trials":3926,"activeCount":100},[],{"trials":3928,"activeCount":100},[3929],{"nctId":3883,"briefTitle":3884,"status":634,"phases":3930,"primaryCompletion":3886,"completion":3886,"start":3197,"enrollment":2286,"conditions":3931,"interventions":3932},[88,89],[3888,3889,3890,3891,3892,3893],[3874,3895,3896],{"trials":3934,"activeCount":100},[],{"trials":3936,"activeCount":100},[],{"trials":3938,"activeCount":100},[],{"intervention":3376,"totalTrials":96,"cells":3940},{"EARLY_PHASE1":3941,"PHASE1":3943,"PHASE2":3945,"PHASE3":3951,"PHASE4":3953,"NA":3955},{"trials":3942,"activeCount":100},[],{"trials":3944,"activeCount":100},[],{"trials":3946,"activeCount":100},[3947],{"nctId":3366,"briefTitle":3367,"status":634,"phases":3948,"primaryCompletion":3369,"completion":3069,"start":3265,"enrollment":3370,"conditions":3949,"interventions":3950},[88,89],[30,24],[3373,3269,3374,3375,3376,3377],{"trials":3952,"activeCount":100},[],{"trials":3954,"activeCount":100},[],{"trials":3956,"activeCount":100},[],{"intervention":3958,"totalTrials":96,"cells":3959},"ED-Initiated treatment with buprenorphine \u002F naloxone",{"EARLY_PHASE1":3960,"PHASE1":3962,"PHASE2":3964,"PHASE3":3974,"PHASE4":3976,"NA":3978},{"trials":3961,"activeCount":100},[],{"trials":3963,"activeCount":100},[],{"trials":3965,"activeCount":100},[3966],{"nctId":3967,"briefTitle":3968,"status":2047,"phases":3969,"primaryCompletion":3970,"completion":3970,"start":3970,"enrollment":100,"conditions":3971,"interventions":3973},"NCT04737603","Feasibility of Pediatric Emergency Department-Initiated Treatment for Adolescents With Opioid Use Disorder",[89],"2025-07-30",[3972],"Opioid-use Disorder",[3958],{"trials":3975,"activeCount":100},[],{"trials":3977,"activeCount":100},[],{"trials":3979,"activeCount":100},[],{"intervention":3981,"totalTrials":96,"cells":3982},"Timoptic",{"EARLY_PHASE1":3983,"PHASE1":3985,"PHASE2":3987,"PHASE3":3998,"PHASE4":4000,"NA":4002},{"trials":3984,"activeCount":100},[],{"trials":3986,"activeCount":100},[],{"trials":3988,"activeCount":100},[3989],{"nctId":3990,"briefTitle":3991,"status":532,"phases":3992,"primaryCompletion":3069,"completion":3069,"start":3993,"enrollment":272,"conditions":3994,"interventions":3997},"NCT00368602","Beta Blocker for Chronic Wound Healing",[89],"2005-06",[3995,3996],"Ulcer","Burns",[3981],{"trials":3999,"activeCount":100},[],{"trials":4001,"activeCount":100},[],{"trials":4003,"activeCount":100},[],{"intervention":4005,"totalTrials":96,"cells":4006},"Niraparib",{"EARLY_PHASE1":4007,"PHASE1":4009,"PHASE2":4011,"PHASE3":4040,"PHASE4":4042,"NA":4044},{"trials":4008,"activeCount":100},[],{"trials":4010,"activeCount":100},[],{"trials":4012,"activeCount":100},[4013],{"nctId":4014,"briefTitle":4015,"status":532,"phases":4016,"primaryCompletion":4017,"completion":1666,"start":4018,"enrollment":4019,"conditions":4020,"interventions":4038},"NCT04030559","Niraparib Before Surgery in Treating Patients With High Risk Localized Prostate Cancer and DNA Damage Response Defects",[89],"2024-01-10","2020-02-25",11,[4021,4022,4023,4024,4025,4026,4027,4028,4029,4030,4031,4032,4033,4034,4035,4036,4037],"ATM Gene Mutation","BRCA1 Gene Mutation","BRCA2 Gene Mutation","BRIP1 Gene Mutation","CDK12 Gene Mutation","CHEK1 Gene Mutation","CHEK2 Gene Mutation","DNA Damage Response Gene Mutation","DNA Repair Gene Mutation","FANCA Gene Mutation","FANCD2 Gene Mutation","FANCL Gene Mutation","GEN1 Gene Mutation","NBN Gene Mutation","Prostate Carcinoma","RAD51 Gene Mutation","RAD51C Gene Mutation",[4005,4039],"Niraparib Tosylate Monohydrate",{"trials":4041,"activeCount":100},[],{"trials":4043,"activeCount":100},[],{"trials":4045,"activeCount":100},[],{"intervention":4039,"totalTrials":96,"cells":4047},{"EARLY_PHASE1":4048,"PHASE1":4050,"PHASE2":4052,"PHASE3":4058,"PHASE4":4060,"NA":4062},{"trials":4049,"activeCount":100},[],{"trials":4051,"activeCount":100},[],{"trials":4053,"activeCount":100},[4054],{"nctId":4014,"briefTitle":4015,"status":532,"phases":4055,"primaryCompletion":4017,"completion":1666,"start":4018,"enrollment":4019,"conditions":4056,"interventions":4057},[89],[4021,4022,4023,4024,4025,4026,4027,4028,4029,4030,4031,4032,4033,4034,4035,4036,4037],[4005,4039],{"trials":4059,"activeCount":100},[],{"trials":4061,"activeCount":100},[],{"trials":4063,"activeCount":100},[],{"intervention":4065,"totalTrials":96,"cells":4066},"Ketoconazole",{"EARLY_PHASE1":4067,"PHASE1":4069,"PHASE2":4071,"PHASE3":4080,"PHASE4":4082,"NA":4084},{"trials":4068,"activeCount":100},[],{"trials":4070,"activeCount":100},[],{"trials":4072,"activeCount":100},[4073],{"nctId":4074,"briefTitle":4075,"status":634,"phases":4076,"primaryCompletion":1028,"completion":3294,"start":2426,"enrollment":142,"conditions":4077,"interventions":4078},"NCT00895310","Use of Low Dose Ketoconazole in Prostate Cancer That Does Not Respond to Hormone Therapy and Prior Chemotherapy",[89],[27],[4065,4079],"Hydrocortisone",{"trials":4081,"activeCount":100},[],{"trials":4083,"activeCount":100},[],{"trials":4085,"activeCount":100},[],{"intervention":4079,"totalTrials":96,"cells":4087},{"EARLY_PHASE1":4088,"PHASE1":4090,"PHASE2":4092,"PHASE3":4098,"PHASE4":4100,"NA":4102},{"trials":4089,"activeCount":100},[],{"trials":4091,"activeCount":100},[],{"trials":4093,"activeCount":100},[4094],{"nctId":4074,"briefTitle":4075,"status":634,"phases":4095,"primaryCompletion":1028,"completion":3294,"start":2426,"enrollment":142,"conditions":4096,"interventions":4097},[89],[27],[4065,4079],{"trials":4099,"activeCount":100},[],{"trials":4101,"activeCount":100},[],{"trials":4103,"activeCount":100},[],{"intervention":4105,"totalTrials":96,"cells":4106},"Sertraline",{"EARLY_PHASE1":4107,"PHASE1":4109,"PHASE2":4111,"PHASE3":4123,"PHASE4":4125,"NA":4127},{"trials":4108,"activeCount":100},[],{"trials":4110,"activeCount":100},[],{"trials":4112,"activeCount":100},[4113],{"nctId":4114,"briefTitle":4115,"status":634,"phases":4116,"primaryCompletion":4117,"completion":4117,"start":4118,"enrollment":1486,"conditions":4119,"interventions":4122},"NCT03279471","Specifying and Treating Anxiety in Autism Research",[89],"2023-02-22","2017-10-01",[4120,4121],"Autism Spectrum Disorder","Anxiety",[4105],{"trials":4124,"activeCount":100},[],{"trials":4126,"activeCount":100},[],{"trials":4128,"activeCount":100},[],{"intervention":4130,"totalTrials":96,"cells":4131},"exenatide",{"EARLY_PHASE1":4132,"PHASE1":4134,"PHASE2":4136,"PHASE3":4147,"PHASE4":4149,"NA":4151},{"trials":4133,"activeCount":100},[],{"trials":4135,"activeCount":100},[],{"trials":4137,"activeCount":100},[4138],{"nctId":4139,"briefTitle":4140,"status":532,"phases":4141,"primaryCompletion":3196,"completion":4142,"start":3264,"enrollment":96,"conditions":4143,"interventions":4146},"NCT00529204","Effects Of Exenatide On Liver Biochemistry, Liver Histology And Lipid Metabolism In Patients With Fatty Liver Disease",[89],"2010-02",[4144,4145],"Diabetes Complications","Fatty Liver",[4130],{"trials":4148,"activeCount":100},[],{"trials":4150,"activeCount":100},[],{"trials":4152,"activeCount":100},[],{"intervention":763,"totalTrials":96,"cells":4154},{"EARLY_PHASE1":4155,"PHASE1":4157,"PHASE2":4159,"PHASE3":4165,"PHASE4":4167,"NA":4169},{"trials":4156,"activeCount":100},[],{"trials":4158,"activeCount":100},[],{"trials":4160,"activeCount":100},[4161],{"nctId":754,"briefTitle":755,"status":532,"phases":4162,"primaryCompletion":757,"completion":757,"start":758,"enrollment":519,"conditions":4163,"interventions":4164},[89],[760,761],[763,730],{"trials":4166,"activeCount":100},[],{"trials":4168,"activeCount":100},[],{"trials":4170,"activeCount":100},[],{"intervention":4172,"totalTrials":96,"cells":4173},"24GyE proton and Anti-VEGF",{"EARLY_PHASE1":4174,"PHASE1":4176,"PHASE2":4178,"PHASE3":4192,"PHASE4":4194,"NA":4196},{"trials":4175,"activeCount":100},[],{"trials":4177,"activeCount":100},[],{"trials":4179,"activeCount":100},[4180],{"nctId":4181,"briefTitle":4182,"status":634,"phases":4183,"primaryCompletion":4184,"completion":4184,"start":4185,"enrollment":4186,"conditions":4187,"interventions":4189},"NCT01213082","ProspectiveTrial of Proton Beam Combined With Anti-VEGF Therapy for Exudative Age-related Macular Degeneration (AMD)",[88,89],"2017-01-31","2010-09",34,[4188],"Exudative Age-related Macular Degeneration",[4172,4190,4191],"16GyE and anti-VEGF","Sham Irradiation and anti-VEGF",{"trials":4193,"activeCount":100},[],{"trials":4195,"activeCount":100},[],{"trials":4197,"activeCount":100},[],{"intervention":4190,"totalTrials":96,"cells":4199},{"EARLY_PHASE1":4200,"PHASE1":4202,"PHASE2":4204,"PHASE3":4210,"PHASE4":4212,"NA":4214},{"trials":4201,"activeCount":100},[],{"trials":4203,"activeCount":100},[],{"trials":4205,"activeCount":100},[4206],{"nctId":4181,"briefTitle":4182,"status":634,"phases":4207,"primaryCompletion":4184,"completion":4184,"start":4185,"enrollment":4186,"conditions":4208,"interventions":4209},[88,89],[4188],[4172,4190,4191],{"trials":4211,"activeCount":100},[],{"trials":4213,"activeCount":100},[],{"trials":4215,"activeCount":100},[],{"intervention":4191,"totalTrials":96,"cells":4217},{"EARLY_PHASE1":4218,"PHASE1":4220,"PHASE2":4222,"PHASE3":4228,"PHASE4":4230,"NA":4232},{"trials":4219,"activeCount":100},[],{"trials":4221,"activeCount":100},[],{"trials":4223,"activeCount":100},[4224],{"nctId":4181,"briefTitle":4182,"status":634,"phases":4225,"primaryCompletion":4184,"completion":4184,"start":4185,"enrollment":4186,"conditions":4226,"interventions":4227},[88,89],[4188],[4172,4190,4191],{"trials":4229,"activeCount":100},[],{"trials":4231,"activeCount":100},[],{"trials":4233,"activeCount":100},[],{"intervention":672,"totalTrials":96,"cells":4235},{"EARLY_PHASE1":4236,"PHASE1":4238,"PHASE2":4240,"PHASE3":4246,"PHASE4":4248,"NA":4250},{"trials":4237,"activeCount":100},[],{"trials":4239,"activeCount":100},[],{"trials":4241,"activeCount":100},[4242],{"nctId":663,"briefTitle":664,"status":634,"phases":4243,"primaryCompletion":666,"completion":666,"start":667,"enrollment":9,"conditions":4244,"interventions":4245},[89],[669,670],[672,624],{"trials":4247,"activeCount":100},[],{"trials":4249,"activeCount":100},[],{"trials":4251,"activeCount":100},[],{"intervention":3516,"totalTrials":96,"cells":4253},{"EARLY_PHASE1":4254,"PHASE1":4256,"PHASE2":4258,"PHASE3":4264,"PHASE4":4266,"NA":4268},{"trials":4255,"activeCount":100},[],{"trials":4257,"activeCount":100},[],{"trials":4259,"activeCount":100},[4260],{"nctId":3508,"briefTitle":3509,"status":634,"phases":4261,"primaryCompletion":3005,"completion":3511,"start":3512,"enrollment":914,"conditions":4262,"interventions":4263},[89],[30],[3515,3516],{"trials":4265,"activeCount":100},[],{"trials":4267,"activeCount":100},[],{"trials":4269,"activeCount":100},[],{"intervention":3075,"totalTrials":96,"cells":4271},{"EARLY_PHASE1":4272,"PHASE1":4274,"PHASE2":4276,"PHASE3":4282,"PHASE4":4284,"NA":4286},{"trials":4273,"activeCount":100},[],{"trials":4275,"activeCount":100},[],{"trials":4277,"activeCount":100},[4278],{"nctId":3064,"briefTitle":3065,"status":634,"phases":4279,"primaryCompletion":3067,"completion":3068,"start":3069,"enrollment":537,"conditions":4280,"interventions":4281},[89],[3071,3037,3072,3073],[3075,3015,3076,3077],{"trials":4283,"activeCount":100},[],{"trials":4285,"activeCount":100},[],{"trials":4287,"activeCount":100},[],{"intervention":3076,"totalTrials":96,"cells":4289},{"EARLY_PHASE1":4290,"PHASE1":4292,"PHASE2":4294,"PHASE3":4300,"PHASE4":4302,"NA":4304},{"trials":4291,"activeCount":100},[],{"trials":4293,"activeCount":100},[],{"trials":4295,"activeCount":100},[4296],{"nctId":3064,"briefTitle":3065,"status":634,"phases":4297,"primaryCompletion":3067,"completion":3068,"start":3069,"enrollment":537,"conditions":4298,"interventions":4299},[89],[3071,3037,3072,3073],[3075,3015,3076,3077],{"trials":4301,"activeCount":100},[],{"trials":4303,"activeCount":100},[],{"trials":4305,"activeCount":100},[],{"intervention":3077,"totalTrials":96,"cells":4307},{"EARLY_PHASE1":4308,"PHASE1":4310,"PHASE2":4312,"PHASE3":4318,"PHASE4":4320,"NA":4322},{"trials":4309,"activeCount":100},[],{"trials":4311,"activeCount":100},[],{"trials":4313,"activeCount":100},[4314],{"nctId":3064,"briefTitle":3065,"status":634,"phases":4315,"primaryCompletion":3067,"completion":3068,"start":3069,"enrollment":537,"conditions":4316,"interventions":4317},[89],[3071,3037,3072,3073],[3075,3015,3076,3077],{"trials":4319,"activeCount":100},[],{"trials":4321,"activeCount":100},[],{"trials":4323,"activeCount":100},[],{"intervention":3705,"totalTrials":96,"cells":4325},{"EARLY_PHASE1":4326,"PHASE1":4328,"PHASE2":4330,"PHASE3":4336,"PHASE4":4338,"NA":4340},{"trials":4327,"activeCount":100},[],{"trials":4329,"activeCount":100},[],{"trials":4331,"activeCount":100},[4332],{"nctId":3698,"briefTitle":3699,"status":634,"phases":4333,"primaryCompletion":3701,"completion":2161,"start":2285,"enrollment":142,"conditions":4334,"interventions":4335},[89],[3703],[3689,3705],{"trials":4337,"activeCount":100},[],{"trials":4339,"activeCount":100},[],{"trials":4341,"activeCount":100},[],{"intervention":4343,"totalTrials":96,"cells":4344},"Dovitinib",{"EARLY_PHASE1":4345,"PHASE1":4347,"PHASE2":4349,"PHASE3":4360,"PHASE4":4362,"NA":4364},{"trials":4346,"activeCount":100},[],{"trials":4348,"activeCount":100},[],{"trials":4350,"activeCount":100},[4351],{"nctId":4352,"briefTitle":4353,"status":634,"phases":4354,"primaryCompletion":2402,"completion":4355,"start":4356,"enrollment":33,"conditions":4357,"interventions":4359},"NCT01676714","Study of Dovitinib and Biomarkers in Advanced Non-Small Cell Lung Cancer or Advanced Colorectal Cancer",[89],"2016-06","2013-02",[4358,3145],"Non-Small Cell Lung Cancer",[4343],{"trials":4361,"activeCount":100},[],{"trials":4363,"activeCount":100},[],{"trials":4365,"activeCount":100},[],{"intervention":4367,"totalTrials":96,"cells":4368},"Methotrexate",{"EARLY_PHASE1":4369,"PHASE1":4371,"PHASE2":4373,"PHASE3":4384,"PHASE4":4386,"NA":4388},{"trials":4370,"activeCount":100},[],{"trials":4372,"activeCount":100},[],{"trials":4374,"activeCount":100},[4375],{"nctId":4376,"briefTitle":4377,"status":634,"phases":4378,"primaryCompletion":4379,"completion":4379,"start":3198,"enrollment":1380,"conditions":4380,"interventions":4382},"NCT00368654","Evaluate Whether Combination Therapy With Methotrexate and Raptiva in Psoriasis Patients is Safe and Increases Efficacy",[88,89],"2008-05",[4381],"Psoriasis",[4367,4383],"Raptiva",{"trials":4385,"activeCount":100},[],{"trials":4387,"activeCount":100},[],{"trials":4389,"activeCount":100},[],{"intervention":4383,"totalTrials":96,"cells":4391},{"EARLY_PHASE1":4392,"PHASE1":4394,"PHASE2":4396,"PHASE3":4402,"PHASE4":4404,"NA":4406},{"trials":4393,"activeCount":100},[],{"trials":4395,"activeCount":100},[],{"trials":4397,"activeCount":100},[4398],{"nctId":4376,"briefTitle":4377,"status":634,"phases":4399,"primaryCompletion":4379,"completion":4379,"start":3198,"enrollment":1380,"conditions":4400,"interventions":4401},[88,89],[4381],[4367,4383],{"trials":4403,"activeCount":100},[],{"trials":4405,"activeCount":100},[],{"trials":4407,"activeCount":100},[],{"intervention":4409,"totalTrials":96,"cells":4410},"Clobetasol 0.05% ointment",{"EARLY_PHASE1":4411,"PHASE1":4413,"PHASE2":4415,"PHASE3":4426,"PHASE4":4428,"NA":4430},{"trials":4412,"activeCount":100},[],{"trials":4414,"activeCount":100},[],{"trials":4416,"activeCount":100},[4417],{"nctId":4418,"briefTitle":4419,"status":2047,"phases":4420,"primaryCompletion":4421,"completion":4421,"start":4422,"enrollment":100,"conditions":4423,"interventions":4425},"NCT02319616","Topical Clobetasol for the Treatment of Toxic Epidermal Necrolysis",[88,89],"2019-02-06","2016-11",[4424],"Toxic Epidermal Necrolysis",[4409],{"trials":4427,"activeCount":100},[],{"trials":4429,"activeCount":100},[],{"trials":4431,"activeCount":100},[],{"intervention":4433,"totalTrials":96,"cells":4434},"Abraxane",{"EARLY_PHASE1":4435,"PHASE1":4437,"PHASE2":4439,"PHASE3":4450,"PHASE4":4452,"NA":4454},{"trials":4436,"activeCount":100},[],{"trials":4438,"activeCount":100},[],{"trials":4440,"activeCount":100},[4441],{"nctId":4442,"briefTitle":4443,"status":532,"phases":4444,"primaryCompletion":3324,"completion":3324,"start":4445,"enrollment":4446,"conditions":4447,"interventions":4448},"NCT00470548","Abraxane and Alimta in Advanced Solid Tumors",[88,89],"2007-04",49,[21,30,24],[4433,4449],"Alimta",{"trials":4451,"activeCount":100},[],{"trials":4453,"activeCount":100},[],{"trials":4455,"activeCount":100},[],{"intervention":4449,"totalTrials":96,"cells":4457},{"EARLY_PHASE1":4458,"PHASE1":4460,"PHASE2":4462,"PHASE3":4468,"PHASE4":4470,"NA":4472},{"trials":4459,"activeCount":100},[],{"trials":4461,"activeCount":100},[],{"trials":4463,"activeCount":100},[4464],{"nctId":4442,"briefTitle":4443,"status":532,"phases":4465,"primaryCompletion":3324,"completion":3324,"start":4445,"enrollment":4446,"conditions":4466,"interventions":4467},[88,89],[21,30,24],[4433,4449],{"trials":4469,"activeCount":100},[],{"trials":4471,"activeCount":100},[],{"trials":4473,"activeCount":100},[],{"intervention":3650,"totalTrials":96,"cells":4475},{"EARLY_PHASE1":4476,"PHASE1":4478,"PHASE2":4480,"PHASE3":4486,"PHASE4":4488,"NA":4490},{"trials":4477,"activeCount":100},[],{"trials":4479,"activeCount":100},[],{"trials":4481,"activeCount":100},[4482],{"nctId":3642,"briefTitle":3643,"status":532,"phases":4483,"primaryCompletion":3645,"completion":3225,"start":3646,"enrollment":1380,"conditions":4484,"interventions":4485},[88,89],[3648],[3624,3650],{"trials":4487,"activeCount":100},[],{"trials":4489,"activeCount":100},[],{"trials":4491,"activeCount":100},[],{"intervention":4493,"totalTrials":96,"cells":4494},"L-arginine",{"EARLY_PHASE1":4495,"PHASE1":4497,"PHASE2":4499,"PHASE3":4508,"PHASE4":4510,"NA":4512},{"trials":4496,"activeCount":100},[],{"trials":4498,"activeCount":100},[],{"trials":4500,"activeCount":100},[4501],{"nctId":4502,"briefTitle":4503,"status":634,"phases":4504,"primaryCompletion":4505,"completion":3343,"start":3395,"enrollment":19,"conditions":4506,"interventions":4507},"NCT00280683","Effects of L-arginine Supplementation in Adults With Moderate to Severe Asthma",[89],"2008-11",[2189],[4493],{"trials":4509,"activeCount":100},[],{"trials":4511,"activeCount":100},[],{"trials":4513,"activeCount":100},[],{"intervention":4515,"totalTrials":96,"cells":4516},"T-Vec",{"EARLY_PHASE1":4517,"PHASE1":4519,"PHASE2":4521,"PHASE3":4534,"PHASE4":4536,"NA":4538},{"trials":4518,"activeCount":100},[],{"trials":4520,"activeCount":100},[],{"trials":4522,"activeCount":100},[4523],{"nctId":4524,"briefTitle":4525,"status":4526,"phases":4527,"primaryCompletion":4528,"completion":4529,"start":4530,"enrollment":2187,"conditions":4531,"interventions":4533},"NCT04427306","Neoadjuvant T-VEC in High Risk Early Melanoma","SUSPENDED",[89],"2022-06-27","2024-05-21","2020-05-21",[4532],"Melanoma",[4515],{"trials":4535,"activeCount":100},[],{"trials":4537,"activeCount":100},[],{"trials":4539,"activeCount":100},[],{"intervention":4541,"totalTrials":96,"cells":4542},"Inhaled Cannabis",{"EARLY_PHASE1":4543,"PHASE1":4545,"PHASE2":4547,"PHASE3":4561,"PHASE4":4563,"NA":4565},{"trials":4544,"activeCount":100},[],{"trials":4546,"activeCount":100},[],{"trials":4548,"activeCount":100},[4549],{"nctId":4550,"briefTitle":4551,"status":532,"phases":4552,"primaryCompletion":4553,"completion":4553,"start":4554,"enrollment":4555,"conditions":4556,"interventions":4557},"NCT00682929","Cannabis for Spasticity in Multiple Sclerosis",[88,89],"2011-08-17","2004-04-14",41,[3893],[4541,4558,4559,4560],"Oral THC","Oral Placebo","Inhaled placebo",{"trials":4562,"activeCount":100},[],{"trials":4564,"activeCount":100},[],{"trials":4566,"activeCount":100},[],{"intervention":4558,"totalTrials":96,"cells":4568},{"EARLY_PHASE1":4569,"PHASE1":4571,"PHASE2":4573,"PHASE3":4579,"PHASE4":4581,"NA":4583},{"trials":4570,"activeCount":100},[],{"trials":4572,"activeCount":100},[],{"trials":4574,"activeCount":100},[4575],{"nctId":4550,"briefTitle":4551,"status":532,"phases":4576,"primaryCompletion":4553,"completion":4553,"start":4554,"enrollment":4555,"conditions":4577,"interventions":4578},[88,89],[3893],[4541,4558,4559,4560],{"trials":4580,"activeCount":100},[],{"trials":4582,"activeCount":100},[],{"trials":4584,"activeCount":100},[],{"intervention":4559,"totalTrials":96,"cells":4586},{"EARLY_PHASE1":4587,"PHASE1":4589,"PHASE2":4591,"PHASE3":4597,"PHASE4":4599,"NA":4601},{"trials":4588,"activeCount":100},[],{"trials":4590,"activeCount":100},[],{"trials":4592,"activeCount":100},[4593],{"nctId":4550,"briefTitle":4551,"status":532,"phases":4594,"primaryCompletion":4553,"completion":4553,"start":4554,"enrollment":4555,"conditions":4595,"interventions":4596},[88,89],[3893],[4541,4558,4559,4560],{"trials":4598,"activeCount":100},[],{"trials":4600,"activeCount":100},[],{"trials":4602,"activeCount":100},[],{"intervention":4560,"totalTrials":96,"cells":4604},{"EARLY_PHASE1":4605,"PHASE1":4607,"PHASE2":4609,"PHASE3":4615,"PHASE4":4617,"NA":4619},{"trials":4606,"activeCount":100},[],{"trials":4608,"activeCount":100},[],{"trials":4610,"activeCount":100},[4611],{"nctId":4550,"briefTitle":4551,"status":532,"phases":4612,"primaryCompletion":4553,"completion":4553,"start":4554,"enrollment":4555,"conditions":4613,"interventions":4614},[88,89],[3893],[4541,4558,4559,4560],{"trials":4616,"activeCount":100},[],{"trials":4618,"activeCount":100},[],{"trials":4620,"activeCount":100},[],{"intervention":3030,"totalTrials":625,"cells":4622},{"EARLY_PHASE1":4623,"PHASE1":4625,"PHASE2":4643,"PHASE3":4645,"PHASE4":4647,"NA":4649},{"trials":4624,"activeCount":100},[],{"trials":4626,"activeCount":100},[4627,4631,4635,4639],{"nctId":3022,"briefTitle":3023,"status":3024,"phases":4628,"start":3026,"enrollment":3027,"conditions":4629,"interventions":4630},[88],[21],[3030,3015],{"nctId":3042,"briefTitle":3043,"status":3024,"phases":4632,"start":3045,"conditions":4633,"interventions":4634},[88],[3037],[3030,3039,3015,3040],{"nctId":3049,"briefTitle":3050,"status":3024,"phases":4636,"start":3035,"conditions":4637,"interventions":4638},[88],[27],[3030,3054,3015,3040],{"nctId":3056,"briefTitle":3057,"status":3024,"phases":4640,"start":3035,"conditions":4641,"interventions":4642},[88],[21],[3030,3054,3015,3040],{"trials":4644,"activeCount":100},[],{"trials":4646,"activeCount":100},[],{"trials":4648,"activeCount":100},[],{"trials":4650,"activeCount":100},[],{"intervention":3040,"totalTrials":625,"cells":4652},{"EARLY_PHASE1":4653,"PHASE1":4655,"PHASE2":4673,"PHASE3":4675,"PHASE4":4677,"NA":4679},{"trials":4654,"activeCount":100},[],{"trials":4656,"activeCount":100},[4657,4661,4665,4669],{"nctId":3032,"briefTitle":3033,"status":3024,"phases":4658,"start":3035,"conditions":4659,"interventions":4660},[88],[3037],[3039,3015,3040],{"nctId":3042,"briefTitle":3043,"status":3024,"phases":4662,"start":3045,"conditions":4663,"interventions":4664},[88],[3037],[3030,3039,3015,3040],{"nctId":3049,"briefTitle":3050,"status":3024,"phases":4666,"start":3035,"conditions":4667,"interventions":4668},[88],[27],[3030,3054,3015,3040],{"nctId":3056,"briefTitle":3057,"status":3024,"phases":4670,"start":3035,"conditions":4671,"interventions":4672},[88],[21],[3030,3054,3015,3040],{"trials":4674,"activeCount":100},[],{"trials":4676,"activeCount":100},[],{"trials":4678,"activeCount":100},[],{"trials":4680,"activeCount":100},[],{"intervention":3503,"totalTrials":519,"cells":4682},{"EARLY_PHASE1":4683,"PHASE1":4685,"PHASE2":4703,"PHASE3":4705,"PHASE4":4707,"NA":4709},{"trials":4684,"activeCount":100},[],{"trials":4686,"activeCount":100},[4687,4691],{"nctId":3496,"briefTitle":3497,"status":532,"phases":4688,"primaryCompletion":3499,"completion":3421,"start":2425,"enrollment":3500,"conditions":4689,"interventions":4690},[88],[30,24],[3489,3503,3504],{"nctId":4692,"briefTitle":4693,"status":634,"phases":4694,"primaryCompletion":4695,"completion":4355,"start":4696,"enrollment":1258,"conditions":4697,"interventions":4699},"NCT02194049","Cisplatin, Etoposide and PI3K Inhibitor BKM120 in Treating Patients With Advanced Solid Tumors or Small Cell Lung Cancer",[88],"2016-04","2014-07",[4698,24],"Extensive Stage Small Cell Lung Cancer",[4700,4701,4702],"BKM120","cisplatin","etoposide",{"trials":4704,"activeCount":100},[],{"trials":4706,"activeCount":100},[],{"trials":4708,"activeCount":100},[],{"trials":4710,"activeCount":100},[],{"intervention":3039,"totalTrials":519,"cells":4712},{"EARLY_PHASE1":4713,"PHASE1":4715,"PHASE2":4725,"PHASE3":4727,"PHASE4":4729,"NA":4731},{"trials":4714,"activeCount":100},[],{"trials":4716,"activeCount":100},[4717,4721],{"nctId":3032,"briefTitle":3033,"status":3024,"phases":4718,"start":3035,"conditions":4719,"interventions":4720},[88],[3037],[3039,3015,3040],{"nctId":3042,"briefTitle":3043,"status":3024,"phases":4722,"start":3045,"conditions":4723,"interventions":4724},[88],[3037],[3030,3039,3015,3040],{"trials":4726,"activeCount":100},[],{"trials":4728,"activeCount":100},[],{"trials":4730,"activeCount":100},[],{"trials":4732,"activeCount":100},[],{"intervention":3424,"totalTrials":519,"cells":4734},{"EARLY_PHASE1":4735,"PHASE1":4737,"PHASE2":4752,"PHASE3":4754,"PHASE4":4756,"NA":4758},{"trials":4736,"activeCount":100},[],{"trials":4738,"activeCount":100},[4739,4748],{"nctId":4740,"briefTitle":4741,"status":532,"phases":4742,"primaryCompletion":3678,"completion":4743,"start":4744,"enrollment":3500,"conditions":4745,"interventions":4746},"NCT00804310","Lapatinib and Ixabepilone in Treating Patients With Advanced Solid Tumors",[88],"2011-09","2009-08",[24],[4747,3424],"ixabepilone",{"nctId":3418,"briefTitle":3419,"status":634,"phases":4749,"primaryCompletion":2285,"completion":3421,"start":2816,"enrollment":2236,"conditions":4750,"interventions":4751},[88],[24],[3424,3425,3426,3427,3374,3375,3428,3429,3430,3377,3424,3431],{"trials":4753,"activeCount":100},[],{"trials":4755,"activeCount":100},[],{"trials":4757,"activeCount":100},[],{"trials":4759,"activeCount":100},[],{"intervention":4761,"totalTrials":519,"cells":4762},"Enzalutamide",{"EARLY_PHASE1":4763,"PHASE1":4765,"PHASE2":4791,"PHASE3":4793,"PHASE4":4795,"NA":4797},{"trials":4764,"activeCount":100},[],{"trials":4766,"activeCount":100},[4767,4780],{"nctId":4768,"briefTitle":4769,"status":634,"phases":4770,"primaryCompletion":4771,"completion":4772,"start":4773,"enrollment":2187,"conditions":4774,"interventions":4778},"NCT03123978","Enzalutamide and Niclosamide in Treating Patients With Recurrent or Metastatic Castration-Resistant Prostate Cancer",[88],"2022-01-14","2022-04-19","2017-01-09",[4775,4776,4777],"Metastatic Prostate Carcinoma","Recurrent Prostate Carcinoma","Stage IV Prostate Cancer",[4761,4779],"Niclosamide",{"nctId":4781,"briefTitle":4782,"status":634,"phases":4783,"primaryCompletion":4784,"completion":4785,"start":4786,"enrollment":4787,"conditions":4788,"interventions":4789},"NCT02339168","Enzalutamide and Metformin Hydrochloride in Treating Patients With Hormone-Resistant Prostate Cancer",[88],"2024-10-15","2025-02-24","2016-06-22",25,[27],[4761,4790],"Metformin Hydrochloride",{"trials":4792,"activeCount":100},[],{"trials":4794,"activeCount":100},[],{"trials":4796,"activeCount":100},[],{"trials":4798,"activeCount":100},[],{"intervention":3054,"totalTrials":519,"cells":4800},{"EARLY_PHASE1":4801,"PHASE1":4803,"PHASE2":4813,"PHASE3":4815,"PHASE4":4817,"NA":4819},{"trials":4802,"activeCount":100},[],{"trials":4804,"activeCount":100},[4805,4809],{"nctId":3049,"briefTitle":3050,"status":3024,"phases":4806,"start":3035,"conditions":4807,"interventions":4808},[88],[27],[3030,3054,3015,3040],{"nctId":3056,"briefTitle":3057,"status":3024,"phases":4810,"start":3035,"conditions":4811,"interventions":4812},[88],[21],[3030,3054,3015,3040],{"trials":4814,"activeCount":100},[],{"trials":4816,"activeCount":100},[],{"trials":4818,"activeCount":100},[],{"trials":4820,"activeCount":100},[],{"intervention":4822,"totalTrials":96,"cells":4823},"Roflumilast",{"EARLY_PHASE1":4824,"PHASE1":4826,"PHASE2":4837,"PHASE3":4839,"PHASE4":4841,"NA":4843},{"trials":4825,"activeCount":100},[],{"trials":4827,"activeCount":100},[4828],{"nctId":4829,"briefTitle":4830,"status":532,"phases":4831,"primaryCompletion":4832,"completion":4833,"start":4834,"enrollment":3500,"conditions":4835,"interventions":4836},"NCT04108377","Phosphodiesterase 4 Inhibitor, Roflumilast, and the Effects of Inhibition in Severe Asthma",[88],"2022-12-11","2023-08-15","2019-01-21",[2189],[4822],{"trials":4838,"activeCount":100},[],{"trials":4840,"activeCount":100},[],{"trials":4842,"activeCount":100},[],{"trials":4844,"activeCount":100},[],{"intervention":4846,"totalTrials":96,"cells":4847},"Prevacid",{"EARLY_PHASE1":4848,"PHASE1":4850,"PHASE2":4860,"PHASE3":4862,"PHASE4":4864,"NA":4866},{"trials":4849,"activeCount":100},[],{"trials":4851,"activeCount":100},[4852],{"nctId":4853,"briefTitle":4854,"status":634,"phases":4855,"primaryCompletion":4379,"completion":4379,"start":3536,"enrollment":4856,"conditions":4857,"interventions":4859},"NCT00864396","Twice Daily Prevacid for the Treatment of Laryngopharyngeal Reflux",[88],59,[4858],"Laryngopharyngeal Reflux",[4846],{"trials":4861,"activeCount":100},[],{"trials":4863,"activeCount":100},[],{"trials":4865,"activeCount":100},[],{"trials":4867,"activeCount":100},[],{"intervention":4869,"totalTrials":96,"cells":4870},"Botulinum Toxin Type A",{"EARLY_PHASE1":4871,"PHASE1":4873,"PHASE2":4884,"PHASE3":4886,"PHASE4":4888,"NA":4890},{"trials":4872,"activeCount":100},[],{"trials":4874,"activeCount":100},[4875],{"nctId":4876,"briefTitle":4877,"status":634,"phases":4878,"primaryCompletion":4879,"completion":4879,"start":4880,"enrollment":28,"conditions":4881,"interventions":4883},"NCT03203174","The Use of Microneedles With Topical Botulinum Toxin for Treatment of Palmar Hyperhidrosis",[88],"2016-08-02","2015-01",[4882],"Hyperhidrosis",[4869],{"trials":4885,"activeCount":100},[],{"trials":4887,"activeCount":100},[],{"trials":4889,"activeCount":100},[],{"trials":4891,"activeCount":100},[],{"intervention":4893,"totalTrials":96,"cells":4894},"Casodex",{"EARLY_PHASE1":4895,"PHASE1":4897,"PHASE2":4910,"PHASE3":4912,"PHASE4":4914,"NA":4916},{"trials":4896,"activeCount":100},[],{"trials":4898,"activeCount":100},[4899],{"nctId":4900,"briefTitle":4901,"status":634,"phases":4902,"primaryCompletion":4903,"completion":4904,"start":4905,"enrollment":3568,"conditions":4906,"interventions":4908},"NCT02064036","Stereotactic Boost and Long-Term Androgen Deprivation for Adenocarcinoma of the Prostate",[88],"2020-12-03","2021-10-29","2013-06-06",[4907],"Adenocarcinoma of the Prostate",[4893,4909],"Leuprolide",{"trials":4911,"activeCount":100},[],{"trials":4913,"activeCount":100},[],{"trials":4915,"activeCount":100},[],{"trials":4917,"activeCount":100},[],{"intervention":4909,"totalTrials":96,"cells":4919},{"EARLY_PHASE1":4920,"PHASE1":4922,"PHASE2":4928,"PHASE3":4930,"PHASE4":4932,"NA":4934},{"trials":4921,"activeCount":100},[],{"trials":4923,"activeCount":100},[4924],{"nctId":4900,"briefTitle":4901,"status":634,"phases":4925,"primaryCompletion":4903,"completion":4904,"start":4905,"enrollment":3568,"conditions":4926,"interventions":4927},[88],[4907],[4893,4909],{"trials":4929,"activeCount":100},[],{"trials":4931,"activeCount":100},[],{"trials":4933,"activeCount":100},[],{"trials":4935,"activeCount":100},[],{"intervention":3504,"totalTrials":96,"cells":4937},{"EARLY_PHASE1":4938,"PHASE1":4940,"PHASE2":4946,"PHASE3":4948,"PHASE4":4950,"NA":4952},{"trials":4939,"activeCount":100},[],{"trials":4941,"activeCount":100},[4942],{"nctId":3496,"briefTitle":3497,"status":532,"phases":4943,"primaryCompletion":3499,"completion":3421,"start":2425,"enrollment":3500,"conditions":4944,"interventions":4945},[88],[30,24],[3489,3503,3504],{"trials":4947,"activeCount":100},[],{"trials":4949,"activeCount":100},[],{"trials":4951,"activeCount":100},[],{"trials":4953,"activeCount":100},[],{"intervention":4700,"totalTrials":96,"cells":4955},{"EARLY_PHASE1":4956,"PHASE1":4958,"PHASE2":4964,"PHASE3":4966,"PHASE4":4968,"NA":4970},{"trials":4957,"activeCount":100},[],{"trials":4959,"activeCount":100},[4960],{"nctId":4692,"briefTitle":4693,"status":634,"phases":4961,"primaryCompletion":4695,"completion":4355,"start":4696,"enrollment":1258,"conditions":4962,"interventions":4963},[88],[4698,24],[4700,4701,4702],{"trials":4965,"activeCount":100},[],{"trials":4967,"activeCount":100},[],{"trials":4969,"activeCount":100},[],{"trials":4971,"activeCount":100},[],{"intervention":4701,"totalTrials":96,"cells":4973},{"EARLY_PHASE1":4974,"PHASE1":4976,"PHASE2":4982,"PHASE3":4984,"PHASE4":4986,"NA":4988},{"trials":4975,"activeCount":100},[],{"trials":4977,"activeCount":100},[4978],{"nctId":4692,"briefTitle":4693,"status":634,"phases":4979,"primaryCompletion":4695,"completion":4355,"start":4696,"enrollment":1258,"conditions":4980,"interventions":4981},[88],[4698,24],[4700,4701,4702],{"trials":4983,"activeCount":100},[],{"trials":4985,"activeCount":100},[],{"trials":4987,"activeCount":100},[],{"trials":4989,"activeCount":100},[],{"intervention":4991,"totalTrials":96,"cells":4992},"Intravitreal autologous CD34+ cells",{"EARLY_PHASE1":4993,"PHASE1":4995,"PHASE2":5005,"PHASE3":5007,"PHASE4":5009,"NA":5011},{"trials":4994,"activeCount":100},[],{"trials":4996,"activeCount":100},[4997],{"nctId":4998,"briefTitle":4999,"status":634,"phases":5000,"primaryCompletion":5001,"completion":5001,"start":5002,"enrollment":625,"conditions":5003,"interventions":5004},"NCT04925687","Phase 1 Study of Intravitreal Autologous CD34+ Stem Cell Therapy for Retinitis Pigmentosa",[88],"2023-11-01","2021-06-01",[1566],[4991],{"trials":5006,"activeCount":100},[],{"trials":5008,"activeCount":100},[],{"trials":5010,"activeCount":100},[],{"trials":5012,"activeCount":100},[],{"intervention":5014,"totalTrials":96,"cells":5015},"Ursolic acid",{"EARLY_PHASE1":5016,"PHASE1":5018,"PHASE2":5030,"PHASE3":5032,"PHASE4":5034,"NA":5036},{"trials":5017,"activeCount":100},[],{"trials":5019,"activeCount":100},[5020],{"nctId":5021,"briefTitle":5022,"status":2047,"phases":5023,"primaryCompletion":5024,"completion":5025,"start":5026,"enrollment":100,"conditions":5027,"interventions":5029},"NCT03216876","A Study Of Ursolic Acid For Primary Sclerosing Cholangitis",[88],"2019-01","2019-07","2017-09",[5028],"Primary Sclerosing Cholangitis",[5014],{"trials":5031,"activeCount":100},[],{"trials":5033,"activeCount":100},[],{"trials":5035,"activeCount":100},[],{"trials":5037,"activeCount":100},[],{"intervention":3578,"totalTrials":96,"cells":5039},{"EARLY_PHASE1":5040,"PHASE1":5042,"PHASE2":5048,"PHASE3":5050,"PHASE4":5052,"NA":5054},{"trials":5041,"activeCount":100},[],{"trials":5043,"activeCount":100},[5044],{"nctId":3563,"briefTitle":3564,"status":634,"phases":5045,"primaryCompletion":3566,"completion":3566,"start":3567,"enrollment":3568,"conditions":5046,"interventions":5047},[88],[3570,3571,3572,3573,3574,3575,3576,24],[3556,3578],{"trials":5049,"activeCount":100},[],{"trials":5051,"activeCount":100},[],{"trials":5053,"activeCount":100},[],{"trials":5055,"activeCount":100},[],{"intervention":5057,"totalTrials":96,"cells":5058},"Topiramate",{"EARLY_PHASE1":5059,"PHASE1":5061,"PHASE2":5072,"PHASE3":5074,"PHASE4":5076,"NA":5078},{"trials":5060,"activeCount":100},[],{"trials":5062,"activeCount":100},[5063],{"nctId":5064,"briefTitle":5065,"status":634,"phases":5066,"primaryCompletion":5067,"completion":5067,"start":5068,"enrollment":1244,"conditions":5069,"interventions":5071},"NCT01426542","Preventing Brain Injury in Infants With Congenital Heart Disease",[88],"2017-07-28","2011-03",[5070],"Cyanotic Congenital Heart Disease",[5057],{"trials":5073,"activeCount":100},[],{"trials":5075,"activeCount":100},[],{"trials":5077,"activeCount":100},[],{"trials":5079,"activeCount":100},[],{"intervention":4747,"totalTrials":96,"cells":5081},{"EARLY_PHASE1":5082,"PHASE1":5084,"PHASE2":5090,"PHASE3":5092,"PHASE4":5094,"NA":5096},{"trials":5083,"activeCount":100},[],{"trials":5085,"activeCount":100},[5086],{"nctId":4740,"briefTitle":4741,"status":532,"phases":5087,"primaryCompletion":3678,"completion":4743,"start":4744,"enrollment":3500,"conditions":5088,"interventions":5089},[88],[24],[4747,3424],{"trials":5091,"activeCount":100},[],{"trials":5093,"activeCount":100},[],{"trials":5095,"activeCount":100},[],{"trials":5097,"activeCount":100},[],{"intervention":1347,"totalTrials":96,"cells":5099},{"EARLY_PHASE1":5100,"PHASE1":5102,"PHASE2":5108,"PHASE3":5110,"PHASE4":5112,"NA":5114},{"trials":5101,"activeCount":100},[],{"trials":5103,"activeCount":100},[5104],{"nctId":1328,"briefTitle":1329,"status":634,"phases":5105,"primaryCompletion":1331,"completion":1332,"start":1333,"enrollment":1334,"conditions":5106,"interventions":5107},[88],[1336,1337,1338,1339,1340,1341,1342,1343,1344],[1301,1346,1347],{"trials":5109,"activeCount":100},[],{"trials":5111,"activeCount":100},[],{"trials":5113,"activeCount":100},[],{"trials":5115,"activeCount":100},[],{"intervention":3228,"totalTrials":96,"cells":5117},{"EARLY_PHASE1":5118,"PHASE1":5120,"PHASE2":5126,"PHASE3":5128,"PHASE4":5130,"NA":5132},{"trials":5119,"activeCount":100},[],{"trials":5121,"activeCount":100},[5122],{"nctId":3220,"briefTitle":3221,"status":634,"phases":5123,"primaryCompletion":3223,"completion":3224,"start":3225,"enrollment":2187,"conditions":5124,"interventions":5125},[88],[1670,1671,1673],[661,3228],{"trials":5127,"activeCount":100},[],{"trials":5129,"activeCount":100},[],{"trials":5131,"activeCount":100},[],{"trials":5133,"activeCount":100},[],{"intervention":4779,"totalTrials":96,"cells":5135},{"EARLY_PHASE1":5136,"PHASE1":5138,"PHASE2":5144,"PHASE3":5146,"PHASE4":5148,"NA":5150},{"trials":5137,"activeCount":100},[],{"trials":5139,"activeCount":100},[5140],{"nctId":4768,"briefTitle":4769,"status":634,"phases":5141,"primaryCompletion":4771,"completion":4772,"start":4773,"enrollment":2187,"conditions":5142,"interventions":5143},[88],[4775,4776,4777],[4761,4779],{"trials":5145,"activeCount":100},[],{"trials":5147,"activeCount":100},[],{"trials":5149,"activeCount":100},[],{"trials":5151,"activeCount":100},[],{"intervention":3398,"totalTrials":96,"cells":5153},{"EARLY_PHASE1":5154,"PHASE1":5156,"PHASE2":5162,"PHASE3":5164,"PHASE4":5166,"NA":5168},{"trials":5155,"activeCount":100},[],{"trials":5157,"activeCount":100},[5158],{"nctId":3391,"briefTitle":3392,"status":634,"phases":5159,"primaryCompletion":3394,"completion":3154,"start":3395,"enrollment":1244,"conditions":5160,"interventions":5161},[88],[30,24],[3373,3398],{"trials":5163,"activeCount":100},[],{"trials":5165,"activeCount":100},[],{"trials":5167,"activeCount":100},[],{"trials":5169,"activeCount":100},[],{"intervention":3257,"totalTrials":96,"cells":5171},{"EARLY_PHASE1":5172,"PHASE1":5174,"PHASE2":5180,"PHASE3":5182,"PHASE4":5184,"NA":5186},{"trials":5173,"activeCount":100},[],{"trials":5175,"activeCount":100},[5176],{"nctId":3249,"briefTitle":3250,"status":634,"phases":5177,"primaryCompletion":3252,"completion":3252,"start":3253,"enrollment":2684,"conditions":5178,"interventions":5179},[88],[3255],[3257,3242],{"trials":5181,"activeCount":100},[],{"trials":5183,"activeCount":100},[],{"trials":5185,"activeCount":100},[],{"trials":5187,"activeCount":100},[],{"intervention":5189,"totalTrials":96,"cells":5190},"Panobinostat, Cisplatin, Pemetrexed",{"EARLY_PHASE1":5191,"PHASE1":5193,"PHASE2":5206,"PHASE3":5208,"PHASE4":5210,"NA":5212},{"trials":5192,"activeCount":100},[],{"trials":5194,"activeCount":100},[5195],{"nctId":5196,"briefTitle":5197,"status":634,"phases":5198,"primaryCompletion":2891,"completion":5199,"start":5200,"enrollment":5201,"conditions":5202,"interventions":5205},"NCT01336842","Study of Cisplatin and Pemetrexed in Combination With Panobinostat in Solid Tumors",[88],"2017-06","2011-04",23,[5203,5204],"Solid Tumors","Non-Small Cell Lung Cancer (NSCLC)",[5189],{"trials":5207,"activeCount":100},[],{"trials":5209,"activeCount":100},[],{"trials":5211,"activeCount":100},[],{"trials":5213,"activeCount":100},[],{"intervention":3755,"totalTrials":96,"cells":5215},{"EARLY_PHASE1":5216,"PHASE1":5218,"PHASE2":5224,"PHASE3":5226,"PHASE4":5228,"NA":5230},{"trials":5217,"activeCount":100},[],{"trials":5219,"activeCount":100},[5220],{"nctId":3750,"briefTitle":3751,"status":634,"phases":5221,"primaryCompletion":3394,"completion":2817,"start":3395,"enrollment":3370,"conditions":5222,"interventions":5223},[88],[24],[3713,3755],{"trials":5225,"activeCount":100},[],{"trials":5227,"activeCount":100},[],{"trials":5229,"activeCount":100},[],{"trials":5231,"activeCount":100},[],{"intervention":3336,"totalTrials":96,"cells":5233},{"EARLY_PHASE1":5234,"PHASE1":5236,"PHASE2":5242,"PHASE3":5244,"PHASE4":5246,"NA":5248},{"trials":5235,"activeCount":100},[],{"trials":5237,"activeCount":100},[5238],{"nctId":3320,"briefTitle":3321,"status":634,"phases":5239,"primaryCompletion":3323,"completion":3323,"start":3324,"enrollment":19,"conditions":5240,"interventions":5241},[88],[3326,3327,3328,3329,3330,3331,3332,3333],[3335,3336],{"trials":5243,"activeCount":100},[],{"trials":5245,"activeCount":100},[],{"trials":5247,"activeCount":100},[],{"trials":5249,"activeCount":100},[],{"intervention":5251,"totalTrials":96,"cells":5252},"Temsirolimus, Pazopanib",{"EARLY_PHASE1":5253,"PHASE1":5255,"PHASE2":5264,"PHASE3":5266,"PHASE4":5268,"NA":5270},{"trials":5254,"activeCount":100},[],{"trials":5256,"activeCount":100},[5257],{"nctId":5258,"briefTitle":5259,"status":634,"phases":5260,"primaryCompletion":5261,"completion":5261,"start":4142,"enrollment":537,"conditions":5262,"interventions":5263},"NCT01072890","Temsirolimus and Pazopanib in Patients With Advanced Solid Tumors",[88],"2012-02",[5203],[5251],{"trials":5265,"activeCount":100},[],{"trials":5267,"activeCount":100},[],{"trials":5269,"activeCount":100},[],{"trials":5271,"activeCount":100},[],{"intervention":5273,"totalTrials":96,"cells":5274},"Lidocaine",{"EARLY_PHASE1":5275,"PHASE1":5277,"PHASE2":5287,"PHASE3":5289,"PHASE4":5291,"NA":5293},{"trials":5276,"activeCount":100},[],{"trials":5278,"activeCount":100},[5279],{"nctId":5280,"briefTitle":5281,"status":634,"phases":5282,"primaryCompletion":5283,"completion":5284,"start":292,"enrollment":1380,"conditions":5285,"interventions":5286},"NCT04716699","Systemic and Local Levels of Lidocaine During Surgery for the Removal of Glioblastoma",[88],"2021-12-26","2022-01-24",[1515],[5273],{"trials":5288,"activeCount":100},[],{"trials":5290,"activeCount":100},[],{"trials":5292,"activeCount":100},[],{"trials":5294,"activeCount":100},[],{"intervention":5296,"totalTrials":96,"cells":5297},"Eltrombopag",{"EARLY_PHASE1":5298,"PHASE1":5300,"PHASE2":5312,"PHASE3":5314,"PHASE4":5316,"NA":5318},{"trials":5299,"activeCount":100},[],{"trials":5301,"activeCount":100},[5302],{"nctId":5303,"briefTitle":5304,"status":4526,"phases":5305,"primaryCompletion":5306,"completion":5306,"start":5307,"enrollment":33,"conditions":5308,"interventions":5311},"NCT04485416","Pilot Trial of Eltrombopag in Patients Undergoing Chemotherapy for Malignant Solid Tumors",[88],"2025-05-17","2021-07-16",[5309,5310],"Solid Tumor, Childhood","Solid Tumor",[5296],{"trials":5313,"activeCount":100},[],{"trials":5315,"activeCount":100},[],{"trials":5317,"activeCount":100},[],{"trials":5319,"activeCount":100},[],{"intervention":5321,"totalTrials":96,"cells":5322},"Nitrosomonas eutropha",{"EARLY_PHASE1":5323,"PHASE1":5325,"PHASE2":5335,"PHASE3":5337,"PHASE4":5339,"NA":5341},{"trials":5324,"activeCount":100},[],{"trials":5326,"activeCount":100},[5327],{"nctId":5328,"briefTitle":5329,"status":634,"phases":5330,"primaryCompletion":5331,"completion":5331,"start":5332,"enrollment":142,"conditions":5333,"interventions":5334},"NCT02938650","Nitrosomonas Eutropha on Nitrolipids in the Skin",[88],"2017-05","2016-10",[35],[5321],{"trials":5336,"activeCount":100},[],{"trials":5338,"activeCount":100},[],{"trials":5340,"activeCount":100},[],{"trials":5342,"activeCount":100},[],{"intervention":3425,"totalTrials":96,"cells":5344},{"EARLY_PHASE1":5345,"PHASE1":5347,"PHASE2":5353,"PHASE3":5355,"PHASE4":5357,"NA":5359},{"trials":5346,"activeCount":100},[],{"trials":5348,"activeCount":100},[5349],{"nctId":3418,"briefTitle":3419,"status":634,"phases":5350,"primaryCompletion":2285,"completion":3421,"start":2816,"enrollment":2236,"conditions":5351,"interventions":5352},[88],[24],[3424,3425,3426,3427,3374,3375,3428,3429,3430,3377,3424,3431],{"trials":5354,"activeCount":100},[],{"trials":5356,"activeCount":100},[],{"trials":5358,"activeCount":100},[],{"trials":5360,"activeCount":100},[],{"intervention":3426,"totalTrials":96,"cells":5362},{"EARLY_PHASE1":5363,"PHASE1":5365,"PHASE2":5371,"PHASE3":5373,"PHASE4":5375,"NA":5377},{"trials":5364,"activeCount":100},[],{"trials":5366,"activeCount":100},[5367],{"nctId":3418,"briefTitle":3419,"status":634,"phases":5368,"primaryCompletion":2285,"completion":3421,"start":2816,"enrollment":2236,"conditions":5369,"interventions":5370},[88],[24],[3424,3425,3426,3427,3374,3375,3428,3429,3430,3377,3424,3431],{"trials":5372,"activeCount":100},[],{"trials":5374,"activeCount":100},[],{"trials":5376,"activeCount":100},[],{"trials":5378,"activeCount":100},[],{"intervention":3427,"totalTrials":96,"cells":5380},{"EARLY_PHASE1":5381,"PHASE1":5383,"PHASE2":5389,"PHASE3":5391,"PHASE4":5393,"NA":5395},{"trials":5382,"activeCount":100},[],{"trials":5384,"activeCount":100},[5385],{"nctId":3418,"briefTitle":3419,"status":634,"phases":5386,"primaryCompletion":2285,"completion":3421,"start":2816,"enrollment":2236,"conditions":5387,"interventions":5388},[88],[24],[3424,3425,3426,3427,3374,3375,3428,3429,3430,3377,3424,3431],{"trials":5390,"activeCount":100},[],{"trials":5392,"activeCount":100},[],{"trials":5394,"activeCount":100},[],{"trials":5396,"activeCount":100},[],{"intervention":3428,"totalTrials":96,"cells":5398},{"EARLY_PHASE1":5399,"PHASE1":5401,"PHASE2":5407,"PHASE3":5409,"PHASE4":5411,"NA":5413},{"trials":5400,"activeCount":100},[],{"trials":5402,"activeCount":100},[5403],{"nctId":3418,"briefTitle":3419,"status":634,"phases":5404,"primaryCompletion":2285,"completion":3421,"start":2816,"enrollment":2236,"conditions":5405,"interventions":5406},[88],[24],[3424,3425,3426,3427,3374,3375,3428,3429,3430,3377,3424,3431],{"trials":5408,"activeCount":100},[],{"trials":5410,"activeCount":100},[],{"trials":5412,"activeCount":100},[],{"trials":5414,"activeCount":100},[],{"intervention":3429,"totalTrials":96,"cells":5416},{"EARLY_PHASE1":5417,"PHASE1":5419,"PHASE2":5425,"PHASE3":5427,"PHASE4":5429,"NA":5431},{"trials":5418,"activeCount":100},[],{"trials":5420,"activeCount":100},[5421],{"nctId":3418,"briefTitle":3419,"status":634,"phases":5422,"primaryCompletion":2285,"completion":3421,"start":2816,"enrollment":2236,"conditions":5423,"interventions":5424},[88],[24],[3424,3425,3426,3427,3374,3375,3428,3429,3430,3377,3424,3431],{"trials":5426,"activeCount":100},[],{"trials":5428,"activeCount":100},[],{"trials":5430,"activeCount":100},[],{"trials":5432,"activeCount":100},[],{"intervention":3430,"totalTrials":96,"cells":5434},{"EARLY_PHASE1":5435,"PHASE1":5437,"PHASE2":5443,"PHASE3":5445,"PHASE4":5447,"NA":5449},{"trials":5436,"activeCount":100},[],{"trials":5438,"activeCount":100},[5439],{"nctId":3418,"briefTitle":3419,"status":634,"phases":5440,"primaryCompletion":2285,"completion":3421,"start":2816,"enrollment":2236,"conditions":5441,"interventions":5442},[88],[24],[3424,3425,3426,3427,3374,3375,3428,3429,3430,3377,3424,3431],{"trials":5444,"activeCount":100},[],{"trials":5446,"activeCount":100},[],{"trials":5448,"activeCount":100},[],{"trials":5450,"activeCount":100},[],{"intervention":4790,"totalTrials":96,"cells":5452},{"EARLY_PHASE1":5453,"PHASE1":5455,"PHASE2":5461,"PHASE3":5463,"PHASE4":5465,"NA":5467},{"trials":5454,"activeCount":100},[],{"trials":5456,"activeCount":100},[5457],{"nctId":4781,"briefTitle":4782,"status":634,"phases":5458,"primaryCompletion":4784,"completion":4785,"start":4786,"enrollment":4787,"conditions":5459,"interventions":5460},[88],[27],[4761,4790],{"trials":5462,"activeCount":100},[],{"trials":5464,"activeCount":100},[],{"trials":5466,"activeCount":100},[],{"trials":5468,"activeCount":100},[],{"intervention":5470,"totalTrials":96,"cells":5471},"Tretinoin",{"EARLY_PHASE1":5472,"PHASE1":5483,"PHASE2":5485,"PHASE3":5487,"PHASE4":5489,"NA":5491},{"trials":5473,"activeCount":100},[5474],{"nctId":5475,"briefTitle":5476,"status":634,"phases":5477,"primaryCompletion":5478,"completion":5478,"start":5479,"enrollment":1334,"conditions":5480,"interventions":5481},"NCT02620813","De Novo Lipogenesis of Sebaceous Glands in Acne",[87],"2017-10-12","2015-10",[721],[5470,5482],"Isotretinoin",{"trials":5484,"activeCount":100},[],{"trials":5486,"activeCount":100},[],{"trials":5488,"activeCount":100},[],{"trials":5490,"activeCount":100},[],{"trials":5492,"activeCount":100},[],{"intervention":5494,"totalTrials":96,"cells":5495},"18F-αvβ6-BP",{"EARLY_PHASE1":5496,"PHASE1":5507,"PHASE2":5509,"PHASE3":5511,"PHASE4":5513,"NA":5515},{"trials":5497,"activeCount":100},[5498],{"nctId":5499,"briefTitle":5500,"status":634,"phases":5501,"primaryCompletion":5502,"completion":5502,"start":5503,"enrollment":3500,"conditions":5504,"interventions":5506},"NCT04376593","PET\u002FCT Imaging in COVID-19 Patients",[87],"2026-02-23","2020-05-01",[117,5505],"SARS-CoV-2 Infection",[5494],{"trials":5508,"activeCount":100},[],{"trials":5510,"activeCount":100},[],{"trials":5512,"activeCount":100},[],{"trials":5514,"activeCount":100},[],{"trials":5516,"activeCount":100},[],{"intervention":5518,"totalTrials":96,"cells":5519},"Carbon-14-labeled carboplatin",{"EARLY_PHASE1":5520,"PHASE1":5531,"PHASE2":5533,"PHASE3":5535,"PHASE4":5537,"NA":5539},{"trials":5521,"activeCount":100},[5522],{"nctId":5523,"briefTitle":5524,"status":532,"phases":5525,"primaryCompletion":4422,"completion":4422,"start":3111,"enrollment":5526,"conditions":5527,"interventions":5530},"NCT01261299","Clinical Study of Microdosing Carboplatin in Lung or Bladder Cancer",[87],21,[5528,5529],"Carcinoma, Non-Small-Cell Lung","Urinary Bladder Neoplasms",[5518],{"trials":5532,"activeCount":100},[],{"trials":5534,"activeCount":100},[],{"trials":5536,"activeCount":100},[],{"trials":5538,"activeCount":100},[],{"trials":5540,"activeCount":100},[],{"intervention":5542,"totalTrials":96,"cells":5543},"Proton beam irradiation and ranibizumab",{"EARLY_PHASE1":5544,"PHASE1":5555,"PHASE2":5557,"PHASE3":5559,"PHASE4":5561,"NA":5563},{"trials":5545,"activeCount":100},[5546],{"nctId":5547,"briefTitle":5548,"status":634,"phases":5549,"primaryCompletion":5550,"completion":5550,"start":5551,"enrollment":2187,"conditions":5552,"interventions":5554},"NCT00517010","Pilot Study of Lucentis Combined With Proton Beam Irradiation in Treating Wet Age-related Macular Degeneration",[87],"2010-06","2007-05",[5553],"Age-related Macular Degeneration",[5542],{"trials":5556,"activeCount":100},[],{"trials":5558,"activeCount":100},[],{"trials":5560,"activeCount":100},[],{"trials":5562,"activeCount":100},[],{"trials":5564,"activeCount":100},[],{"intervention":5566,"totalTrials":96,"cells":5567},"[18F]F-AraG Imaging",{"EARLY_PHASE1":5568,"PHASE1":5579,"PHASE2":5581,"PHASE3":5583,"PHASE4":5585,"NA":5587},{"trials":5569,"activeCount":100},[5570],{"nctId":5571,"briefTitle":5572,"status":634,"phases":5573,"primaryCompletion":5574,"completion":5574,"start":5575,"enrollment":3500,"conditions":5576,"interventions":5578},"NCT04678440","[18F]F-AraG\u002FTotal Body PET Imaging and Healthy Subjects and Lung Cancer Patients",[87],"2023-02-07","2021-03-31",[5577],"Lung Cancer, Nonsmall Cell",[5566],{"trials":5580,"activeCount":100},[],{"trials":5582,"activeCount":100},[],{"trials":5584,"activeCount":100},[],{"trials":5586,"activeCount":100},[],{"trials":5588,"activeCount":100},[],{"intervention":5590,"totalTrials":96,"cells":5591},"Bakuchiol",{"EARLY_PHASE1":5592,"PHASE1":5605,"PHASE2":5607,"PHASE3":5609,"PHASE4":5611,"NA":5613},{"trials":5593,"activeCount":100},[5594],{"nctId":5595,"briefTitle":5596,"status":634,"phases":5597,"primaryCompletion":5598,"completion":5598,"start":5599,"enrollment":2286,"conditions":5600,"interventions":5603},"NCT03112863","Comparison of the Cosmetic Effects of Bakuchiol and Retinol",[87],"2019-03-01","2017-03-24",[5601,5602],"Wrinkle","Photoaging",[5590,5604],"Retinol",{"trials":5606,"activeCount":100},[],{"trials":5608,"activeCount":100},[],{"trials":5610,"activeCount":100},[],{"trials":5612,"activeCount":100},[],{"trials":5614,"activeCount":100},[],{"intervention":5604,"totalTrials":96,"cells":5616},{"EARLY_PHASE1":5617,"PHASE1":5623,"PHASE2":5625,"PHASE3":5627,"PHASE4":5629,"NA":5631},{"trials":5618,"activeCount":100},[5619],{"nctId":5595,"briefTitle":5596,"status":634,"phases":5620,"primaryCompletion":5598,"completion":5598,"start":5599,"enrollment":2286,"conditions":5621,"interventions":5622},[87],[5601,5602],[5590,5604],{"trials":5624,"activeCount":100},[],{"trials":5626,"activeCount":100},[],{"trials":5628,"activeCount":100},[],{"trials":5630,"activeCount":100},[],{"trials":5632,"activeCount":100},[],{"intervention":5634,"totalTrials":96,"cells":5635},"Fluorine F 18 Ara-G",{"EARLY_PHASE1":5636,"PHASE1":5652,"PHASE2":5654,"PHASE3":5656,"PHASE4":5658,"NA":5660},{"trials":5637,"activeCount":100},[5638],{"nctId":5639,"briefTitle":5640,"status":2047,"phases":5641,"primaryCompletion":5642,"completion":5642,"start":5643,"enrollment":100,"conditions":5644,"interventions":5651},"NCT04186988","[18F]-AraG for the Detection of T-Cell Activation in Advanced Non-small Cell Lung Cancer Patients Undergoing PD-1\u002FPD-L1-Directed Therapy",[87],"2020-03-12","2019-11-05",[1629,5645,1639,5646,5647,5648,1642,5649,5650],"Metastatic Lung Non-Small Cell Carcinoma","Stage IIIA Lung Cancer AJCC v8","Stage IIIB Lung Cancer AJCC v8","Stage IIIC Lung Cancer AJCC v8","Stage IVA Lung Cancer AJCC v8","Stage IVB Lung Cancer AJCC v8",[5634],{"trials":5653,"activeCount":100},[],{"trials":5655,"activeCount":100},[],{"trials":5657,"activeCount":100},[],{"trials":5659,"activeCount":100},[],{"trials":5661,"activeCount":100},[],{"intervention":5663,"totalTrials":96,"cells":5664},"Acetaminophen\u002Fhydrocodone",{"EARLY_PHASE1":5665,"PHASE1":5675,"PHASE2":5677,"PHASE3":5679,"PHASE4":5681,"NA":5683},{"trials":5666,"activeCount":100},[5667],{"nctId":5668,"briefTitle":5669,"status":634,"phases":5670,"primaryCompletion":5479,"completion":5479,"start":4880,"enrollment":96,"conditions":5671,"interventions":5673},"NCT02373254","NSAIDS Versus Opioids in Acute SER II Ankle Fractures",[87],[5672],"Ankle Fracture",[5674,5663],"Ibuprofen",{"trials":5676,"activeCount":100},[],{"trials":5678,"activeCount":100},[],{"trials":5680,"activeCount":100},[],{"trials":5682,"activeCount":100},[],{"trials":5684,"activeCount":100},[],{"intervention":5686,"totalTrials":96,"cells":5687},"Transdermal Lidocaine",{"EARLY_PHASE1":5688,"PHASE1":5699,"PHASE2":5701,"PHASE3":5703,"PHASE4":5705,"NA":5707},{"trials":5689,"activeCount":100},[5690],{"nctId":5691,"briefTitle":5692,"status":634,"phases":5693,"primaryCompletion":5694,"completion":2160,"start":5695,"enrollment":142,"conditions":5696,"interventions":5698},"NCT02088866","Commercial Lidocaine Patch as a Treatment for Ear-ringing",[87],"2015-08","2014-03",[5697],"Tinnitus",[5686],{"trials":5700,"activeCount":100},[],{"trials":5702,"activeCount":100},[],{"trials":5704,"activeCount":100},[],{"trials":5706,"activeCount":100},[],{"trials":5708,"activeCount":100},[],{"intervention":1314,"totalTrials":96,"cells":5710},{"EARLY_PHASE1":5711,"PHASE1":5717,"PHASE2":5719,"PHASE3":5721,"PHASE4":5723,"NA":5725},{"trials":5712,"activeCount":100},[5713],{"nctId":1306,"briefTitle":1307,"status":634,"phases":5714,"primaryCompletion":1309,"completion":1309,"start":1310,"enrollment":1258,"conditions":5715,"interventions":5716},[87],[1312],[1314,661,1301],{"trials":5718,"activeCount":100},[],{"trials":5720,"activeCount":100},[],{"trials":5722,"activeCount":100},[],{"trials":5724,"activeCount":100},[],{"trials":5726,"activeCount":100},[],{"intervention":5728,"totalTrials":625,"cells":5729},"Aminolevulinic Acid",{"EARLY_PHASE1":5730,"PHASE1":5741,"PHASE2":5753,"PHASE3":5755,"PHASE4":5757,"NA":5759},{"trials":5731,"activeCount":100},[5732],{"nctId":5733,"briefTitle":5734,"status":634,"phases":5735,"primaryCompletion":5736,"completion":5736,"start":2891,"enrollment":1380,"conditions":5737,"interventions":5739},"NCT03114111","Pilot Study for the Use of Photodynamic Therapy in the Treatment of Seborrheic Dermatitis",[87],"2019-12-04",[5738],"Seborrheic Dermatitis",[5740],"aminolevulinic acid",{"trials":5742,"activeCount":100},[5743],{"nctId":5744,"briefTitle":5745,"status":2047,"phases":5746,"primaryCompletion":5747,"completion":5748,"start":5749,"enrollment":100,"conditions":5750,"interventions":5752},"NCT06252727","Fluorescent Aided Resection and Evaluation of Soft Tissue Sarcomas (FLARES)",[88],"2026-02","2026-05","2024-07",[3680,5751],"Soft Tissue Sarcoma Adult",[5728],{"trials":5754,"activeCount":100},[],{"trials":5756,"activeCount":100},[],{"trials":5758,"activeCount":100},[],{"trials":5760,"activeCount":100},[5761,5768],{"nctId":5762,"briefTitle":5763,"status":634,"phases":5764,"primaryCompletion":5695,"completion":5695,"start":1560,"enrollment":1766,"conditions":5765,"interventions":5767},"NCT01812837","The Use of Microneedles in Photodynamic Therapy",[92],[5766],"Actinic Keratosis",[5728],{"nctId":5769,"briefTitle":5770,"status":634,"phases":5771,"primaryCompletion":4786,"completion":4786,"start":5772,"enrollment":1334,"conditions":5773,"interventions":5775},"NCT02594644","The Use of Microneedles to Expedite Treatment Time in Photodynamic Therapy",[92],"2014-11-06",[5774],"Keratosis, Actinic",[5728],{"intervention":5482,"totalTrials":519,"cells":5777},{"EARLY_PHASE1":5778,"PHASE1":5784,"PHASE2":5786,"PHASE3":5788,"PHASE4":5790,"NA":5792},{"trials":5779,"activeCount":100},[5780],{"nctId":5475,"briefTitle":5476,"status":634,"phases":5781,"primaryCompletion":5478,"completion":5478,"start":5479,"enrollment":1334,"conditions":5782,"interventions":5783},[87],[721],[5470,5482],{"trials":5785,"activeCount":100},[],{"trials":5787,"activeCount":100},[],{"trials":5789,"activeCount":100},[],{"trials":5791,"activeCount":100},[],{"trials":5793,"activeCount":100},[5794],{"nctId":5795,"briefTitle":5796,"status":634,"phases":5797,"primaryCompletion":3294,"completion":2159,"start":3068,"enrollment":142,"conditions":5798,"interventions":5800},"NCT02180425","The Lipid Profile of the Skin Surface in Acne",[],[5799],"Acne",[5801,5482],"Tretinoin or Adapalene",{"intervention":5674,"totalTrials":519,"cells":5803},{"EARLY_PHASE1":5804,"PHASE1":5810,"PHASE2":5812,"PHASE3":5814,"PHASE4":5816,"NA":5818},{"trials":5805,"activeCount":100},[5806],{"nctId":5668,"briefTitle":5669,"status":634,"phases":5807,"primaryCompletion":5479,"completion":5479,"start":4880,"enrollment":96,"conditions":5808,"interventions":5809},[87],[5672],[5674,5663],{"trials":5811,"activeCount":100},[],{"trials":5813,"activeCount":100},[],{"trials":5815,"activeCount":100},[],{"trials":5817,"activeCount":100},[],{"trials":5819,"activeCount":100},[5820],{"nctId":5821,"briefTitle":5822,"status":634,"phases":5823,"primaryCompletion":2160,"completion":2160,"start":4880,"enrollment":36,"conditions":5824,"interventions":5826},"NCT02902913","Impact of Extra Virgin Olive Oil Oleocanthal Content on Platelet Reactivity",[92],[5825],"Cardiovascular Diseases",[5674],{"intervention":5828,"totalTrials":519,"cells":5829},"Memantine",{"EARLY_PHASE1":5830,"PHASE1":5832,"PHASE2":5834,"PHASE3":5836,"PHASE4":5838,"NA":5840},{"trials":5831,"activeCount":100},[],{"trials":5833,"activeCount":100},[],{"trials":5835,"activeCount":100},[],{"trials":5837,"activeCount":100},[],{"trials":5839,"activeCount":100},[],{"trials":5841,"activeCount":100},[5842,5851],{"nctId":5843,"briefTitle":5844,"status":634,"phases":5845,"primaryCompletion":5846,"completion":5846,"start":2213,"enrollment":2867,"conditions":5847,"interventions":5850},"NCT00584948","Memantine Treatment in Fragile X-Associated Tremor\u002FAtaxia Syndrome",[92],"2012-09",[5848,5849],"Fragile X-Associated Tremor\u002FAtaxia Syndrome","Fragile X Premutation Carriers",[5828],{"nctId":5852,"briefTitle":5853,"status":2047,"phases":5854,"primaryCompletion":5855,"completion":5856,"start":5857,"enrollment":100,"conditions":5858,"interventions":5860},"NCT00986115","Efficacy and Safety of the Use of Memantine for Preserving Cognition in Adult Patients With Epilepsy",[92],"2012-01","2012-04","2010-07",[5859],"Epilepsy",[5828],{"intervention":5862,"totalTrials":96,"cells":5863},"Dexmedetomidine",{"EARLY_PHASE1":5864,"PHASE1":5866,"PHASE2":5868,"PHASE3":5870,"PHASE4":5872,"NA":5874},{"trials":5865,"activeCount":100},[],{"trials":5867,"activeCount":100},[],{"trials":5869,"activeCount":100},[],{"trials":5871,"activeCount":100},[],{"trials":5873,"activeCount":100},[],{"trials":5875,"activeCount":100},[5876],{"nctId":5877,"briefTitle":5878,"status":634,"phases":5879,"primaryCompletion":2426,"completion":5880,"start":2259,"enrollment":2236,"conditions":5881,"interventions":5883},"NCT00710437","Effects of Dexmedetomidine on the Intraoperative Electroencephalogram During Endarterectomy Surgery",[],"2009-11",[5882],"Endarterectomy, Carotid",[5862],{"intervention":5885,"totalTrials":96,"cells":5886},"Heparin",{"EARLY_PHASE1":5887,"PHASE1":5889,"PHASE2":5891,"PHASE3":5893,"PHASE4":5895,"NA":5897},{"trials":5888,"activeCount":100},[],{"trials":5890,"activeCount":100},[],{"trials":5892,"activeCount":100},[],{"trials":5894,"activeCount":100},[],{"trials":5896,"activeCount":100},[],{"trials":5898,"activeCount":100},[5899],{"nctId":5900,"briefTitle":5901,"status":532,"phases":5902,"primaryCompletion":5903,"completion":5903,"start":5904,"enrollment":251,"conditions":5905,"interventions":5906},"NCT02755818","Study of the Relationship Between Body Composition, Insulin Resistance and HDL Levels",[],"2019-02-28","2008-10-22",[18,920],[5885],{"intervention":5908,"totalTrials":96,"cells":5909},"Imiquimod",{"EARLY_PHASE1":5910,"PHASE1":5912,"PHASE2":5914,"PHASE3":5916,"PHASE4":5918,"NA":5920},{"trials":5911,"activeCount":100},[],{"trials":5913,"activeCount":100},[],{"trials":5915,"activeCount":100},[],{"trials":5917,"activeCount":100},[],{"trials":5919,"activeCount":100},[],{"trials":5921,"activeCount":100},[5922],{"nctId":5923,"briefTitle":5924,"status":532,"phases":5925,"primaryCompletion":5926,"completion":5926,"start":5927,"enrollment":2187,"conditions":5928,"interventions":5929},"NCT04809662","Comparing Immune Responses to Topical Imiquimod",[],"2023-11-07","2021-03-16",[228],[5908],{"intervention":5931,"totalTrials":96,"cells":5932},"Ultrasound guided pectoral nerve block",{"EARLY_PHASE1":5933,"PHASE1":5935,"PHASE2":5937,"PHASE3":5939,"PHASE4":5941,"NA":5943},{"trials":5934,"activeCount":100},[],{"trials":5936,"activeCount":100},[],{"trials":5938,"activeCount":100},[],{"trials":5940,"activeCount":100},[],{"trials":5942,"activeCount":100},[],{"trials":5944,"activeCount":100},[5945],{"nctId":5946,"briefTitle":5947,"status":532,"phases":5948,"primaryCompletion":5949,"completion":5949,"start":5950,"enrollment":1380,"conditions":5951,"interventions":5953},"NCT03201809","Comparison of Preoperative Ultrasound Guided Pectoralis Nerve Block Placement Versus Intra-operative Placement: A Prospective Randomized Trial",[92],"2020-03-23","2016-09-01",[5952],"Post-operative Pain",[5931],{"intervention":5955,"totalTrials":96,"cells":5956},"Thiamine 100 MG\u002FML",{"EARLY_PHASE1":5957,"PHASE1":5959,"PHASE2":5961,"PHASE3":5963,"PHASE4":5965,"NA":5967},{"trials":5958,"activeCount":100},[],{"trials":5960,"activeCount":100},[],{"trials":5962,"activeCount":100},[],{"trials":5964,"activeCount":100},[],{"trials":5966,"activeCount":100},[],{"trials":5968,"activeCount":100},[5969],{"nctId":5970,"briefTitle":5971,"status":634,"phases":5972,"primaryCompletion":5973,"completion":5973,"start":5974,"enrollment":5975,"conditions":5976,"interventions":5978},"NCT03626337","Thiamine Responsive Disorders (TRD) Among Infants in Lao PDR",[],"2021-02-25","2019-06-17",1394,[5977],"Thiamine Deficiency",[5955],{"intervention":5980,"totalTrials":96,"cells":5981},"Zinc Oxide and Avobenzone",{"EARLY_PHASE1":5982,"PHASE1":5984,"PHASE2":5986,"PHASE3":5988,"PHASE4":5990,"NA":5992},{"trials":5983,"activeCount":100},[],{"trials":5985,"activeCount":100},[],{"trials":5987,"activeCount":100},[],{"trials":5989,"activeCount":100},[],{"trials":5991,"activeCount":100},[],{"trials":5993,"activeCount":100},[5994],{"nctId":5995,"briefTitle":5996,"status":634,"phases":5997,"primaryCompletion":5998,"completion":5998,"start":5999,"enrollment":3568,"conditions":6000,"interventions":6002},"NCT05865431","Singlet Oxygen Quantification After Skin Exposure to Ultraviolet A (UVA) Light",[92],"2018-02-02","2017-03-17",[6001],"Sun Damaged Skin",[5980],{"intervention":6004,"totalTrials":96,"cells":6005},"Etanercept",{"EARLY_PHASE1":6006,"PHASE1":6008,"PHASE2":6010,"PHASE3":6012,"PHASE4":6014,"NA":6016},{"trials":6007,"activeCount":100},[],{"trials":6009,"activeCount":100},[],{"trials":6011,"activeCount":100},[],{"trials":6013,"activeCount":100},[],{"trials":6015,"activeCount":100},[],{"trials":6017,"activeCount":100},[6018],{"nctId":6019,"briefTitle":6020,"status":2047,"phases":6021,"primaryCompletion":2235,"completion":6022,"start":6023,"enrollment":100,"conditions":6024,"interventions":6026},"NCT03178955","Circadian RA Study in Rheumatoid Arthritis Subjects",[],"2019-08-16","2017-03-27",[6025],"Rheumatoid Arthritis",[6004],{"intervention":6028,"totalTrials":96,"cells":6029},"Genistein Combined Polysaccharide",{"EARLY_PHASE1":6030,"PHASE1":6032,"PHASE2":6034,"PHASE3":6036,"PHASE4":6038,"NA":6040},{"trials":6031,"activeCount":100},[],{"trials":6033,"activeCount":100},[],{"trials":6035,"activeCount":100},[],{"trials":6037,"activeCount":100},[],{"trials":6039,"activeCount":100},[],{"trials":6041,"activeCount":100},[6042],{"nctId":6043,"briefTitle":6044,"status":634,"phases":6045,"primaryCompletion":6046,"completion":6047,"start":6048,"enrollment":6049,"conditions":6050,"interventions":6051},"NCT00269555","Effects of GCP on Prostate Cancer.",[92],"2006-01","2006-09","2004-05",62,[27],[6028],{"intervention":5801,"totalTrials":96,"cells":6053},{"EARLY_PHASE1":6054,"PHASE1":6056,"PHASE2":6058,"PHASE3":6060,"PHASE4":6062,"NA":6064},{"trials":6055,"activeCount":100},[],{"trials":6057,"activeCount":100},[],{"trials":6059,"activeCount":100},[],{"trials":6061,"activeCount":100},[],{"trials":6063,"activeCount":100},[],{"trials":6065,"activeCount":100},[6066],{"nctId":5795,"briefTitle":5796,"status":634,"phases":6067,"primaryCompletion":3294,"completion":2159,"start":3068,"enrollment":142,"conditions":6068,"interventions":6069},[],[5799],[5801,5482],{"intervention":6071,"totalTrials":96,"cells":6072},"41 Ca",{"EARLY_PHASE1":6073,"PHASE1":6075,"PHASE2":6077,"PHASE3":6079,"PHASE4":6081,"NA":6083},{"trials":6074,"activeCount":100},[],{"trials":6076,"activeCount":100},[],{"trials":6078,"activeCount":100},[],{"trials":6080,"activeCount":100},[],{"trials":6082,"activeCount":100},[],{"trials":6084,"activeCount":100},[6085],{"nctId":6086,"briefTitle":6087,"status":532,"phases":6088,"primaryCompletion":3701,"completion":2088,"start":2866,"enrollment":28,"conditions":6089,"interventions":6090},"NCT00918645","Calcium-41 (41Ca) Chloride Aqueous Solution in Diagnosing Patients With Prostate Cancer and Bone Metastasis",[92],[1290,27],[6071],{"intervention":6092,"totalTrials":96,"cells":6093},"minocycline hydrochloride",{"EARLY_PHASE1":6094,"PHASE1":6096,"PHASE2":6098,"PHASE3":6100,"PHASE4":6102,"NA":6104},{"trials":6095,"activeCount":100},[],{"trials":6097,"activeCount":100},[],{"trials":6099,"activeCount":100},[],{"trials":6101,"activeCount":100},[],{"trials":6103,"activeCount":100},[],{"trials":6105,"activeCount":100},[6106],{"nctId":6107,"briefTitle":6108,"status":634,"phases":6109,"primaryCompletion":3421,"completion":3421,"start":6110,"enrollment":1005,"conditions":6111,"interventions":6112},"NCT01053156","Trial of Minocycline to Treat Children With Fragile X Syndrome",[92],"2010-01",[1489],[6092],{"intervention":6114,"totalTrials":96,"cells":6115},"Letrozole",{"EARLY_PHASE1":6116,"PHASE1":6118,"PHASE2":6120,"PHASE3":6122,"PHASE4":6124,"NA":6126},{"trials":6117,"activeCount":100},[],{"trials":6119,"activeCount":100},[],{"trials":6121,"activeCount":100},[],{"trials":6123,"activeCount":100},[],{"trials":6125,"activeCount":100},[],{"trials":6127,"activeCount":100},[6128],{"nctId":6129,"briefTitle":6130,"status":634,"phases":6131,"primaryCompletion":6132,"completion":6132,"start":6133,"enrollment":6134,"conditions":6135,"interventions":6137},"NCT00997373","Letrozole as a Treatment of Endometrial Cancer",[92],"2013-09","2009-10",43,[6136],"Endometrial Carcinoma",[6114],{"intervention":6139,"totalTrials":96,"cells":6140},"raltegravir",{"EARLY_PHASE1":6141,"PHASE1":6143,"PHASE2":6145,"PHASE3":6147,"PHASE4":6149,"NA":6151},{"trials":6142,"activeCount":100},[],{"trials":6144,"activeCount":100},[],{"trials":6146,"activeCount":100},[],{"trials":6148,"activeCount":100},[],{"trials":6150,"activeCount":100},[],{"trials":6152,"activeCount":100},[6153],{"nctId":6154,"briefTitle":6155,"status":634,"phases":6156,"primaryCompletion":4185,"completion":6157,"start":6158,"enrollment":4787,"conditions":6159,"interventions":6161},"NCT00661960","Pilot Project of Virologic and Immunologic Correlates of GALT Immune Reconstitution Following Raltegravir Therapy",[92],"2011-07","2008-03",[2288,6160],"AIDS",[6139,6162],"efavirenz",{"intervention":6162,"totalTrials":96,"cells":6164},{"EARLY_PHASE1":6165,"PHASE1":6167,"PHASE2":6169,"PHASE3":6171,"PHASE4":6173,"NA":6175},{"trials":6166,"activeCount":100},[],{"trials":6168,"activeCount":100},[],{"trials":6170,"activeCount":100},[],{"trials":6172,"activeCount":100},[],{"trials":6174,"activeCount":100},[],{"trials":6176,"activeCount":100},[6177],{"nctId":6154,"briefTitle":6155,"status":634,"phases":6178,"primaryCompletion":4185,"completion":6157,"start":6158,"enrollment":4787,"conditions":6179,"interventions":6180},[92],[2288,6160],[6139,6162],{"intervention":6182,"totalTrials":96,"cells":6183},"perflutren lipid microspheres",{"EARLY_PHASE1":6184,"PHASE1":6186,"PHASE2":6188,"PHASE3":6190,"PHASE4":6192,"NA":6194},{"trials":6185,"activeCount":100},[],{"trials":6187,"activeCount":100},[],{"trials":6189,"activeCount":100},[],{"trials":6191,"activeCount":100},[],{"trials":6193,"activeCount":100},[],{"trials":6195,"activeCount":100},[6196],{"nctId":6197,"briefTitle":6198,"status":634,"phases":6199,"primaryCompletion":2425,"completion":2425,"start":4445,"enrollment":537,"conditions":6200,"interventions":6202},"NCT00584402","Contrast Sonography for Evaluation of Liver Tumors Prior to Radiofrequency Ablation",[92],[6201],"Liver Neoplasms",[6182],{"intervention":6204,"totalTrials":96,"cells":6205},"Fluoxetine",{"EARLY_PHASE1":6206,"PHASE1":6208,"PHASE2":6210,"PHASE3":6212,"PHASE4":6214,"NA":6216},{"trials":6207,"activeCount":100},[],{"trials":6209,"activeCount":100},[],{"trials":6211,"activeCount":100},[],{"trials":6213,"activeCount":100},[],{"trials":6215,"activeCount":100},[],{"trials":6217,"activeCount":100},[6218],{"nctId":6219,"briefTitle":6220,"status":634,"phases":6221,"primaryCompletion":5261,"completion":6222,"start":4744,"enrollment":519,"conditions":6223,"interventions":6226},"NCT00986310","Efficacy of Fluoxetine in Reducing Ictal Hypoventilation in Patients With Partial Epilepsy",[92],"2012-06",[6224,6225],"Uncontrolled Partial Epilepsy","Ictal Hypoventilation",[6204],{"intervention":6228,"totalTrials":96,"cells":6229},"Amitriptyline",{"EARLY_PHASE1":6230,"PHASE1":6232,"PHASE2":6234,"PHASE3":6236,"PHASE4":6238,"NA":6240},{"trials":6231,"activeCount":100},[],{"trials":6233,"activeCount":100},[],{"trials":6235,"activeCount":100},[],{"trials":6237,"activeCount":100},[],{"trials":6239,"activeCount":100},[],{"trials":6241,"activeCount":100},[6242],{"nctId":6243,"briefTitle":6244,"status":634,"phases":6245,"primaryCompletion":6246,"completion":6246,"start":6247,"enrollment":3155,"conditions":6248,"interventions":6250},"NCT04292470","Physiology of GERD and Treatment Response",[92],"2021-11-04","2020-11-05",[6249],"GERD",[6228]]